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ABSTRACT 
 
As the world population battles drug-resistant tuberculosis (TB), there is an 
urgent need for novel anti-tubercular drugs. This dissertation documents the studies of 
glyoxylate shunt enzymes, isocitrate lyase (ICL) and malate synthase (GlcB), in 
Mycobacterium tuberculosis (Mtb) as drug targets for the therapeutic development of 
TB. Two different drug discovery approaches were used. A mechanism based approach 
was utilized for isocitrate lyase, while a fragment based approach was applied for malate 
synthase, and both approaches employed X-ray crystallography as a primary technique. 
Through the mechanism based approach, an ICL inhibitor complexed crystal structure 
was solved to 2.6 Å resolution after the treatment with itaconate. From the structure, the 
active site cysteine (Cys191) underwent covalent modification to form an S-
methylsuccinyl adduct. The inhibitory mechanism was based on the direct nucleophilic 
attack on the itaconate vinyl group by Cys191 after activation via a nearby general base. 
Additional crystal structure of ICL following the inactivation by 2-vinyl isocitrate (2-
VIC) at 1.8 Å resolution confirmed the formation of an S-homopyruvoyl adduct of 
Cys191. The structure was consistent with the proposed inhibitory mechanism where 2-
VIC first bound in the active site in the same manner as the substrate isocitrate. A base 
catalyzed aldo cleavage of the C2-C3 bond of 2-VIC then produced 2-vinyl glyoxylate 
and the aci-succinate. Cys191 was deprotonated to generate succinate, as in the lyase 
mechanism, followed by the Michael addition of Cys191 thiolate to 2-vinyl glyoxylate to 
form the final S-homopyruoyl adduct. 
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A fragment based approach was used to advance drug discovery and further 
probe the active site of Mtb GlcB. Two libraries of 1580 fragments were screened 
against GlcB using differential scanning fluorimetry (DSF) to identify binding hits, and 
18 complexed crystal structures were solved at 1.9-2.5 Å resolutions. The fragment 
bound GlcB crystal structures captured the conformations of the active site, which have 
not been reported for Mtb GlcB. The movements of two loops around the active site 
gave rise to a second portal to the surface and the narrowing of the active site tunnel. 
This series of conformational changes was hypothesized as a pathway for substrate-
product exchange. The structures of the enzyme at various stages of product formation 
and dissociation, as well as an apo enzyme structure, were further elucidated to confirm 
the hypothesis. As a result, a detailed, mechanism driven substrate-product exchange in 
catalysis was formulated. One novel interaction from the fragments and the enzyme was 
further incorporated into the existing phenyl-diketo acid (PDKA) inhibitor, providing 
new drug designs. The resulting lead molecule was 100 times more potent compared to 
the parent PDKA, and was shown to make the same interaction and induce the same 
movement in the active site as the original fragment. The comprehensive knowledge 
from the structural studies of the two glyoxylate shunt enzymes provided new 
information that could lead to a greater understanding of Mtb’s physiology and guide the 
discovery of more effective treatments of TB. 
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CHAPTER I  
INTRODUCTION AND LITERATURE REVIEW 
 
In 2009, the Nobel Prize in Chemistry was awarded to crystallographer Ada E. 
Yonath, along with Venkatraman Ramakrishnan and Thomas A. Steitz for their 
structural and functional studies of ribosomes. Their achievement was using X-ray 
crystallography to map the positions of hundreds of thousands of atoms which make up 
the protein factories in the cells. I was a third year chemistry graduate student and could 
not have a higher honor of meeting the crystallographer herself in person at the Argonne 
National Laboratory housing the advanced photon source synchrotron outside Chicago, 
Illinois, in August 2010. Regardless of how brief this encounter appeared, it has inspired 
me to become a better crystallographer. 
Over the years I have learned more than X-ray crystallography. The journey to 
becoming a better crystallographer has evolved to partake in the greater good of drug 
discovery. It included optimizing enzyme activity and whole cell assays, generating 
scientific reports, designing inhibitors, and mentoring students. Moreover, I have found 
meaning and enjoyment in conducting research that would benefit the society, the 
humanity, and life in general. Biomolecules such as proteins and nucleic acids are the 
key to the mystery of life which are comprised predominantly of common elements 
including carbon, nitrogen, oxygen, phosphorus, and hydrogen. Their unique features do 
not only emerge from their atomic composition but also from their distinct three-
dimensional (3D) structures. The studies of the spatial distributions and interatomic 
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interactions that make up the unique 3D structures of biomolecules fall under the field of 
structural biology. 
Structural biology and X-ray crystallography 
Structural biology is an integrated discipline of molecular biology, biochemistry, 
and biophysics involving the molecular structure of biological macromolecules, such as 
proteins and nucleic acids
1
. Advances in the medical and biological sciences in the last 
fifty years have significantly exceeded developments in other fields of sciences with a 
remarkable part owing to structural biology. This area of study includes techniques for 
the acquisition of data that characterize the conformations of biological macromolecules 
at resolutions of or near atomic level. In addition, the speed at which the 3D structures 
were determined has increased tremendously. A margin between the structural data and a 
researcher’s expertise to recognize and interpret the conformational information 
inevitably occurs. Therefore the ability to visualize and comprehend the constancy and 
flexibility of macromolecules relies on how to correlate their structural and biological 
properties. Structural biology further capitalizes the use of macromolecular structural 
database with vastly available visualization tools, programs, and software. 
Three common techniques are used in structural biology to visualize the 3D 
structures of macromolecules at the atomic level including X-ray crystallography, 
nuclear magnetic resonance (NMR), and electron microscopy (EM). X-ray 
crystallography is by far the most prevailing of the three methods. The latter two 
methods are limited by the sizes of the macromolecules and low resolution, whereas X-
ray crystallography has the capability to solve the eukaryotic ribosome complex of more 
 3 
 
than 3000 kDa in size and reach a resolution better than 1 Å. As of November 2015, 
there are 101,163 structures in the RCSB Protein Data Bank (PDB) determined by X-ray 
crystallography, while 11,082 and 889 structures were elucidated by MNR and EM, 
respectively (www.rcsb.org). Nonetheless, NMR and EM have their advantages over X-
ray crystallography. NMR can reveal information about structures and dynamics in 
solution, which are valuable for studying the atomic structures of flexible proteins, and 
EM requires smaller sample volume than X-ray crystallography. Due to its superior 
advantages X-ray crystallography is the main focus of methodology used in the research 
described throughout this dissertation and will be discussed further. 
Typically the most difficult step of protein crystallography is the first one, the 
preparation of suitable crystals, and major factors such as precipitants, crystallization 
variables, and supersaturation attainment are considered
1
. With the developments of 
nano-scale (< 1 l) liquid handler and automation, hundreds of crystallization conditions 
can often be screened in a high-throughput format using a few milligrams of purified 
protein. The most common practice for crystal formation and growth is the hanging drop 
method by the use of simple apparatus for brining a protein solution to saturation. A 
droplet of 2-5 l mixture of protein and mother liquor (solution containing 
crystallization condition) is placed on a silanized glass coverslip. The coverslip holding 
the protein droplet is sealed using vacuum grease over a reservoir of mother liquor 
containing precipitant of a concentration higher than that in the protein droplet. As water 
evaporates from the droplet, both the protein and precipitant concentrations increase 
gradually and crystals begin to form. The rate of crystal growth can be slowed to achieve 
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fewer but larger crystals by altering the difference between the precipitant concentration 
in the droplet and the reservoir. After protein crystals become available, the next step is 
the data collection. The X-ray data collection system usually starts with a source at a 
particular wavelength of energy selected by a crystal monochromator or a filter. A 
collimation system is also needed to produce parallel beams for exposing the X-ray to 
the crystal. A unique set of spots or reflections are generated when monochromatic X-
rays from a parallel source impinge on a crystal and diffraction occurs. In an X-ray 
diffraction experiment, the wave is scattered when a single X-ray photon encounters an 
electron. The intensity and location of the reflections are recorded as an image by a 
detector, and they change as the crystal is rotated to give another image leading to a 
different pattern of reflections. The data collection process continues until all the 
possible reflections have been recorded. Orienting the crystal is done by a precession 
camera or a goniometer, a device that is capable of producing any movement of crystal 
with a precision on the order of < 0.01°.  
A key component to any X-ray crystallography experiment is the data recording 
and manipulating system for analyzing the intensities of the 3D lattice of X-ray 
reflections. Each reflection is characterized by three integers, h, k, and l, also known as 
the Miller indices. To assign all the reflections in a set of collected images, three pieces 
of information are needed: 1) the exact orientation of the crystal at the start of the 
collection; 2) a detailed log of crystal’s motion during the collection; and 3) the angle 2 
where  is the scattering angle in Bragg’s law shown in Figure 1: 
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Figure 1: Bragg’s law. 
 
 
                (1.1) 
The starting orientation can be derived from the study of the positions of preliminary X-
ray reflections. The log of crystal’s movement is recorded by the computer with software 
that controls the movement of the goniometer. The angle 2 is obtained by the position 
of the X-ray reflection on the detector. 
Determination of protein structure usually goes through the process of 
refinement, which can be described by the concepts of structure factors and phases. A 
diffraction pattern of an object consists of reflections, and after analyzing the pattern, the 
waves are transformed back to the object’s shape and appearance. Each of the scattered 
waves in diffraction is called the structure factor Fhkl which is a complex variable with 
both amplitude and phase. Once amplitudes and phases are obtained, an electron density 
map can be generated which is then interpreted with reference to a model. Amplitudes 
are measured directly from the intensities of the X-ray reflections, whereas phases are 
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more difficult to obtain. Two methods are used to calculate phases, namely multiple 
isomorphous replacement (MIR) by heavy atom derivatives and molecular replacement 
by homologous structure. Since structures with the coordinates of homologous proteins 
are readily available, the use of heavy atom derivatives is omitted in the research 
described throughout this dissertation; however the method is briefly summarized. MIR 
was first developed by Max Perutz for his studies on the structure of hemoglobin
2
, and it 
remains as a trial-and-error procedure for solving phases. Chemicals containing elements 
with atomic numbers of 70 or higher are used to bind to protein in crystal at a finite 
number of sites. After soaking a heavy atom into a native protein crystal, the positions of 
the heavy atoms are determined by difference Patterson methods, provided that the unit 
cell remains unchanged. A Patterson map is calculated from the absolute values of 
structure factors alone, and the differences between the amplitudes of the crystals 
containing heavy atoms (FH) and the native protein (FP) are used to locate heavy atoms, 
as shown in Figure 2 and the equation below: 
FHP = FH + FP     (1.2) 
 
 
 
Figure 2: The equation of FHP = FH + FP defines a triangle of the effect of heavy atom 
derivatives on the native protein crystal. 
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Locations of the heavy atoms can be simplified by the Fourier transform of FH to 
calculate Patterson map which does not contain phase information. Once the location of 
the heavy atom in the unit cell has been determined, both the real and imaginary 
components of the heavy atom structure factor can be calculated. Figure 3 depicts the 
method of MIR, and the lower half of the figure shows that the phase angle hkl can be 
calculated by using a Harker construction
1
. Two circles drawn from each end of the 
vector FH with radii |FP| and |FHP| intersect at two locations, and the angle FP makes with 
the real axis is the phase angle for the reflection. Two intersections and a twofold 
ambiguity exist, but the correct phase angle can be solved with a second new heavy atom 
derivative. 
With the availability of tunable X-rays at a synchrotron source, anomalous 
scattering of certain elements at or near their X-ray absorption edges was developed to 
simplify the procedure for solving phase. Multiwavelength anomalous dispersion 
(MAD) is an effective method that relies on the measurement of the differences 
produced by one or more anomalously scattering atoms in the crystal. The differences 
can be observed in reflections related by the Miller indices h, k, l, and -h, -k, -l. Without 
any anomalous scattering, structure factors of h, k, l and -h, -k, -l are equivalent, and h, k, 
l and -h, -k, -l reflections are called Friedel or Bijvoet pairs
1
. Selenium is a commonly 
used anomalous scatterer for producing Friedel pairs with large differences in reflections 
and can be incorporated into proteins by over-expression in E. coli that are auxotrophic 
for methionine. The positions of the selenium atoms are then obtained by Patterson 
methods and phases can be solved in the similar manner as the MIR heavy atom method.  
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Figure 3: Multiple isomorphous replacement. 
 
 
The method of molecular replacement is used when the coordinates of a 
homologous protein are known to avoid the cumbersome steps of using heavy atom 
derivatives. The success of molecular replacement depends on the level of homology 
between the unknown protein (target) and the known protein (probe). The coordinates of 
the atoms in the probe and the X-ray diffraction data from the target crystal are needed 
to carry out the computational steps of molecular replacement. A rotational 
transformation is first obtained and the probe is placed in the correct orientation in the 
target unit cell after the comparison of the Patterson function of both the target and the 
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probe. From the coordinates of the probe structure, the structure factors and the Patterson 
function of the probe are calculated. On the other hand, the Patterson function of the 
target is calculated from the observed amplitudes from the target crystal data set. The 3D 
Patterson function of the probe is oriented by a rotation function until maximum overlap 
is achieved between the Patterson function of the probe and the Patterson from the 
target, resulting in the correct orientation of the probe in the target unit cell. The correct 
translational position of the properly oriented probe in the target unit cell is then 
determined by analysis of increments on a 3D grid using the coordinates of the correctly 
oriented probe. The calculated structure factors of the probe and the target are compared 
until a good correlation is found. Lastly the electron density map is produced from the 
amplitudes of the target crystal and the phases calculated from the rotated and translated 
coordinates of the probe in the target unit cell. The new model incorporated with the 
target undergoes building and refinement for the final structural determination. 
Obtaining structural data has been imperative for the research described in this 
dissertation. Structural studies can fill in the gap between the genomic data and the 
protein function when the essentiality of a gene is determined. Solving protein structure 
provides not only the information about the protein’s function but also insights into the 
mechanism related to its function. The structural studies by X-ray crystallography are 
particularly useful in inhibitor optimization, as seen in the upcoming chapters. Advances 
in X-ray crystallography and structural biology have been imparted to the medical 
sciences through drug discoveries that improve the quality of life. However the world 
population is still battling with diseases that currently threaten humanity and one of them 
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is tuberculosis (TB). The World Health Organization (WHO) declared TB as a global 
health emergency in 1993, and TB continues to kill approximately two million people 
each year. The breakdown in healthcare services, the spread of human 
immunodeficiency virus (HIV), and the emergence of drug-resistant strains are 
contributing to the worsening impact of this disease
3
. 
History and overview of tuberculosis 
Tuberculosis is the most widespread mortal disease with the longest history 
known to men. The first unequivocal evidence of TB dated back over 17,000 years 
through the identification of the DNA fragments by molecular DNA techniques, and the 
results provided the definitive diagnosis of TB in a fossil
4
. Although the earliest traces of 
TB were found in the remains of bison and not human, the disease has plagued mankind 
for thousands of years. Skeletal remains of a mother and a child dating from 7000 BC, 
found in a Neolithic settlement in the Mediterranean costal region of Israel, indicated the 
first presence of TB disease in humans
5
. Additional evidences of early TB were 
discovered in the spines of ancient Egyptian mummies from 3000-2400 BC
6
 and from 
the cave of Arena Candide (Liguria) in Italy dated to the first half of the fourth 
millennium BC
7
. The ancient Greeks were also acquainted with the disease; Hippocrates 
identified TB as the most widespread disease of the times involving coughing up blood 
and fever
8
. In the New World, the first evidence of TB was found in Paracas-Caverna 
culture of Andean society (circa 750 BC to circa 100 AD)
9
, long before the arrival of 
Christopher Columbus. 
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Throughout history, there have been many names associated with the disease 
prior to the discovery of the cause of TB. It was referred to as “consumption,” as it 
seemed to consume people from within, with a bloody cough, fever, pallor, and long 
relentless wasting
10
. Other names included phthisis (Greek for consumption) and phthisis 
pulmonalis (phthisis of the lung); scrofula (TB in adults), affecting the lymphatic system 
and resulting in swollen neck glands; tabes mesenterica, TB of the abdomen, and lupus 
vulgaris, TB of the skin. TB was also called “wasting disease;” “white plague11,” since 
sufferers appeared markedly pale; “king’s-evil12,” as it was believed that a king’s touch 
would heal scrofula; and “Pott’s disease,” or “gibbus” of the spine and joints. TB is 
referred to as “Koch's disease,” after the scientist, Robert Koch, who discovered the 
causative bacillus. Whichever name it is known, TB remains as one of history’s greatest 
killers; it was estimated to be responsible for 20% of the deaths in 17th-century London 
and 30% of those in 19th-century Paris
13
. Although not as aggressive as plague, TB has 
killed more people in history than the Black Death, leprosy, or HIV
14
. An estimated one 
billion people around the world have been felled by TB in the past two centuries, and the 
fatalities continue. 
The study of TB, sometimes known as phthisiatry, dated back to a series of five 
books, The Canon of Medicine, written by Ibn Sina (Avicenna) in the 1020s
15
. He was 
the first physician to identify pulmonary TB as a contagious disease, recognize the 
association with diabetes, and proposed the spread of the disease through contact with 
soil and water. He further developed a quarantine method in order to limit the spread of 
TB. The Canon of Medicine became increasingly influential through the medieval 
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period, and remains as a main textbook in university courses by 1340. In the late 15
th
 
century the series passed through 15 Latin editions and was one of the most frequently 
printed medical books of the 15
th
 and 16
th
 centuries.  
There were numerous unfounded beliefs, diagnosis, and treatments in the old 
ages due to the lack of the disease’s cause. One of the popular beliefs was that the 
disease was hereditary, passing on genetically from generation to generation, allowing 
predisposition for the disease to the population. Observation was made that both parents 
in a household were consumptives, and their children subsequently developed the 
disease in their lifetimes. Folklore often associated consumption with vampires; a 
deceased consumptive would return from the dead as a vampire and cause the wasting 
away of the surviving family members
16
. Consumptives in Europe found relief when 
removing themselves from the cold and damp weather to warm and sunny climate of the 
Mediterranean regions. They were recommended a healthy diet, lots of fluid, fresh air, 
and physical exercise. Another unfounded and popular treatment in the medieval period 
was a king’s touch. They believed kings possess a divine healing power to cure people 
with scrofulous glands in the neck. Being an indolent form of TB, scrofula usually 
resolved by itself, giving credence to the popular phrase the royal touch. It was 
established that the pulmonary form was associated with “tubercles” by Richard Morton 
in 1689, due to the variety of its symptoms. In 1822, a physician named James Carson 
suggested the use of artificial pneumothorax as a surgical procedure to treat pulmonary 
consumption
17
. The procedure involved making incisions in the thorax on the infected 
side of the lungs to introduce air into the chest cavity, allowing the affected lobes to 
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collapse, thereby healing the patient. Other similar methods including thoracoplasty
18
 
and pneumoperitoneum
19
 were also developed based on the same principle of collapsing 
the infected lungs.  
After it was identified as a single disease in the 1820s, it was finally named 
“tuberculosis” in 1839 by Johann Lukas Schönlein20. A report in 1849 indicated 
favorable results with the use of cod-liver oil, an excellent source of vitamin D3, in the 
treatment of over 400 patients with TB
21
. Studies conducted in the early 19
th
 century 
showed that animal protein consumed in the form of meat offered enhanced resistance 
against active TB
22
, and it was a general consensus that poor nutrition contributes to 
greater TB susceptibility. At that time patients also frequently sought opium to calm the 
continuous coughing and to ease diarrhea and pain caused by intestinal TB. In the hope 
of curing the disease with the constant temperature and purity of the cave air, the 
concept of sanatorium became popularized by Hermann Brehmer, who opened the first 
TB sanatorium in 1854 in Görbersdorf, Germany (today Sokołowsko, Poland)23. Others 
soon followed suit after Brehmer’s success. Edward Livingston Trudeau, a physician and 
a TB patient himself, established the first sanatorium in the US in 1882. 
The TB-causing bacillus Mycobacterium tuberculosis was identified and 
described by a German physician and microbiologist Robert Koch during his time as the 
government advisor with the Imperial Department of Health in Berlin in the 1880s. At 
that time, it was widely believed that TB was an inherited disease; however, Koch was 
convinced that the disease was caused by a bacterium and was infectious. Koch’s 
previous discovery of the causative agent of anthrax during the 1870s led to the 
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formation of a generic set of postulates which could be used in the determination of the 
cause of most infectious diseases. Koch’s four postulates24 are: 1) The organism must 
always be present, in every case of the disease; 2) The organism must be isolated from a 
host containing the disease and grown in pure culture; 3) Samples of the organism taken 
from pure culture must cause the same disease when inoculated into a healthy, 
susceptible animal in the laboratory; and 4) The organism must be isolated from the 
inoculated animal and must be identified as the same original organism first isolated 
from the originally diseased host. He succeeded in isolating the bacillus and allowing it 
to grow to pure culture, and after testing on guinea pigs, he found that his experiments 
with TB satisfied all four of his postulates. In 1882, he published his findings on TB, in 
which he reported the causative agent of the disease to be the slow-growing 
Mycobacterium tuberculosis. He received the Nobel Prize in physiology or medicine in 
1905 for his research.  
Human TB is caused by infection with members of the Mycobacterium 
tuberculosis complex, including Mycobacterium tuberculosis, Mycobacterium 
africanum, Mycobacterium bovis, Mycobacterium caprae, Mycobacterium microti, 
Mycobacterium pennipedii, and Mycobacterium canettii
25
. Mycobacterium tuberculosis 
(M. tuberculosis or Mtb) is an obligate intracellular pathogen that can infect several 
animal species, although human beings are the principal hosts
26
. It is an immotile, non-
encapsulated, and non-spore forming bacillus. Due to the highly aerobic physiology of 
Mtb its growth requires high levels of oxygen, and it grows most vigorously in tissues 
with high oxygen content, such as the lungs. Mtb has an unusually waxy coating on its 
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cell surface, primarily due to the high content of mycolic acid, which makes the bacteria 
impervious to Gram staining. Correspondingly, the Ziehl-Neelsen stain, or acid-fast 
stain, is used instead of the Gram stain. Mtb divides every 15-20 hours, which is 
extremely slow compared with other bacteria. The slow replication rate and the ability to 
persist in a latent state result in the need for long preventative therapy for patients with 
Mtb infection. 
Modern TB diagnosis and treatment methods 
Following the success of vaccination in preventing smallpox established during 
the 18th century, scientists thought to find a relief in TB by correlating bovine TB to 
cowpox. They hypothesized that infection of bovine TB might protect against infection 
of human TB. In the late 19th century, the clinical trials conducted in Italy using 
Mycobacterium bovis (M. bovis) ended disastrously showing M. bovis as virulent as Mtb. 
Albert Calmette, a French physician and bacteriologist, and his assistant and later 
colleague, Camille Guérin, a veterinarian, were working at the Institut Pasteur de Lille 
(Lille, France) in 1908. Their work included sub-culturing virulent strains of the tubercle 
bacillus and testing different culture media. They isolated the BCG (Bacillus of 
Calmette-Guérin) strain after 239 times of sub-culturing from a virulent strain on 
glycerine potato medium during 13 years. The research continued throughout World 
War I until 1919 when the now avirulent bacilli were unable to cause TB disease in 
research animals. They transferred to the Paris Pasteur Institute in 1919, and the BCG 
vaccine was first used in humans in 1921
27
.  
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At the beginning, the BCG vaccine received poorly by the public, and one 
catastrophe in particular further damaged the general acceptance. In the summer of 1930 
in Lübeck, Germany, 240 infants were vaccinated within the first 10 days of birth; 
almost all developed TB and 72 of them died. It was later discovered that the BCG 
vaccine administered there had been contaminated with a virulent strain that was being 
stored in the same incubator. After the practice of vaccination against TB by pioneers 
such as Robert George Ferguson, BCG was adopted by the Health Committee of the 
League of Nations (predecessor to the WHO) in 1928. Due to its opposition, however, 
the vaccine only became widely used after World War II. From 1945 to 1948, relief 
organizations (International Tuberculosis Campaign or Joint Enterprises) vaccinated 
over 8 million babies in Eastern Europe and prevented the predicted typical increase of 
TB after a major war. The vaccine has been given to four billion people so far and to 
more than 90% of the children in the world today, making it the most widely used 
vaccine in the world
28
.  
It was not until 1946 with the development of the first antibiotic that effective TB 
treatment and cure became possible. Streptomycin, the first of a class of drugs called 
aminoglycosides, was isolated in 1943 by a graduate student Albert Schatz, in the 
laboratory of Selman Abraham Waksman at Rutgers University in a research project 
funded by Merck
29,30
. It was purified from actinobacterium Streptomyces griseus with 
proven activity against Mtb, and the Nobel Prize was awarded in 1952 for its discovery. 
However, uncertainties remained about its consistency in treating patients, followed by 
the rapid development of drug resistance with the use of a single agent against TB. The 
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Medical Research Council (MRC) TB unit in the United Kingdom conducted the first 
recorded randomized and controlled clinical trial on streptomycin. Their studies showed 
that TB improvement was greatest in the first three months of therapy, after which 
deterioration in patient’s health began due in part to the emergence of resistance31. In the 
1950s, several other TB drugs with various mechanisms of action were discovered and 
developed, including para-amino salicylic acid, isoniazid, pyrazinamide, cycloserine, 
and kanamycin
25
. They provided combination therapy which had the treatment duration 
of 18 months or more at that time. In the following four decades, a collaborative effort 
between the United States Public Health Service (USPHS) and the MRC TB developed 
the current short-course therapeutic regimen comprising isoniazid, rifampicin, 
pyrazinamide, and ethambutol that allowed shorter treatment duration
32
. 
The twentieth WHO report on the worldwide incidence of TB indicated that TB 
remains as a global health emergency despite timely diagnosis and treatment
3
. It 
estimated that 9.6 million people have developed TB, and 1.5 million have died from it 
in 2014. TB ranks as the leading cause of death from an infectious disease worldwide 
alongside with HIV. Currently, one-third of the world population is latently infected 
with Mtb, reflecting the bacteria’s remarkable ability to persist for the lifetime of the 
host despite the robust immune responses
33
. Mtb is transmitted primarily via the 
respiratory route, and infection occurs in the lungs, but it can spread to other organs by 
the bloodstream. Bacteria that reach the lung alveoli are internalized by macrophages 
where they replicate within the vacuoles
34
. Bacterial growth slows or stops with the 
activation of antimicrobial mechanism of macrophages by the adaptive immune 
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response; however, the bacteria are not eliminated, but rather enter the state of chronic 
persistence
35
.  
 Effective TB treatments rely on accurate diagnosis in a timely fashion. Sputum 
smear microscopy has been the primary method for diagnosis of pulmonary TB in low 
and middle income countries
28
, where ~95% of TB cases and 98% of TB deaths occur. It 
is simple, fast, inexpensive, and highly specific in areas with TB prevalence, and it 
identifies the most infectious case with wide diversity in various populations. However, 
the method lacks sensitivity when the bacteria load is less than 10,000/ml in the sputum 
sample and has a poor track record in extrapulmonary TB, pediatric TB, and TB co-
infection with HIV
36
. Sputum processing with bleach or sodium hydroxide and 
centrifugation in a meta-analysis increased sensitivity by 13% compared to smear 
microscopy
36
. Fluorescence microscopy introduced in the 1930s incorporates a 
fluorescence dye for staining and improves the sensitivity of conventional smear 
microscopy by 10% with shorter turnaround time and similar specificity to the 
conventional microscopy
37
.  
 In countries with more advanced laboratory capacity, cases of TB are also 
diagnosed via culture methods. Traditionally, cultures have used the Löwenstein-Jensen 
(LJ), Kirchner, or Middlebrook media (7H9, 7H10, and 7H11)
38
. A culture of the acid-
fast bacilli (AFB) can distinguish the various forms of mycobacteria, albeit conclusive 
results take four to eight weeks. New automated systems have developed to improve 
speed, including the MB/BacT
39
 and the Mycobacterial Growth Indicator Tube 
(MGIT)
40
. The microscopically observed drug susceptibility (MODS) assay culture is 
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another alternative diagnostic tool offering speed, accuracy, and sensitivity, as well as 
simultaneous identification of multidrug-resistant TB
41
. Automated liquid culture 
systems are currently the standard for TB diagnosis with greater speed and yield than 
solid media
28
. They are recommended to use in combination with antigen-based species 
confirmation and drug susceptibility testing (DST)
42
. Line probe assays (LPAs) are used 
for the rapid molecular detection of drug resistance in smear-positive specimens or 
culture isolates
42
, and nucleic acid amplification tests (NAATs) use full automation to 
detect rifampicin resistant mutation
43
.  
 For the diagnosis of latent TB infection, the Mantoux tuberculin skin test has 
been the only screen available for the past century. It failed to reliably distinguish 
individuals with Mtb infection from those sensitized to other bacteria, such as BCG. The 
interferon- release assays (IGRAs) have been developed to overcome the false positive 
diagnosis
44
. They measure interferon- titers after in vitro stimulation of peripheral blood 
mononuclear cells with antigens expressed by members of the Mtb complex. The IGRAs 
have now become the gold standard for identifying individuals with immune systems 
that have previously encountered Mtb
28
. 
 The current TB treatment regimens comprise of first-line anti-tubercular drugs 
isoniazid, rifampicin, ethambutol, and pyrazinamide. The US no longer considers 
streptomycin as a first-line drug per the health institutes ATS/IDSA/CDC because of 
high rates of resistance, though it is still recommended as such by the WHO. The second 
line drugs (WHO groups 2, 3 and 4 antibiotics) are only used to treat disease that is 
resistant to the first-line therapy. They include aminoglycosides (group 2, e.g., amikacin, 
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kanamycin), polypeptides (group 2, e.g., capreomycin, viomycin, enviomycin), 
fluoroquinolones (group 3, e.g., ciprofloxacin, moxifloxacin), thioamides (group 4, e.g., 
ethionamide, prothionamide), cycloserine (group 4), and terizidone (group 5). The 
standard short course treatment through directly observed therapy (DOT) for TB is 
isoniazid, along with pyridoxal phosphate to obviate peripheral neuropathy, rifampicin, 
pyrazinamide, and ethambutol for two months, then isoniazid and rifampicin alone for 
an additional four months. The patient is considered to be free of living bacteria after six 
months, although a relapse rate of up to 7% has been reported
45
. For latent TB, the 
standard treatment is six to nine months of daily isoniazid alone or three months of 
weekly with a total of 12 doses of isoniazid/rifapentine combination
46
. If the infectious 
organism is fully sensitive, the treatment is with isoniazid, rifampicin, and pyrazinamide 
for two months, followed by isoniazid and rifampicin for four months without the need 
of ethambutol. 
 As high as 5% of TB cases are caused by drug resistant strains of TB, known as 
multidrug-resistant TB (MDR-TB), which are untreatable by at least two first-line 
antibiotics, mainly isoniazid and rifampicin
42
. As much as 1% of new TB cases are 
classified as extensively drug-resistant TB (XDR-TB), which are resistant to both first-
line drugs and many second-line drugs, severely reducing the treatment options and 
increasing rate of fatality. Recent reports use the term totally drug-resistant TB (TDR-
TB) to describe TB caused by Mtb strains that are resistant to all available first- and 
second-line drugs. Cases have been reported across the globe in Italy
47
, India
48
, and 
Iran
49
. As the number of cases with drug resistant TB increases, the burden on the health 
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care systems hinders the ability of health officials to provide effective treatment to the 
infected populations. Therefore, there is an urgent demand for a truly novel anti-
tubercular treatment for combating the TB pandemic. 
Strategies for drug discovery 
 In order to develop effective anti-tubercular therapeutics, the drug discovery 
approach needs to be rational and not through physiological observations and discoveries 
that have dominated in the past. One approach is the target-based drug discovery. A 
target is usually a single gene, gene product or molecular mechanism that has been 
identified on the basis of genetic analysis or biological observations
50
. For example, the 
target enzymes are selected based on their essentiality to the survival of the 
microorganism under different growth conditions. Enzyme as virulence factor makes an 
interesting drug target due to its requirement for establishing an infection in the host 
organism. Figure 4
50
 shows the flow of target-based drug discovery, and the approach 
begins with a druggable target enzyme in the pathogen. A target is identified and 
validated, followed by assay development and screens of compound libraries to find hits 
and leads. The designs of potent inhibitors rely on the accurate knowledge of the 3D 
structure of the target enzyme and its active site
51
 typically by X-ray crystallography and 
NMR spectroscopic methods, with the former summarized at the beginning of this 
chapter. A structure guided medicinal chemistry approach is then used to design 
inhibitors of the target enzyme based on the knowledge of the active site with high 
specificity and selectivity. During the development process, structure-activity 
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relationship (SAR) studies are conducted in which the chemical structure of an inhibitor 
is modified to investigate the effect of the modification on its biological activity. 
 
 
Figure 4: Target-based drug discovery. Reprinted with permission from Reference 50. 
 
 
The Tuberculosis Structural Genomics Consortium (TBSGC) has been initiated 
to provide a structural genomic approach for drug discovery of biologically and 
medically important proteins in Mtb
52
. The important drug targets include the proteins 
proven essential to the survival and growth of Mtb through gene deletion or disruption 
studies. They also include the genes identified through comparisons of the whole 
genome sequencing of wild type and the drug resistant strains of Mtb genome. The 
consortium aimed to determine crystal structures in a high-throughput format with 
technological advances in gene cloning, protein expression, purification, and 
crystallization and X-ray crystal structure determination. Crystal structures of known 
drug targets complexed with known inhibitors provide further understanding of the 
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mechanisms of inhibition. In addition, the aim of TBSGC is to design new inhibitors or 
modify existing inhibitors with greater potencies by efficiently exploiting the 
hydrophobic, polar, and electrostatic interactions in the active site. 
The TBSGC is a collaboration of 76 institutions in 15 countries including North 
America, Europe, and Asia
53
. Members of the consortium collaborate with the 
commitment of solving crystal structures of proteins in Mtb, specifically in relation to 
developing novel anti-tubercular drugs. Each member has access to the consortium’s 
collective knowledge through many forms of communication such as shared databases, 
web pages, and direct interactions. The goals of the consortium are
53
: 1) to construct a 
knowledge base to contribute to the understanding of Mtb pathogenesis and aid in drug 
design; 2) to develop scalable technologies to make structural genomics research 
accessible to a large number of researchers; 3) to solve the structures of biologically 
important proteins as a basis for drug discovery efforts; and 4) to demonstrate the 
benefits of a distributed consortium approach for large-scale research. 
A breakthrough in structural genomics came with the complete genome sequence 
of Mtb strain H37Rv; it comprises 4,411,529 base pairs and contains 4142 genes
54
. 
Numerous enzymes involved in diverse metabolic and biosynthetic pathways have been 
proven drug targets for successful inhibition studies
55
. However, nearly half of the 4142 
open-reading frames (ORFs) remain as conserved hypothetical proteins or simply 
proteins with unknown functions
56; therefore, the consortium’s secondary goal was to 
identify the function of unknown genes in the Mtb genome. Newly annotated genes aid 
in mapping the important biological pathways in Mtb and the drug discovery process by 
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determining new structures with possible biological relevance. Updated in 2009, the 
consortium has solved approximately 600 protein structures covering 216 unique 
genes
53
. The structures have provided insights into the biology of Mtb, and many of 
them are currently being pursued as drug targets in active inhibitor campaigns. 
  Traditionally, drug discovery relies on high-throughput screening (HTS) of large 
libraries of compounds (~10
6
) assimilated over time. This methodology suffers from 
poor quality and high maintenance of the library, and the compounds are not very drug-
like with high lipophilicity and poor solubility. False positives often arise, and genuine 
hits may not be good starting points for drug development. In recent years, fragment-
based methods have emerged as a complementary and contrasting approach to the 
traditional HTS of large compound libraries for early stage drug development. 
Compared to traditional compound libraries, fragment libraries are smaller with fewer 
compounds. Compounds in the fragment libraries are also smaller and simpler with 
lower molecular weights (MW < 300 g/mol), and their reduced size and functionality 
relegates them to bind to target proteins with weak affinities (Kd > 0.1 mM). Despite 
their weak affinities, fragments exhibit high ligand efficiency (G of binding per heavy 
atoms) and high intrinsic binding energy to overcome a large entropic barrier upon 
binding 
57,58
. Thus one of the advantages of using fragments is the high-quality 
interactions they make with the target to bind with sufficient affinity for detection. 
Another advantage of the fragment methodology is that a fragment library with ~10
3
 
fragments can sample a significantly larger portion of chemical space, compared with 
~10
5
-10
6
 larger molecules in a typical compound library
59
. Figure 5
60
 shows the 
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multistage workflow of fragment-based approach to inhibitor design. The process of 
fragment based drug discovery include design and assembly of fragment libraries, 
screening of fragments against a suitable form of the target enzyme, validation of the hits 
after they are generated, and elaboration of fragments into more potent inhibitors.  
 
 
Figure 5: The multistage strategy adopted for fragment screening, verification, and 
elaboration into enzyme inhibitors. Reprinted with permission from Reference 60. 
 
 
 The assembly of fragments for a screening library plays an important first step of 
the fragment methodology. Ideally fragments tend to follow the Rule of Three
61
 or RO3 
(MW < 300 g/mol, H-bond donor and acceptor ≤ 3 each, and clog P ≤ 3), and they need 
to be soluble at 100 mM-1 M in DMSO and at ~10 mM diluted in buffers. Fragments 
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need to include functionalities that facilitate fragment elaboration while minimizing the 
number of reactive, unstable, or toxic scaffolds. Other criteria for consideration include 
size of the library, diversity of the fragments, and ease of maintenance and storage. 
Deconstructing structures of known inhibitors and natural products
62
 as well as using 
computational tools
63
 can all provide useful information for library design. 
 Sensitive and robust biophysical methods must be used for fragment screening in 
order to detect binding of fragments with weak affinities in 0.1-10 mM range
59
. The 
initial screen is likely to be done by thermal denaturing (thermal shift, TS or Tm), 
surface plasmon resonance (SPR), or other adopted and less common approaches such as 
mass spectrometry (MS) and virtual screening. Subsequent screening by NMR 
spectroscopy or isothermal titration calorimetry (ITC) can provide more conclusive 
binding evidence, followed by structural studies to determine the exact binding mode of 
the fragment. 
 Upon validation of the hits, the fragments are structurally elaborated to improve 
potency in an iterative process of rational design and synthesis, guided by SAR studies. 
Understanding of the fragment binding modes is of great importance and can usually be 
achieved by using X-ray crystallography or protein-based two-dimensional (2D) or 3D 
NMR spectroscopic methods
64,65
. Three main techniques for fragment elaboration are 
used to increase potency of the inhibitors, including fragment merging, linking, and 
growing
59
. Ideally, the high ligand efficiency and the binding mode of the fragments are 
maintained throughout the elaboration process with improved potency of the newly 
synthesized molecule compared to the original fragments. 
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Initially, fragment based drug discovery found success when applied against 
kinase targets that were highly druggable and well-suited with the approach. It quickly 
became a more common approach, implementing to a wide range of protein families 
with structures readily available. Over the years, fragment screening has allowed the 
initiation of lead discovery of novel inhibitors for targets such as phospho-tyrosine 
protein phosphatase, cyclin dependent kinase 2
66
, -secretase67, thrombin68, and protein 
kinase B
69
. An important advance in drug discovery was made in 2011 when Zelboraf 
(PLX4032) became the first drug approved by the FDA using the fragment-based 
approach for cancer therapeutics
70,71
. Currently fragment based methods are used against 
targets as diverse as protein-protein interactions
72,73
, transcription factors
74
, protein 
chaperones
75,76,77
, and RNA
78
.  
Both target-based approach by screening traditional compound libraries and 
fragment-based approach to drug discovery can be applied to a wide range of targets 
once a target is identified and validated. Recently, numerous enzymes involved in 
different metabolic and biosynthetic pathways have been successfully targeted for 
inhibition studies
55
, and carbon metabolism of Mtb has emerged as a frontier in 
fundamental research and drug discovery
79
. Advances in liquid chromatography (LC) 
and MS have allowed both qualitative and quantitative detections of metabolites in a cell 
and enabled the traces of their biochemical steps and transformations within the cell. 
Those advances have accentuated the need for understanding Mtb’s central carbon 
metabolism. They have also prompted for more detailed interpretations of the metabolic 
pathways and the phenotypes of mutated Mtb strains where genes involved in carbon 
 28 
 
metabolism have been deleted. Further evidences from high-throughput screens 
demonstrated that small molecules can selectively inhibit some enzymes of Mtb’s central 
carbon metabolism while sparing human hosts. 
 
 
 
Figure 6: Bioinformatic inventory of the CCM network in Mtb. Reprinted with 
permission from Reference 79. 
 
 
Carbon metabolism and pathogenicity of Mycobacterium tuberculosis 
 Pathogens acquire and metabolize energy sources using components that are 
structurally distinct and sometimes absent from their host counterparts
80
. Therefore 
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understanding the physiological requirements of bacteria and studying the metabolic 
pathways are important constituents of structural genomics and drug discovery to 
prevent bacterial growth and survival. Mtb is a heterotrophic pathogen capable of 
subsisting on a variety of carbon substrates, including sugars, tricarboxylic acids, and 
fatty acids
80
. Figure 6
79
 shows a genomically annotated inventory of known or 
homologically predicted enzymes of central carbon metabolism (CCM) in Mtb. It entails 
the enzymatic transformation of carbon through glycolysis, gluconeogenesis, the pentose 
phosphate pathway, and the tricarboxylic acid (TCA or citric acid) cycle, to the 
physiology of the bacterium
79
. Evidences have implicated Mtb’s CCM as a key 
determinant of its pathogenicity. Sassetti and Rubin used transposon site hybridization 
(TraSH) to analyze the genes required by Mtb for optimal growth
81
. They identified 
several central biosynthetic and metabolic pathways with the majority of steps mediated 
by genes that are predicted to meet the growth requirement. In another study, TraSH was 
used to identify 194 genes that were specifically required for survival during infection in 
a mouse model
82
. They reported that 45% of the genes identified can be classified based 
on the predicted functions with lipid metabolism. Carbohydrates and inorganic ion 
transport and metabolism are also among the categories with the highest number of 
genes.  
 Carbon catabolism provides the bacterial cell with energy in the forms of 
reducing equivalents and ATP, as well as essential biosynthetic precursors including 
glucose-6-phosphate, fructose-6-phosphate, 3-phosphoglycerate, phosphoenolpyruvate 
(PEP), acetyl-CoA, propionyl-CoA, oxaloacetate, and -ketoglutarate. Mtb has intact 
 30 
 
glycolytic and pentose phosphate pathways based on genomic analysis with pyruvate 
carboxylase mediating the carbon flow of glycolysis during growth on carbohydates
80
. 
Acetyl-CoA derived from carbohydrates or fatty acids is further oxidized to CO2 by the 
TCA cycle, which plays the role of central process in energy metabolism. The TCA 
cycle is by no means a carbon sink, but a coupling between anaplerotic influx of C4 and 
C5 intermediates and the exit of intermediates from the cycle via cataplerosis
83
. 
Anaplerotic reactions are the replenishment of the TCA cycle intermediates that are 
diverted to biosynthetic pathways after two carbons exit the cycle. Unlike other 
organisms, Mtb utilizes two distinct TCA paths for -ketoglutarate84. One path functions 
concurrently with -oxidation under the reaction of -ketoglutarate to succinate by the 
enzyme ketoglutarate ferredoxin oxidoreductase (KOR). The other path functions in the 
absence of -oxidation via the -aminobutyrate (GABA) shunt, in which succinyl-CoA 
is replaced by succinic semialdehyde, as shown in Figure 6. 
Gluconeogenesis is responsible for glucose anabolism from non-carbohydrate 
substrates such as fatty acids, and in Mtb, gluconeogenesis is fueled by the intermediates 
of the TCA cycle. Gluconeogenic pathways comprise essentially the same set of 
enzymes as glycolysis, catalyzing readily the reversible reactions. However, glycolytic 
conversion of fructose-6-phosphate to fructose-1,6-bisphosphate, catalyzed by 
phosphofructokinase, is effectively irreversible, and the reverse reaction in 
gluconeogenesis is catalyzed by fructose-1,6-bisphosphatase. The entry point into 
gluconeogenesis in Mtb is phosphoenolpyruvate (PEP), which is generated from 
oxaloacetate by phosphoenolpyruvate carboxykinase (PEPCK). Metabolomic analyses 
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have shown that PEPCK is the sole enzyme in Mtb capable of driving the TCA cycle 
derived carbons for the biosynthesis of glycolytic and gluconeogenic precursors
85
. 
Several studies have suggested that Mtb preferentially uses fatty acids during in 
vivo growth. Experiments of biochemical differentiation showed that respiration of Mtb 
grown in mouse lungs was strongly stimulated by fatty acids but unresponsive to 
carbohydrates
86
. Analysis of genes coding for functions of intermediary metabolism 
suggests that Mtb switches its carbon source from glucose and glycerol to fatty acids in 
an infection-mimicking environment
87
. The genes encoding fatty acid -oxidation 
enzymes are extensively duplicated in the Mtb genome
54
, and those of glyoxylate cycle 
are considerably up-regulated during the infection of macrophages and mice. 
Furthermore, the enzyme that catalyzes the first step of gluconeogenesis, PEPCK, is 
required for growth on fatty acids, and both PEPCK and gluconeogenesis are essential 
for persistent infection
82,85
. Ultimately, the survival of Mtb in chronic infection relies on 
a metabolic shift in the carbon source from carbohydrates to C2 substrates generated 
from fatty acids. The -oxidation cycle is the dominant route for oxidative degradation 
of fatty acids in bacteria. Through successive rounds of -oxidation, even-chain fatty 
acids are degraded to acetyl-CoA and odd-chain fatty acids or branched-chain amino 
acids are degraded to acetyl-CoA and propionyl-CoA, which can be oxidized further via 
the citric acid cycle and methylcitrate cycle, respectively.   
 Fatty acids are substrates for both the TCA cycle and gluconeogenesis, which 
carry out energy and biomass production in the cell, respectively
88
. When Mtb enters the 
chronic stage of persistent infection, glycolysis is decreased, and there are high levels of 
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-oxidation due to the shift of carbon source to fatty acids. When biomass production 
solely relies on fatty acids, bacteria must avoid carbon loss in the form of CO2 during 
oxidation in the TCA cycle. Therefore a carbon preserving bypass, the glyoxylate shunt, 
is significantly up-regulated to allow anaplerotic replenishment of the TCA cycle 
intermediates that are necessary for gluconeogenesis. 
 
 
 
Figure 7: Glyoxylate shunt as a carbon preserving bypass of the TCA cycle. Also 
shown: methylcitrate cycle as a part of propionyl-CoA metabolism. 
 
 
 In 1957 Kornberg, Krebs, and Madsen demonstrated that the synthesis of C4 
dicarboxylic acids from acetate occur by a modified TCA cycle that was termed the 
glyoxylate cycle with the pathway named the glyoxylate shunt
89,90
. There are two 
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enzymes on the glyoxylate shunt, isocitrate lyase (ICL) and malate synthase (GlcB or 
MS). ICL catalyzes the aldo-cleavage of isocitrate into glyoxylate and succinate, and 
GlcB catalyzes the Claisen-like condensation of glyoxylate and acetyl-CoA to generate 
malate and CoA, as shown in Figure 7. The glyoxylate shunt bypasses the two CO2 
generating steps of the TCA cycle, and the net result of the glyoxylate cycle is the 
production of malate and succinate from two molecules of acetyl-CoA derived from 
acetate or fatty acids. Mtb relies heavily on the glyoxylate shunt during growth on fatty 
acids, when PEP and pyruvate concentrations are insufficient to support anaplerosis of 
the TCA cycle. The glyoxylate cycle facilitates the biosynthesis of essential cell 
nutrients from C2 units (acetyl-CoA) by generating C4 intermediates that serve as 
biosynthetic precursors
89
. It can also generate the essential C3 biosynthetic precursors 
PEP and pyruvate in conjunction with PEPCK and malic enzyme
91
. 
 The glyoxylate shunt has been reported in archaea, bacteria, protists, plants, 
fungi, nematodes (with an ICL-MS gene fusion)
92
, and lower eukaryotes but is absent in 
placental mammals
93
. In microorganisms it provides a means to survive on fatty acids as 
the sole carbon source, and in plants it serves to utilize seed lipids for growth. The 
glyoxylate shunt is important for the growth of higher seedlings under most conditions, 
since it converts stored lipids to carbohydrates that serve as the primary carbon source 
for photosynthesis
94
. Evidence has suggested that the glyoxylate shunt allows the growth 
of halophytic archaea in the Dead Sea or hypersaline lakes
95
.  
 Numerous studies have highlighted the importance of the glyoxylate shunt in Mtb 
virulence. Earlier work was done using a macrophage-resident population of the related 
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M. bovis by comparing the protein complement to the cells grown in vitro by 2D gel 
analysis
96
. Another study used a complementary DNA (cDNA) selection technique to 
identify Mtb genes regulated upon phagocytosis
97
. Both methods demonstrated the 
induction of ICL as a key response to phagocytosis in Mycobacterium species. Later, 
McKinney et al. have shown that a mutant strain of Mtb with deletion of icl1 or icl2 in 
macrophages or a mouse model is incapable of maintaining a persistent infection, though 
it can establish growth during the acute phase of infection
98
. A mutant strain lacking 
both icl1 and icl2 genes cannot establish growth on fatty acids or in macrophages, and is 
quickly eliminated from the lungs of the infected mice
 99
. 
 Both ICL and GlcB are attractive targets for drug discovery due to the 
essentiality of the glyoxylate shunt in persistent infection and their absences in placental 
mammals. However, they present certain degree of challenge during the drug discovery 
process. This dissertation documented research efforts devoted to the studies of the two 
enzymes of the glyoxylate shunt as potential targets using distinct approaches to drug 
discovery. As described in the following chapters, inhibition of ICL is characterized by 
using a mechanistic approach, while targeting GlcB is accomplished by a fragment based 
approach to drug discovery. Although the approaches are different, studies on both 
enzymes are conducted extensively with structural guidance by X-ray protein 
crystallography.  
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CHAPTER II 
STRUCTURAL CHARACTERIZATIONS OF COVALENT INHIBITORS OF 
ISOCITRATE LYASE 
 
Background and introduction 
 More than half a century ago, Smith and Gunsalus reported the existence of the 
enzyme isocitrate lyase
100
 (ICL). ICL (threo-ds-isocitrate-glyoxylate-lyase; EC 
4.1.3.1)
101
, the first enzyme of the glyoxylate shunt, converts isocitrate (D-isocitrate) to 
glyoxylate and succinate (Figure 8). It can be found in archaea, bacteria, fungi, 
nematodes, plants, and protists, and is a homotetramer requiring Mg
2+
 or Mn
2+
 and an 
active site acid-base pair for activity
102
. In E. coli ICL Lys193, Cys195, His197, and 
His356 are catalytic active site residues, while His184 is involved in the assembly of the 
tetrameric enzyme
103, 104
. Sequence alignment of E. coli ICL and ICL (icl) from Mtb 
shows 62% identity and 76% similarity between them, and all the catalytic and 
important residues in the active site are conserved. Previously Sturgill et al. have 
employed 2D sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) 
to identify a 50-kDa polypeptide from Mycobacterium avium (M. avium), the expression 
of which was significantly regulated upon infection of macrophages
96
. Protein 
sequencing at the N-terminus showed 15 amino acid (AA) resides with 13 of which were 
identical to the sequence of Rv0467 (icl) from Mtb. In Mtb H37Rv (Sanger database), 
another ORF has an overlap of single base pair resulting in two ORFs, namely aceAa 
(Rv1915) and aceAb (Rv1916), while in CSU93 (MT1966; the Institute for Genomic 
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Research database) it is read as one continuous ORF
105
. Rv0467 is referred to as icl 
which encodes for ICL1 (or ICL for the remainder of the dissertation), and the latter 
ORFs Rv1915/1916 are collectively referred to as aceA, which encodes for ICL2. 
 
 
 
Figure 8: General reaction of ICL. 
 
 
 
Figure 9: ICL domain organization. Reprinted with permission from Reference 99. 
 
 
Bioinformatics analysis has revealed three distinct groups of ICL proteins 
differing in length and domain organization (Figure 9
99
). Group 1 ICLs comprise small 
eubacterial ICLs, including Mtb ICL1. Group 2 ICLs include medium length ICLs from 
plants and fungi, which contain a central domain (Domain II) absent in group 1. So far 
group 3 ICLs are only identified in Mycobacterium and have a long C-terminal domain 
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absent in groups 1 and 2 (Domain VI not shown in Figure 10
99
). In addition, they 
contain a central region with high degree of homology to the central domain of the 
eukaryotic ICLs and share ~35% overall identity (Figure 9). 
 
 
 
Figure 10: Superimposition of in silico modeled ICL2 monomer (red) and the X-ray 
crystal structure of ICL1 monomer (blue). Domain II (AA 269-365) was modeled after 
the X-ray crystal structure of Aspergillus nidulans ICL. Reprinted with permission from 
Reference 99. 
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The predicted gene products of icl (428 AA) and aceA (766 AA) share an overall 
27% identity. The 3D in silico modeling of the structure of Mtb ICL2 (red in Figure 10), 
based on the crystal structure of Mtb ICL1
106
 and the group 2 ICL from Aspergillus 
nidulans (A. nidulans)
107
 revealed a high degree of structural similarity. Evidently, the 
active site loops of ICL1 and ICL2 containing the conserved catalytic sequence motif 
KKCGH (circled black in Figure 9), corresponding to AA 193-203 in ICL1 and AA 
213-217 in ICL2, were virtually super-imposable. Despite the low level of homology 
between Mtb ICL1 and ICL2, conservation of their tertiary structures and enzymatic 
activities implied the overlapping biological functions of the two ICL isoforms. 
Studies have demonstrated that ICL is required for growth on fatty acid 
substrates, for virulence in mice, and for growth and survival in macrophages
99
. Deletion 
of icl1 or icl2 alone had little effect on bacterial replication in media containing glycerol, 
glucose, or short-chain fatty acids as carbon source. On the other hand, deletion of both 
icl1 and icl2 eliminated growth on fatty acids but again had little effect on growth 
utilizing carbohydrates. Complementing Mtb mutant strain lacking both icl1 and icl2 
with plasmids containing icl1 or icl2 restored growth on fatty acids, confirming that 
these genes encode functionally redundant enzymes that were both required for fatty 
acid metabolism
99
. Further in vivo studies on wild-type mice infected with Mtb strains 
lacking icl1, icl2, or both reflected the outcomes of mutant Mtb strains growing on fatty 
acid. Deletion of icl1 resulted in the reduction of the bacterial population in the lungs 
during the chronic phase but not the acute phase of infection
98
, and deletion of icl2 had 
no distinguishable effect on Mtb growth and persistence. On the contrary, bacteria 
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lacking both icl1 and icl2 were incapable of growth in mice and were quickly eliminated 
from the lung and spleen, which remained negative in culture
99
. Complementation of the 
mutant with an icl1-containing plasmid restored growth and tissue pathology in the lungs 
and spleen. Lastly, deletion of icl1 impaired Mtb survival in murine macrophages with 
activated human immune interferon (INF-) but had little effect on Mtb survival in non-
activated macrophages. Persistence of Mtb lacking icl1 and icl2 was impaired in murine 
macrophages with both activated and non-activated INF-. Complementation of the 
mutant with plasmids containing icl1 or icl2 restored Mtb replication in non-activated 
macrophages and survival in INF--activated macrophages. 
ICL1 has been shown to play a dual role in both the glyoxylate and methylcitrate 
cycles in Mtb. The genome of Mtb encodes orthologues of two of the three enzymes of 
the methylcitrate cycle (Figure 7 on Page 32), methylcitrate synthase (prpC) and 
methylcitrate dehydratase (prpD), but it does not contain 2-methylisocitrate lyase 
(MCL)
108
. -oxidation of odd-chain fatty acids or branched-chain amino acids results in 
the production of propionyl-CoA. High levels of propionate and propionyl-CoA have 
been implicated in toxicity for bacteria and fungi
109,110
. There are two putative pathways 
for propionyl-CoA metabolism in Mtb: the methylmalonyl-CoA pathway and the 
methylcitrate cycle
79
. The methylcitrate cycle is essential for in vitro growth of Mtb 
despite the presence of a functional methylmalonyl-CoA pathway
111
.The methylcitrate 
cycle is also the predominant pathway for clearance of propionyl-CoA during growth on 
propionate for E. coli and Salmonella typhimurium (S. typhimurium)
109
. The 
methylcitrate cycle metabolizes propionyl-CoA to pyruvate, preventing propionate 
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toxicity from the buildup of propionyl-CoA or methylcitrate cycle intermediates such as 
2-methylisocitrate
112
. In addition, the methylcitrate cycle provides an alternative 
pathway for carbon anaplerosis during growth on odd-chain fatty acids. 
 
 
Table 1: ICL and MCL activity of purified recombinant ICL1 and ICL2 from Mtb. 
Reprinted with permission from Reference 108. 
 
Isocitrate 
 
Methylisocitrate 
  Km (mM) kcat (s
-1
)   Km (mM) kcat (s
-1
) 
ICL1 0.19 5.24 
 
0.72 1.25 
ICL2 1.14 1.38 
 
>15 <0.001 
 
 
Mtb ICL1 is the first reported dual-specific enzyme that shows activity with both 
isocitrate and methylisocitrate as substrates, and is able to support growth on acetate and 
propionate
111
.  Table 1
108
 shows that ICL1 has ICL and MCL activities for both 
isocitrate and methylisocitrate as substrates, respectively. The conversion of 
methylisocitrate generates pyruvate and succinate. According to Table 1, kcat/Km of 
ICL1 for methylisocitrate is still within the range of physiological relevance, though it 
was 16 fold lower than that for isocitrate. Moreover, MCLs are highly enantiomer-
specific for the D-methylisocitrate. MCLs from E. coli, A. nidulans
113
, Saccharomyces 
cerevisiae (S. cerevisiae)
114
, and S. typhimurium
115
 have no detectable activity for 
isocitrate, and no MCL activity is detected from E. coli ICL. ICLs from Neurospora 
crassa, Pseudomonas indigofera (P. indigofera), Chlorella vulgaris, A. nidulans, and S. 
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cerevisiae have been reported to have weak MCL activity but cannot support growth on 
propionate
116,117
.  
In addition to enzyme activity experiments, the crystal structure of ICL1 shows 
that the products of methylisocitrate, pyruvate and succinate, both bind in the active site 
of the enzyme
108
. Though the succinate molecule was absent from the active site for two 
of the four subunits, the Mg
2+
 and pyruvate were always present. The bound pyruvate 
was observed in an almost identical conformation as the bound glyoxylate in the 
structure complexed with glyoxylate and 3-nitropropionate (3-NP)
106
. Moreover, the 
structures of ICL1 bound with glyoxylate versus pyruvate show that the active site of 
ICL can accommodate the addition of a methyl group from pyruvate without perturbing 
the overall structure. The hydrophobic pocket among three residues, Trp283, Phe345, 
and Thr347, had sufficient space (~3 Å) for the methyl group of pyruvate to fit. 
Targeting ICL has been a challenge, mainly due to its relatively small and highly 
charged active site that becomes more constricted and solvent inaccessible upon ligand 
binding. ICL active site loop containing residues 185-196 undergoes a large 
conformational change to adopt either an open conformation as in the free enzyme, or a 
closed conformation seen in the ligand bound enzyme
106
. Successful drug discovery 
relies on eliciting active site interactions that induce this closed conformation. 
Established ICL inhibitors comprised pyruvate analogues such as 3-bromopyruvate
118
, or 
succinate analogues such as 3-NP
117
 and itaconate. However, they are limited to 
relatively low potency (IC50 ≥ 3 M) and high non-specificity. Inhibitors 3-
bromopyruvate and 3-NP were previously reported to inhibit M. avium ICL with Ki 
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values of 3 M and 120 M, respectively117. Inhibitor 3-NP, which is toxic to P. 
indigofera, has been shown to be a suicide inactivator of mammalian succinate 
dehydrogenase
119
. 
The first HTS of natural compounds against Mtb ICL was reported by Bai and 
coworkers
120
. They screened 465 traditional Chinese medicines, and two extracts 
Zingiber officinale and Illicium verum were shown to have inhibitory effect with IC50s at 
47.7 and 18.2 g/ml, respectively. Subsequent work was published on a novel lead 
compound I2906 (1-ethyl-4-hydroxy-2-oxo-N’-tridecaboyl-1,2-dihydroquinoline-3-
carbohydrazide) with an IC50 of 134.4 g/ml
121
. Celerythrine extract from the plant 
Chelidonium majus was also reported as a potential inhibitor which causes fivefold 
reduction in gene expression
122
. 
More synthetic ICL inhibitors have been developed, some of which were based 
on the established product analogues. They included pthalazinyl derivatives (45-61% 
inhibition at 10 M)123, pthalazin-4-ylacetamides (41-66% inhibition at 10 M)124, and 
5-nitro-2-furoic acid hydrozones with furan-2-carbaldehyde (87% inhibition at 10 
M)125. Other synthetic compounds such as 5-nitro-2,6-dioxohexahydro-4-
pyrimidinecar-boxamides (46% at 10 M inhibition)126, isatinyl thiosemicarbazones 
derivatives (63% inhibition at 10 M)127, and 3-nitropropionamide derivatives (0.1 M 
IC50)
128
 have also been developed. More novel synthetic compounds were further 
introduced, including DNAzymes, Mannich bases, peptide inhibitors, and pyruvate-
isoniazid analogues. However, many of the synthetic inhibitors suffered from inactivity 
combined with another Mtb inhibitor in vitro, inactivity in vivo, difficulty in drug 
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delivery, or low potency. Table B-1 in Appendix B summarizes potential synthetic ICL 
inhibitors for Mtb in literature. 
Tremendous amount of efforts have been put in for the discovery of ICL 
inhibitors that would lead to potential drug candidates for the TB treatment. They 
included screening thousands of compounds, as well as making new and extending pre-
existing analogues; alas, no new inhibitors have emerged with qualities suitable for 
further drug development. The available crystal structures of Mtb ICL depict an active 
site composed of numerous anionic and hydrophilic residues that surround the binding 
pockets of glyoxylate and succinate. They further suggest that the active site is 
incompatible with non-polar, uncharged compounds in modern screening libraries. 
Therefore a reassessment of strategies to discover inhibitors of ICL provides an 
alternative approach which includes exploitation of the chemical mechanism of this 
enzyme.  
Based on the chemical mechanism of Mtb ICL from both structural data
106,108
 and 
kinetic analysis
117,129,130
, the presence of an active site nucleophile, Cys191, has allowed 
the enzyme to sustain covalent modification. For instance, 3-bromopyruvate has exerted 
time-dependent inactivation of ICL presumably by alkylating the conserved active site 
cysteine. Further crystal structure of ICL treated with 3-bromopyruvate confirmed that 
Cys191 of Mtb ICL was indeed S-pyruvoylated
106
. In this chapter, the chemical 
mechanism of ICL was first revisited by the crystal structure of ICL C191S treated with 
substrate D-isocitrate. Though the mutated C191S ICL did not appear to have ICL 
activity, the crystal structure showed the presence of both products glyoxylate and 
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succinate. The structure of ICL treated with itaconate (2-methylidenebutanedioate or 2-
methylsuccinate) further supported the susceptibility of the active site Cys191 for 
covalent modification. Lastly, a novel mechanism based ICL inactivator, 2-vinyl-D-
isocitrate (2-VIC, or (2S,3R)-3-hydroxypent-4-ene-1,2,3-tricarboxylate) was 
characterized by structural determination. Time-dependent kinetic analysis showed a 
moderate inactivation, and the proposed mechanism followed the formation of 2-vinyl 
glyoxylate which was covalently linked to the active site cysteine after the inactivation 
by 2-VIC. Crystal structure of ICL in complex with 2-vinyl glyoxylate confirmed the 
formation of an S-4-(2-keto-butanoate) (or S-homopyruvoyl) adduct of the active site 
Cys191. This was consistent with the proposed mechanism of inactivation. 
Methods 
Cloning, expression, and purification 
A 1.29 kb DNA fragment containing the icl gene (Rv0467) was amplified by 
polymerase chain reaction (PCR) from Mtb H37Rv genomic DNA as a template, using 
the following oligonucleotides as the forward and reverse primers, respectively:  
5’ – GGG AAT TCC ATA TGT CTG TCG TCG GCA CCC CGA AAG – 3’ 
5’ – CCC CCA AGC TTC TAG TGG AAC TGG CCC TCT TCG – 3’ 
The amplified DNA fragments were digested with restriction endonucleases, NdeI and 
HindIII, and sub-cloned in the corresponding restriction sites in a pET-30b vector to 
yield a full length wild-type (WT) protein free of any epitope tag.  
 ICL with the Cys191 mutated to Ser was cloned by site directed mutagenesis 
method
131
. PCR amplification was done on the wild type recombinant pET-30b-icl 
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plasmid as the DNA template with following oligonucleotides as the forward and reverse 
primers, respectively: 
5’-GCC TCT GAG AAG AAG AGC GGC CAC CTG GGC G-3’ 
5’-CGC CCA GGT GGC CGC TCT TCT TCT CAG AGG C-3’ 
The expression of WT or C191S mutant ICL was carried out in E. coli BL21 
(DE3) cells using a T7 polymerase base system as described
106
. E. coli cells carrying the 
recombinant kanamycin resistant pET-30b-icl (WT or C191S mutant) plasmid were 
grown to mid-log exponential phase at 37 °C in LB plus 50 g/ml kanamycin and 
induced by 0.5 mM isopropyl--D-1-thiogalactopyranoside (IPTG) at an OD600 of 0.6-
0.8 at 18 °C for 16 hours or overnight. The cells were then harvested, pelleted, and 
stored at -20 °C.  
For purification, the harvested cells were re-suspended in the re-suspending 
buffer with 50 mM Tris-HCl, pH 7.5, 1 mM EDTA, 1 mM DTT, with 20 g/ml DNAse, 
50 g/mL phenylmethylsulfonyl fluoride (PMSF), and 20 g benzamidine. The re-
suspended cells were further lysed using a French press under a pressure up to 15,000 
psi. The lysates were centrifuged at 17,000 rpm for 30 minutes to separate the cellular 
debris from the protein. The supernatant of the lysates containing the soluble protein was 
passed through a 0.5 m filter and subjected to two ammonium sulfate precipitations at 
40% and 80% (w/v), followed by overnight dialysis of the re-suspended pellet from the 
80% ammonium sulfate precipitation in the re-suspending buffer at 4 °C. ICL was then 
purified to apparent homogeneity by successive chromatographic steps first by anion-
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exchange using 2 times 5ml commercial HiTrap Q FF column, followed by gel filtration 
using commercial Superdex 200 HiLoad 16/600 column. Eluting fractions with the 
highest UV absorbance were finally pooled and concentrated using a spin dialysis 
column with a molecular weight cutoff of 100 kDa (EMD Millipore). Aliquots of WT or 
C191S mutant ICL1 at 10-14 mg/ml were flash frozen with liquid nitrogen (N2) and 
stored at -80
 °C in 25 mM Tris-HCl, pH 7.5, 0.5 mM EDTA, 50 mm NaCl, and 0.5 mM 
DTT. The WT or mutant enzyme was determined to be ~95% pure as observed from 
SDS-PAGE. 
Crystallization, data collection, and data analysis 
 For the ICL-isocitrate co-crystallization, 10 mg/ml of ICL C191S mutant was 
first incubated with 10mM D-isocitrate at 17 
o
C overnight prior to setting up crystal 
drops. Orthorhombic crystals (P212121) were produced by hanging drop with 1:1 volume 
ratio of enzyme and mother liquor solution containing 0.1 M Tris-HCl, pH 8.0, 0.2 M 
sodium acetate, 20-30% w/v PEG4000. Crystals were observed after 1-2 weeks by vapor 
diffusion against 500 l mother liquor in a closed reservoir at17 oC.  
Orthorhombic crystals of space group P212121 were obtained by treating the ICL 
WT enzyme with itaconate and 2-VIC. For the ICL-itaconate complex, 10 mM itaconate 
was added to 10 mg/ml ICL1 WT right before setting up crystals. For the ICL-2-VIC 
complex, 10 mg/ml of ICL WT was first incubated with 2-3 mM 2-VIC overnight at 17 
o
C prior to the set-up of crystallization samples. Crystals were produced by vapor 
diffusion method with mother liquor solution containing 0.1 M Tris-HCl, pH 8.0, 0.2 M 
sodium acetate, 20-30% w/v PEG4000. A mixture with 1:1 volume ratio of enzyme and 
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mother liquor was equilibrated within the hanging drop against 500 l mother liquor 
inside a sealed reservoir. Crystals appeared after 2-3 weeks of setting the drops at 17 
o
C.   
Prior to data collection crystals were cryo-protected by fresh mother liquor and 
flash frozen in liquid N2. High resolution diffraction data for ICL-2-VIC crystal and ICL 
C191S-isocitrate were collected at beamline 19ID, the Structural Biology Center (SBC) 
of the Advanced Photon Source (APS synchrotron), Argonne National Laboratory 
(Chicago, IL). Moderate resolution data for ICL-itaconate were collected using R-Axis 
IV++ (Rigaku) X-ray source with rotating anode. All crystals were maintained chilled in 
a stream of liquid N2 at 100-120K throughout data collection. Data were processed using 
the HKL2000
132
 package for ICL-itaconate or HKL3000
133
 package for ICL-2-VIC and 
ICL C191S-isocitrate. Diffraction amplitudes were indexed and integrated using 
DENZO, and scaled using SCALEPACK. The data were further merged and truncated in 
Collaborative Computational Project, Number 4 (CCP4)
134
. The structures of the ICL1-
adduct complex obtained from treatment of ICL WT with itaconate and 2-VIC were 
solved by rigid body followed by restrained refinement using the program REFMAC 
under CCP4 program package. The published structure of the ICL-3-bromopyruvate was 
used as a starting model (PDB ID 1F8M)
106
 for the ICL-itaconate and ICL-2-VIC data 
with all the non-protein atoms excluded. The structure of ICL1-glyoxylate-3NP was 
used as a starting model (PDB ID 1F61)
106
 for the ICL C191S-isocitrate data with 
exclusion of all the non-protein atoms. The ligand models and dictionary files were 
generated using ELBOW from the PHENIX suite
135
 and fitted into electron densities in 
COOT
136
. The final ligand bound models were gradually improved by repeating the 
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process of inspection and manual modification in COOT and refinement in PHENIX 
with simulated annealing.  
The final models of ICL-itaconate, ICL-2-VIC, and ICL C191S-isocitrate 
contained four molecules per asymmetric unit with 428 residues each. The four 
monomers were equivalent, and each contains one magnesium ion and a covalent moiety 
apparently linked to the sulfur atom of residue Cys191 for ICL-itaconate and ICL-2-
VIC. The final refined structures have 97.5%, 97.2%, and 97.9% of the residues in the 
most favored region of the Ramachandran plot for ICL C191S-isocitrate, ICL-itaconate, 
and ICL-2-VIC, respectively. Table B-2 summarizes crystallographic data and 
refinement statistics. Unless otherwise denoted, all figures showing crystal structures are 
rendered in CHIMERA
137
. 
Enzyme activity assay 
All enzyme activity assays were carried out in the forward ICL reaction. An 
enzyme coupled assay was used for the inhibition of itaconate. In the direction of 
isocitrate lysis, product glyoxylate was converted to glycolate by D-lactic dehydrogenase 
from Lactobacillus leichmanii, with the concomitant oxidation of NADH (340 nm = 6,220 
M
-1
cm
-1
). The loss of NADH was monitored spectrophotometrically at 340 nm using a 
96-well microplate reader (POLARstar Omega, BMG Labtech). Reactions were initiated 
by the addition of 2 mM D,L-isocitrate into assay mixtures with 1 M ICL, 2.5 M D-
lactic dehydrogenase, and 0.8 mM NADH in a buffer containing 50 mM MOPS, pH 6.8, 
5 mM MgCl2, and 1 mM DTT. Itaconate in 100% DMSO was serially diluted to half 
concentration and added to the reaction mixture in final condition at 2% DMSO. 
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 A chemical coupled assay was used to determine the activity of ICL C191S 
mutant and for the inactivation study of 2-VIC. Product glyoxylate was reacted with 
phenylhydrazine-HCl to form a phenylhydrazone product (324 nm = 17,000 M
-1
cm
-1
), 
which was measured spectrophotometrically at 324 nm using a 96-well microplate 
reader (POLARstar Omega, BMG Labtech or Synergy, Biotek). For UV absorbance 
readouts using POLARstar Omega for determining the C191S mutant activity, reactions 
were initiated by the addition of 0.5 mM of D,L-isocitrate into assay mixtures with 1 M 
ICL C191S and 10 mM phenylhydrazine in a buffer containing 50 mM phosphate, pH 
7.5, 10 mM MgCl2, and or 12 mM cysteine. For UV absorbance readouts using Synergy 
for the inactivation studies of 2-VIC, reactions were initiated by the addition of 20 nM 
ICL into assay mixtures containing 0.01-1 mM D,L-isocitrate and 10 mM 
phenylhydrazine in an enzyme buffer containing 50 mM HEPES, pH 7.5, 5 mM MgSO4, 
with or without 1 mM DTT. 2-VIC was dissolved in deionized water and further dilution 
was done using either deionized water or enzyme buffer. 
Mycobacteria whole-cell assay 
For the Mtb mc
2
 7000 strain
138
, cells were grown in 7H9 media supplemented 
with OADC, 0.05% Tyloxapol, and 25 g/ml pantothenate to an optical density at 600 
nm (OD600) of 1-1.5. Cells were washed and diluted into testing media to an OD600 of 
0.01; 196 l of the diluted cells was pipeted into each well of sterile 96-well plate. Two 
testing media were used: 7H9 media with 0.4% dextrose, 0.085% NaCl, 0.05% 
Tyloxapol, and 25 g/ml pantothenate; and M9 media with 0.25% sodium acetate, pH 
7.5, 2 mM MgSO4, 0.1 mM CaCl2, 0.05% Tyloxapol, and 25 g/ml pantothenate. Each 
 50 
 
compound was dissolved and diluted in 100% DMSO in 1 half serial dilution, and each 
dilution series was added to each cell-containing well with a final concentration of 
DMSO at 2%. The plates containing 7H9 were incubated for 6 days, while the ones with 
M9 were incubated for 3 weeks before staining with alamar blue (resazurin). All plates 
were incubated at 37 °C with shaking for an additional two days after staining. The 
lowest concentration where resazurin stayed completely unconverted was recorded as 
the MIC99 value. Rifampicin was used as a positive control with MIC99 of 0.125 M 
displayed in 7H9 media supplemented with dextrose and 0.25 M in M9 media 
supplemented with acetate. 
Results and discussion 
Enzyme activity of ICL C191S 
 There was no detectable activity of ICL C191S at 1 M enzyme concentration 
for isocitrate using the phenylhydrazine coupled assay in the forward direction. A similar 
work was done by Gould and coworkers where the C191S mutant was tested for activity 
with both isocitrate and methylisocitrate as substrates
108
. Though they could not detect 
any significant activity using spectrophotometric assay, the presence of the products 
were confirmed by mass spectrometry in the crystal of ICL1 C191S treated with 
substrates. 
Inhibitory activities of itaconate and 2-vinyl isocitrate 
IC50 of itaconate was determined to be 10 M using D-lactic dehydrogenase 
coupled activity assay, compared to Ki = 8.5 M in H2O from the solvent KIEs 
studies
128
. Analysis of the time-dependent inactivation of 2-VIC resulted in the 
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concentration of inactivator leading to half-maximal inactivation Kinact = 22 ± 4 M 
(Murkin et al., manuscript in preparation). To improve whole cell activity, a prodrug 
strategy was adopted by masking the carboxylic acids via esterification as a way to 
enhance cellular uptake
139
. Itaconate and its prodrug form dimethyl itaconate (dimethyl 
2-methylenesuccinate), as well as 2-VIC (no prodrug available), did not have any 
inhibitory activity against mc
2
 7000 Mtb whole cells in either 7H9 supplemented with 
dextrose or M9 supplemented with acetate. Itaconate, dimethyl itaconate, and 2-VIC are 
not very drug-like, therefore they most likely do not penetrate the Mtb cell wall which 
has high lipid content.  
Overall structure of ICL 
 The overall fold of ICL in the complex structures of ICL-itaconate, ICL-2-VIC, 
and ICL C191S-isocitrate was similar to the structures previously determined
106
. ICL1 
was a tetramer (81 Å × 86 Å × 92 Å) with 222 symmetry as indicated in Figure 11A, 
and each subunit was composed of 14 -helices and 14 -strands. Eight -helices (4-
11) and eight -strands (2-5, 8, 12-14) formed a unique / barrel with 
()2()5 topology and represented the largest domain and the core of the overall 
structure, as shown in Figure 11B. A small -domain contained several active site 
residues and consisted of a short five-stranded -sheet (6, 7, 9-11) that lied on top of 
the / barrel. A long insertion in this -sheet starting around Glu247 with 100-160 
amino acids in length was conserved among many ICL enzymes including bacteria E. 
coli and plant Ricinus communis
140
. 
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Helix swapping described by Sharma et al. was also observed in the crystal 
structures of ICL-itaconate and ICL-2-VIC and from ICL C191S-isocitrate. An extra -
helix (12) projected out from the / barrel of each subunit with another two ensuing 
-helices (13, 14), and together they formed interactions with the neighboring 
subunits. The two non-crystallographically related subunits were interlinked by the 
exchange of the C-terminal regions, which contained 12 and 13. The interface 
between the two subunits involved in the helix swapping buried ~18% of the accessible 
surface of each subunit. The twisting of the polypeptide chains in ICL suggested the 
formation of the two subunit complex was concomitant with the overall protein 
folding
141
. The subunit pairs involved in the helix swapping were identified as A and B 
chains, as well as C and D chains, inside the crystallographic unit cell of ICL structure. 
Comparison of the crystal structures of the apo and ligand bound forms of ICL1 
showed significant differences in conformation in the two regions that controlled the 
access to the active site. The first region was the active site loop with residues 185-196 
that contained the signature sequence motif (K189KCGH193), and the second region 
consisted of the last 18 residues 411-428 at the C-terminal end of the adjacent unit (C-
terminal loop). The open active site conformation has been observed in apo enzyme 
structure with Cys191 far from other residues and the active site was highly solvent 
accessible. Upon binding of a ligand, the loop swung 10-15 Å measured at C of His193 
side chain to adopt a closed conformation. Contrary to the open conformation of the free 
or apo enzyme, access to the active site in the closed conformation upon ligand binding 
was completely blocked by the active site loop. Closure of the active site loop invoked a 
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movement of the C-terminal loop of the adjacent subunit. Electron density became clear 
for all but residue 428 of the C-terminal loop in the ligand bound enzyme crystal, 
whereas in the apo enzyme crystal the last 11 residues were disordered and extended into 
the solvent region. When the active site loop closed, the C-terminal loop of the adjacent 
subunit occupied the space created by the closing of the active site loop. 
 
 
 
 
Figure 11: The crystal structure of ICL. A) Ribbon representation of the ICL 
homotetramer. B) The ()2()5 topology for each subunit. 
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Figure 12: A superimposition of subunits A and C from the structure of ICL1 C191S 
bound with pyruvate and succinate, and the apo ICL1 structure (PDB ID 1F61). The 
closed conformation of subunit A is in cornflower blue, while the open conformations of 
subunit C and apo ICL1 are in blue and red, respectively. The pyruvate, succinate and 
Mg
2+
 are depicted in the active site for clarity. Reprinted with permission from 
Reference 108. 
 
 
Crystal structure of isocitrate treated ICL C191S and the proposed mechanism 
The crystal structure of ICL C191S-glyoxylate-succinate was solved at 2.6 Å and 
shared many similarities with the crystal structure of ICL1 C191S-pyruvate-succinate. 
Products of the ICL reaction, glyoxylate and succinate, along with Mg
2+
 ion bound in the 
active site of subunits A and B were clearly observed from the co-crystallization of ICL 
C191S and D-isocitrate. Gould et al. also observed products of methylisocitrate, 
pyruvate and succinate, in two of the four subunits from their ICL C191S crystal 
structure with methylisocitrate
108
. On the other hand, only glyoxylate and Mg
2+
 were 
present, and succinate was either released from the active site or highly disordered in the 
other two subunits C and D. In addition, the active site loop with residues 185-196 was 
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very disordered and its conformation was closer to the open form of the apo enzyme in 
subunits C and D, whereas in subunits A and B, the loop was in closed conformation 
with clear density. The various conformations of the active site loops of the four subunits 
are superimposed in Figure 12
108
. The bound glyoxylate and succinate were found in the 
almost identical conformation as reported for the structure of ICL-glyoxylate-3-NP 
(PDB ID 1F8I)
106
, which was used as the starting model for refinement. Figure 13A 
depicts clear electron density observed in the 2Fo-Fc map contoured at the 1 level, from 
which glyoxylate and pyruvate are built into two of the subunits, A and B. Glyoxylate 
was bound in the active site by coordinating Mg
2+
 ion with its carboxylate and aldehyde 
oxygens (1.8-2.0 Å and 2.0-2.4 Å, respectively). The Mg
2+
 ion was also coordinated by 
three water molecules and one of the carboxylate oxygens of Asp153 side chain (2.0-2.3 
Å) in the octahedral geometry, as shown in Figure 13B. Succinate was bound ~4 Å 
away from glyoxylate, measured from the succinate C01/3 to the glyoxylate C01/4. One 
of its carboxylate group interacts with Thr347, Asn313, Ser315, Ser317, His193  and one 
water molecule via H-bonds (2.5-3.1 Å ), while the second carboxylate group interacts 
with Arg228, Gly192, Glu285, and one water molecule via H-bonds (2.5-3.2 Å). Lastly, 
the C-terminal loop with residues 411-427 were disordered in subunits B, C, and D, and 
clear electron density for this loop was only observed in subunit A. Sharma et al. 
reported that the closure of the active site loop invokes a movement of the C-terminal 
loop of the adjacent unit for the apo enzyme
106
, corresponding to what was observed for 
subunit B. In the resulting orientation with closed active site loop, the C-terminus lies on 
top of the active site, locking it into the catalytic conformation. 
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Figure 13: Active site of ICL with glyoxylate (black) and succinate (dim gray) bound. 
A) A 2Fo-Fc electron density map contoured at 1. B) Active site residues interact with 
glyoxylate and pyruvate via H-bonds. None-carbon atom colors: chartreuse, magnesium; 
red, oxygen; blue, nitrogen.  
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ICL catalyzes the reversible C-C bond cleavage of isocitrate to form glyoxylate 
and succinate with the general reaction shown in Figure 6. Sharma et al. has proposed a 
chemical mechanism for the ICL catalysis in the reverse direction, which was later 
confirmed by the studies using solvent kinetic isotope effects (KIEs)
129,130
. Isocitrate 
synthesis of ICL proceeds via the ordered bi-bi mechanism in which glyoxylate binds 
first to the free enzyme followed by the binding of succinate to form a ternary 
complex
106
. Glyoxylate binds by coordinating Mg
2+
; the negative charge on the aldehyde 
oxygen is stabilized by an oxyanion hole formed by the Mg
2+
, Arg228, and His180. The 
location of Cys191 and the ability of its thiol to alkylate 3-bromopyruvate suggest that it 
acts as a base for the nucleophilic abstraction of the -proton from the C2 position of the 
succinate
106
. Prior to the attack, Cys191 is first deprotonated by a neighboring histidine 
residue (His193), though the distance for the direct proton exchange hints at another 
residue. Applying the logic for the forward reaction, Cys191 acts as an acid to protonate 
the aci-acid form of succinate (4,4-dioxidobut-3-enoate) after the C2-C3 bond cleavage 
of isocitrate. For the crystallization of ICL pre-incubated with substrate D-isocitrate, 
Cys191 was mutated to a serine in hopes of preventing the protonation of the aci-acid 
and capturing the substrate in the active site. However, products glyoxylate and pyruvate 
were observed in the active site in the crystal structure, which suggests that under the 
crystallographic condition serine is able to carry out the nucleophilic attack in the 
reverse reaction, albeit at a much slower rate. Another explanation would be that the aci-
acid was protonated by other means than an active site nucleophile. 
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Figure 14: Proposed chemical mechanism for ICL catalysis. 
 
 
The chemical mechanism based on the product bound ICL C191S crystal 
structure is proposed in Figure 14. The substrate D-isocitrate coordinates a divalent, 
active site Mg
2+
 ion required for activity. For ICL reaction in the forward direction, an 
active site base, presumably His180 or Tyr89, catalyzes the retro-aldo cleavage by 
abstracting a proton from the C2 hydroxyl of isocitrate. This results in glyoxylate and the 
aci-acid, 4,4-dioxidobut-3-enoate. In the subsequent step, Cys191 as the active site acid 
protonates aci-acid to further generate succinate. Succinate is released first from the 
active site, as glyoxylate is buried deeper, which is confirmed by the crystal structure of 
C191S-glyoxylate-succinate. The true identity of the active site base still requires the 
structure of ICL-isocitrate complex and further mutagenesis studies. 
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Figure 15: Active site of ICL with covalently modified C191 with S-methylsuccinate. 
A) A 2Fo-Fc electron density map contoured at 1. B) Active site residues interact with 
S-methylsuccinylated C191 via H-bonds. None-carbon atom colors: chartreuse, 
magnesium; red, oxygen; blue, nitrogen; yellow, sulfur.  
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Crystal structure of itaconate treated ICL and the inhibitory mechanism 
 The complex structure of ICL1 treated with itaconate was solved at 2.6 Å using 
the crystal structure of ICL1-3-bromopyruvate (PDB ID 1F8M) as the starting model for 
refinement. The final refined structure showed that all four monomers were equivalent; 
each one had a Mg
2+
 ion in the active site with clear electron density. In addition, 
Cys191 appeared to be covalently linked to a 2-methylsuccinate moiety for all subunits 
with 2Fo-Fc electron density map contoured at 1 . The covalent bonds (1.7-1.78 Å) 
between cysteine and 2-methylsuccinate moieties were well within the C-S bond length 
(1.73-1.89 Å). Figure 15 shows the active site of ICL1 Cys191 covalently modified with 
2-methylsuccinate. 
The 2-methylsuccinate moiety bound in the active site by coordinating Mg
2+
 ion 
with one of its C4 carboxylate oxygens (2.1-2.5 Å), as shown in Figure 15B. 
Interestingly Mg
2+
 ion in each subunit was coordinated in a distorted pyramidal 
geometry by Asp153, three water molecules, and one carboxylate oxygen from 2-
methylsuccinate (2.1-2.5 Å). The C1 carboxylate oxygens interacted with side chains of 
residues His193, Asn313, Ser315, Ser317, and Thr347 via H-bonds (2.3-3.5 Å). In 
addition to coordinating Mg
2+
 ion, the C4 carboxylate group participated in H-bond 
interactions with the side chain of Arg228, the backbone nitrogen of Gly182, and two 
water molecules (2.3-3.5 Å). The active site loop containing residues 185-196 with ICL 
signature catalytic motif (KKCGH) assumed the closed conformation, as seen previously 
in the complexed crystal structures of ICL treated with 3-bromopyruvate and 3-NP. 
Concurrently, the C-terminal loop of the adjacent unit moved in to the top of the active 
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site loop and further locked in the catalytic conformation, resulting in the active site 
becoming inaccessible. Figure 16 depicts a superimposition of the apo structure and the 
complexed structure of ICL following the treatment with itaconate. The active site loop 
underwent the closed conformational movement from apo structure to complexed 
structure of 15 Å measuring at C of the His193 side chain. The movement of the active 
site loop further created a space for the C-terminus of the adjacent subunit to move in, 
and once occupied, the once-disordered C-terminal region became ordered. The H-bond 
formed between C1 carboxylate of itaconate and His193 is crucial in stabilizing the 
closed loop active site conformation. 
 
 
 
Figure 16: A superimposition of structures of ICL treated with itaconate and apo 
enzyme with the closed conformation of the active site loop and ordered C-terminal loop 
of the adjacent subunit observed in itaconate bound structure (orchid), while the open 
conformation and disordered C-terminal loop observed in apo structure (green). 
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Figure 17: Proposed chemical mechanism for the inactivation of ICL1 by itaconate. 
 
 
Figure 17 describes the proposed inhibitory mechanism for the inactivation of 
ICL by itaconate. Itaconate first bound in the active site by coordinating Mg
2+
 ion with 
one of its carboxylate oxygens in a pyramidal geometry. Active site nucleophile Cys191 
attacked the vinyl group of the itaconate, which resulted in the Michael addition of the 
thiolate and 2-methylsuccinate to form the S-methylsuccinyl adduct. The deprotonation 
of Cys191 prior to the nucleophilic attack was proposed to be carried out by an active 
site base. Sharma et al. has previously proposed His193 based on the mutagenesis 
studies on E. coli ICL
106
. However, His193 and Cys191 are located ~5 Å apart, 
suggesting that direct proton exchange may not occur between them. Asp108 could also  
 63 
 
 
Figure 18: Crystal structure of ICL treated with 2-VIC. A) A 2Fo-Fc electron density 
map contoured to 1 of the active site residues interacting with S-homopyruvoylated 
Cys191. The bound Mg
2+
 ion with coordinating Asp153 and coordinating water 
molecules are also shown. B) Active site residue Cys191 modified with 2-VIC, with 
dotted lines indicating the interactions of the homopyruvoyl group with neighboring 
residues via H-bonds. 
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Figure 18: Continued. C) Superimposition of active site structures of ICL following  
treatment with 3-bromopyruvate (purple), which binds in the succinate sub-site, or 2-
VIC (white) along with interacting active site residues, the Mg
2+
 
 
ion and water 
molecules. D) Superimposition of active site structures of ICL including Cys/Ser191 
treated with 2-VIC (S-homopyruvoylated, white) and 3-NP (dark green) and interacting 
active site residues, Mg
2+
 ion, and water molecules. Dotted lines indicate the interactions 
of the covalent adducts and bound ligands with neighboring residues via H-bonds. 
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be a general base, but the distance between Asp108 and Cys191 was still ~4 Å. Further 
mutagenesis studies on the correct general base are required.  
Crystal structure of 2-VIC treated ICL and the inhibitory mechanism 
Clear electron density was observed after the final refinement in the 2Fo-Fc 
electron density map contoured at the 1, from which an S-homopyruvoyl moiety was 
observed and bound to the active site residue Cys191, as shown as Figure 18A. The 
active site Mg
2+
 ion is coordinated by Asp153 and five water molecules (2.1-2.6 Å), and 
interestingly, the homopyruvoyl adduct did not participate in the coordination of the 
divalent Mg
2+
 ion, as would be expected since the -hydroxyl carboxylate substituent of 
the parent 2-VIC presumably binds to this Mg
2+
 ion in order to undergo retro-aldol 
cleavage to form 2-vinyl-glyoxylate. Instead the product homopyruvoyl group, as 
covalently attached to the sulfur of Cys191, interacted with residues Trp93, His193, 
Asn313, Ser315, Ser317, and Thr347 via the formation of H-bonds. The position of 
Trp93 in this structure appeared to prevent the re-coordination of the tethered 
homopyruvoyl group to the Mg
2+
 ion. The carbonyl group of the homopyruvoyl group 
formed a H-bond with the side chain of Trp93 (dO-N = 2.5 Å). One of the carboxylate 
oxygens of the homopyruvoyl group formed H-bonds with His193 and Ser315 (2.5 Å 
and 3.0 Å bonding distances, respectively), while the other carboxylate oxygen formed 
H-bonds with Asn313, Ser317, and Thr347, (3.3 Å, 2.6 Å, and 2.9 Å bonding distances, 
respectively), as shown in Figure 18B. 
The homopyruvoyl group attached to Cys191 in ICL assumed a conformation 
which was very similar to that of the S-pyruvoylated form of ICL following the 
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alkylation with 3-bromopyruvate
106
. Comparison of the structures of the covalent S-
pyruvoylated and S-homopyruvoylated forms of ICL demonstrated interactions with the 
same five residues: His193, Asn313, Ser315, Ser317, and Thr347 (Figure 18C). As with 
the S-pyruvoylated ICL, comparison of the structures of the inactivator-bound forms of 
ICL showed large conformational changes proximal to the active site
106
. The most 
significant conformational change involved movement of the active site loop (residues 
185-196) which contained the sequence motif (K189KCGH193) bearing the active site 
Cys191. In ICL which has been inactivated either by the affinity labeled 3-
bromopyruvate or 2-VIC, this loop moved by 10-15 Å measured at C of the His193 
side chain to adopt the closed conformation. Unlike the open conformation of the apo 
enzyme, the movement of this loop completely retarded apparent solvent access to the 
active site. This likely provided adequate sequestration of 2-VIC to not only facilitate the 
catalytic formation of 2-vinyl glyoxylate (lyase product of 2-VIC), but also to allow 
sufficient freedom from interaction with solvent for its migration to and reaction with 
Cys191 in an identical manner to that of 3-bromopyruvate. Stability of the closed 
conformation of this loop was achieved by H-bonds formed between the carboxylic 
groups of either 3-bromopyruvate or 2-VIC and the N of His193 side chain.  
In the structure of ICL C191S treated with 3-NP (PDB ID 1F8I), the bound 3-NP 
is structurally indistinguishable from succinate. Together with the enzyme-bound 
glyoxylate coordinating to the Mg
2+
 ion, the ICL-glyoxylate-3-NP structure closely 
resembles the ternary enzyme complex of enzyme-glyoxylate-succinate. When overlaid 
the 3-NP complexed ICL structure (dark green) with the homopyruvoylated-ICL 
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structure (white) as shown in Figure 18D, the S-homopyruvoyl moiety appears to bind 
preferentially in the same binding pocket as the product succinate. Succinate binds by 
interacting with His193, Asn313, Ser315, Ser317, and Thr347 via H-bonds, identical to 
the S-homopyruvate. Interactions with these ionic residues likewise stabilize the binding 
of S-homopyruvoyl group as opposed to residues such as Arg and Tyr surrounding the 
glyoxylate binding pocket. This superimposition of the binding site of the covalent 
homopyruvoyl group with succinate binding site suggests that the succinate formed from 
2-VIC must dissociate from ICL in order to facilitate chemical reaction of 2-vinyl 
glyoxylate with Cys191.  
 A proposed chemical mechanism for the inactivation of ICL by 2-VIC is 
depicted in Figure 19. Inactivator 2-VIC binds to ICL in the same manner as the 
substrate, D-isocitrate, with identical coordination to the active site Mg
2+
 ion.  Base-
catalyzed aldo cleavage of the C2-C3 bond produces the metal-bound 2-vinyl glyoxylate 
(2-oxobut-3-enoate) and the aci-acid form of succinate. Cys191 is then deprotonated to 
form succinate, as in the lyase mechanism, followed by the Michael addition of the 
resulting Cys191 thiolate onto 2-vinyl glyoxylate to form the S-homopyruvoyl adduct. 
Structurally, upon the binding of 2-VIC, the active site loop moves from open to closed 
conformation to lock in the enzyme’s catalytic conformation. Once the reaction turns 
over, the active site opens to allow product succinate to dissociate, and the S-
homopyruvoyl adduct slides to the succinate binding pocket from the glyoxylate binding 
pocket to initiate the re-closing of the active site loop by making H-bond interactions 
with residues lining the succinate binding site. 
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Figure 19: Proposed chemical mechanism for the inactivation of ICL by (2R,3S)-2-vinyl 
isocitrate. 
 
 
Conclusion 
 The crystal structure of Mtb ICL C191S in complex with substrate D-isocitrate 
was determined by X-ray crystallography at 1.8 Å resolution. The C191S mutated 
enzyme was originally constructed with the design to capture isocitrate in the active site. 
As expected, it did not show any detectable activity for isocitrate using the 
phenylhydrazine-coupled activity assay. However the crystal structure of ICL C191S 
treated with isocitrate showed that the product of isocitrate, glyoxylate and succinate, 
bind in the active site. Not all four subunits are equivalent in the crystal structure. Clear 
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density of succinate is only observed in two subunits, whereas succinate was either 
absent or already dissociated from the active site in the other two. The enzyme assumed 
closed active site loop conformation in the two subunits in which succinate was bound 
and open active site loop conformation in the other two subunits in the absence of 
succinate. The result from crystal structure suggested that isocitrate could bind to the 
enzyme in the presence of serine, and that serine in the Cys191 position could carry out 
the reaction of ICL, albeit at a significantly slower rate. 
 Previously determined crystal structure of ICL1 complexed with inhibitor 3-
bromopyruvate has demonstrated the ability of the active site nucleophile Cys191 to 
withstand covalent modification for the basis of inactivation. The crystal structures of 
Mtb ICL1 in complexes with inactivators itaconate and 2-vinyl isocitrate were further 
determined by X-ray crystallography at 2.6 and 1.8 Å resolution, respectively. In both 
structures, the active site Cys191 was covalently modified to S-methylsuccinyl and S-
homopyruvoyl adducts following the inactivations by itaconate and 2-VIC, respectively. 
Unlike the structure of ICL1 C191S treated with substrate isocitrate, the four monomers 
were equivalent with clear density of thiolate-adduct formed from the inactivation in the 
active site. All subunits had the closed active site loop conformation with clear electron 
density, and as a result, the C-terminal loop of the adjacent subunit moved in on top of 
the closed active site loop to render the active site solvent inaccessible. The inactivation 
of 2-VIC was based on the mechanism of the ICL reaction, and the structure of ICL 
treated with the inactivator showing the S-homopyruvoyl adduct covalently linked to the 
active site Cys191, confirming the proposed inhibitory mechanism. 
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Future work 
 Much of the chemical mechanism of ICL catalysis still remains unclear. For the 
forward reaction, an active site base is proposed to abstract the hydroxyl proton at the C2 
position of substrate isocitrate for the aldo cleavage of the C2-C3 bond, and its identity 
remains unknown. Unpublished mutagenesis studies on the active site residues Tyr89 
and His193 have generated inconclusive results. Immediate future work includes the 
identification of the active base, and currently the work has allowed the crystallization of 
ICL WT in the presence of Ca instead of Mg metal as required for activity. This is based 
on the hypothesis that a water molecule, possibly one that coordinates Mg
2+
 ion, instead 
of an active site general base, is carrying out the proton abstraction. 
 Another future study on ICL is to determine the base that deprotonates the 
Cys191 to allow for the nucleophilic attack in the reverse ICL reaction and in the 
mechanism of itaconate inactivation. Sharma et al. has previously purposed that His193 
was likely the base, but the direct proton transfer did not seem possible due to the 
distance between the two residues
106
. Another residue Asp108 was also likely to 
deprotonate Cys191; though the distance was still out of range for direct proton transfer, 
one water molecule between the two residues could serve to relay the proton between 
them. Future mutagenesis studies and crystal structures are needed for this 
determination. 
 Very little has been published on ICL2. Studies have underlined the importance 
of ICL2 showing that a mutant strain of Mtb with deletion of both ICL1 and ICL2 could 
not establish an infection in a murine model, and bacteria were rapidly cleared from the 
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lungs of the infected mice. The enzyme activity on ICL2 from Gould et al. has shown 
that isocitrate reaction for ICL2 is approximately four times slower than that for ICL1 
and methylisocitrate reaction for ICL2 is out of physiological range (citation). 
Immediate future work on ICL2 entails the structure determination. Currently 
crystallization on ICL2 with C-terminal truncation of domain IV with AA 1-581 using 
secondary structure prediction by ICL structure from fungus A. nidulans is underway. 
The truncated ICL2 appeared to be stable without proteolysis during protein purification, 
and enough purified protein has been successfully generated for crystallization trials. 
  
 72 
 
CHAPTER III  
CRYSTAL STRUCTURES OF FRAGMENT BOUND MALATE SYNTHASE 
REVEAL NEW SCAFFOLDS FOR INHIBITOR DESIGNS 
 
Background and introduction  
 Shortly after the discovery of isocitrate lyase by Smith and Gunsalus
100
, Ajl 
showed that malate synthase is able to convert acetyl coenzyme A (acetyl-CoA or 
AcCoA) and glyoxylate to malate and coenzyme A (CoA)  in E. coli
142
. Malate synthase 
(GlcB) is the second enzyme of the glyoxylate shunt, an anaplerotic bypass of the TCA 
cycle utilized by Mtb extensively when it switches carbon source from carbohydrates to 
fatty acids during persistent infection. The shunt bypasses two CO2-generating steps of 
the TCA cycle to allow the incorporation of C2 substrates for the replenishment of 
oxaloacetate under carbon limiting conditions
89
. 
A single malate synthase gene glcB has been identified in Mtb to encode malate 
synthase G (MSG or GlcB). GlcB is an 80-kDa monomeric protein with 741 amino acid 
residues and shares ~60% identity with homologues malate synthase (aceB) from Gram-
positive Corynebacterium glutamicum (C. glutamicum)
143
 and MSG from Gram-
negative E. coli
144
. A second isoform of malate synthase, malate synthase A (MSA) has 
been identified
145
. Typically MSAs have a molecular mass of ~60 kDa including MSA 
from E. coli
146
, Yersinia pestis (Y. pestis)
147
, Vibrio cholera
148
, yeast, and higher plants. 
The prokaryotic MSAs are mostly monomeric while eukaryotic MSAs tend to be 
homomultimers. High sequence identity, ~ 65%, is shared among the MSA isoforms, 
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whereas the similarity between the MSA and MSG isoforms is much lower at 18-20%, 
with E. coli MSA and MSG sharing an 18% identity. Sequence alignments of G 
isoforms from Mtb, Mycobacterium leprae, E. coli, and C. glutamicum, and A isoforms 
from Y. pestis and E. coli show 47 conserved residues among them
149
 with a majority of 
the conserved residues playing a crucial role in the active site and catalysis. 
 The dependence on the glyoxylate shunt for intracellular survival and persistent 
infection of Mtb
98,99
 and the absence of the pathway in placental mammals
92
 have led to 
interest in drug development using the glyoxylate shunt enzymes as potential drug 
targets. Contrary to ICL from the previous chapter, the active site of GlcB has a more 
druggable profile. Crystal structures of both glyoxylate bound and product bound GlcB 
show that the overall protein structure and the active site in particular do not change 
between these two states
149
. Structure-guided inhibitor design was successfully used to 
develop an initial phenyl-diketo acid hit into a series of potent inhibitors of GlcB, which 
has allowed chemical validation of GlcB as a target in a mouse model infected with 
Mtb
139
. The original compound (Z)-2-hydroxy-4-oxo-4-phenylbut-2-enoic acid (PDKA) 
and the bromo substituted lead compound (2-Br-PDKA) exhibited satisfying enzyme 
inhibition with IC50s of 2 and 0.6 M, respectively. The entire PDKA series was further 
shown to have efficacy in an infected murine model with nearly 100-fold reduction in 
bacterial load. Nevertheless the PDKA chemotype suffered from limitations including 
instability, potential reactivity, and high plasma protein binding. The next step thereby 
calls for the search of novel chemical scaffolds for GlcB enzyme inhibition. 
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 Traditionally, drug development entails identifying hits and leads of drug-like 
compounds from HTS and combinatorial chemistry. More recently, attention has led to a 
different approach in which leads are generated from screening libraries of molecules 
that are much smaller and simpler than the conventional drug-like compounds. This is 
often referred to as fragment-based drug discovery. The earliest concept of using 
fragments can be traced to Jencks’s publication on the attribution and additivity of 
binding energies
150
. He proposed that the summation of individual binding energies 
between the fragments to the target led to a higher binding energy of the whole molecule 
to the target. Another noteworthy contribution from early concept of fragments came 
from Verlinde who used the fragment-linking approach to design more potent 
compounds against trypanosomiasis from smaller fragments
151
. 
 To recapitulate from Chapter 1, fragments are weakly binding small molecules 
typically with molecular weights less than 300 g/mol, and fragment libraries are also 
smaller with fewer numbers of molecules. Despite their simplicity and small stature, 
using fragment methodology has many advantages. A library with fewer fragments can 
sample significantly larger portion of chemical space, and fragments provide high-
quality interactions which they make with the target to bind with sufficient affinity for 
detection. Moreover, fragments can be easily incorporated into HTS platforms and 
allowed structural determination by techniques such as NMR and X-ray crystallography. 
The advances in fragment methodology have impacted drug discovery breakthroughs in 
cancer, diseases, and sicknesses. A few of the studies have also employed the fragment 
methodology beyond drug discoveries. Fragment screening was used to identity ligands 
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that bind to riboswitches, which are regions of mRNA whose binding of metabolites 
control gene expression
78
. Thermodynamics characterization of fragment binding has 
assisted in identifying a useful ligand to a target that possesses a highly favorable 
enthalpic contribution to complex formation compared to physiologically relevant 
ligands
152
. Another application involves probing the active site or mapping the ligand 
binding site of protein to better understand mechanism driving biological reactions
153
. 
Therefore fragment methodology provides a suitable means for exploitation of new 
binding scaffolds for GlcB. 
Two fragment libraries with a total of 1580 compounds were screened against 
GlcB using differential screening fluorimetry (DSF). The first fragment library, provided 
by Chris Abell (Cambridge, UK), is commercially available from Maybridge as MB 
RO3 fragment library. It was extended by Abell’s addition of a number of fragments 
with under-represented bioactive scaffolds and ring systems. The second fragment 
library was chosen from among the Enamine Building Blocks compounds starting with a 
lead-like set from ZINC 8 database (Schoichet, UCSF) vendors. The compounds were 
then filtered by molecular weight (<300 g/mol), by similarity with compounds from 
other libraries using a Tanimoto similarity coefficient of 0.7, and by intrinsic reactivity. 
Finally the remaining set was subjected to diversity selection using a 0.46 Tanimoto 
threshold followed by the removal of unavailable compounds. Hits from the screening of 
fragments were complexed with GlcB for structural determinations to confirm binding 
and to further characterize the binding mode of each fragment. Lastly, through the 
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binding mode of fragment and fragment elaboration, designs of inhibitors with higher 
affinities and potencies were generated. 
Methods 
Cloning, expression, and purification 
The making of the construct containing the wild type (WT) GlcB clone has been 
described previously
149
. A 2.23 kb DNA fragment containing the glcB gene was 
amplified by polymerase chain reaction (PCR) from Mtb CDC1551 genomic DNA as a 
template, using the following oligonucleotides as the forward and reverse primers, 
respectively:  
5’-CAG TAC ATA TGA CAG ATC GCG TGT C-3’ 
5’-ATA TTG GAT CCC GCA AGC GGG CGG T-3’ 
The amplified DNA fragments were digested with restriction endonucleases, NdeI and 
BamHI, and sub-cloned in the corresponding restriction sites in a p6HisF-11d vector to 
yield a full length wild-type (WT) protein with N-terminal His6-tag. 
 GlcB with the Cys619 mutated to Ala was cloned by site directed mutagenesis 
method
131
. PCR amplification was done on the wild type recombinant p6HisF-11d-glcB 
plasmid as the DNA template with following oligonucleotides as the forward and reverse 
primers, respectively: 
5’-GTT GAT CAA GGT GTC GGC GCA TCG AAG GTG CCC GAC ATC-3’ 
5’-GAT GTC GGG CAC CTT CGA TGC GCC GAC ACC TTG ATC AAC-3’ 
The expression of GlcB WT was carried out in E. coli HB101(pGP1-2) cells carrying the 
recombinant ampicillin resistant p6HisF-11d-glcB plasmid, and GlcB C619A was 
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expressed in E. coli BL21 (DE3) cells with the corresponding ampicillin resistant 
p6HisF-11d-glcB plasmid with C619A mutation. The cells were grown to mid-log 
exponential phase at 37 °C in LB plus 50 g/ml carbenicillin and induced by 1 mM 
IPTG at an OD600 of 0.6-0.8 at 18 °C for 16 hours or overnight. The cells were then 
harvested, pelleted, and stored at -20 °C. 
For purification, the harvested cells were re-suspended in the re-suspending 
buffer with 25 mM Tris-HCl, pH 7.5, 100 mM NaCl, 5 mM imidazole, with 50 g/ml 
DNAse, 50 g/mL PMSF, and 20 g benzamidine. The re-suspended cells were further 
lysed using a French press under a pressure up to 15,000 psi. The lysates were 
centrifuged at 17,000 rpm for 30 minutes to separate the cellular debris from the protein. 
The supernatant of the lysates containing the soluble protein was passed through a 0.5 
m filter and purified to apparent homogeneity by successive chromatographic steps 
first by Ni-affinity using 2 times 5ml commercial HiTrap Q FF column, followed by gel 
filtration using commercial Superdex 200 HiLoad 16/600 column. Eluting fractions with 
the highest UV absorbance were finally pooled and concentrated using a spin dialysis 
column with a molecular weight cutoff of 100 kDa (EMD Millipore). Aliquots of WT 
GlcB at 5 mg/ml were flash frozen with liquid N2 and stored at -80
 °C in 25 mM Tris-
HCl, pH 7.5. The WT and C619A enzymes were determined to be > 95% pure as 
observed from SDS-PAGE. As the presence of the His6-tag did not affect the outcomes 
of the DSF assay, the enzyme activity assay, or the crystallization, most of the work was 
done using GlcB with the N-terminal His6-tag intact. 
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DSF thermal shift binding assay 
A thermal cycler qPCR (Stratagene Mx3005P, Agilent) and a fluorescence dye 
Sypro Orange were used to conduct DSF assay to screen two fragments libraries against 
GlcB. The fragments were assembled in 96 well plates and dissolved in 100% DMSO to 
~100 mM concentration by using the average molecular weight of 80 fragments in each 
plate for the calculation. The total assay volume was 20 l in each well of the 96 well 
PCR plates. Solutions of 4-5.5 l of 4.5-30 M GlcB in activity buffer (Tris-HCl, pH 
7.5, MgCl2, EDTA), 14 l of 7x Sypro Orange in 600 mM HEPES pH 7.5, and 0.5-2 l 
of 100 mM fragments were added to each well. DMSO was used as a blank and the 
inhibitor 2-bromo-PDKA (2-Br-PDKA) was used as a positive control. The final 
concentrations of GlcB, Sypro orange, and fragments were 1.5-10 M, 4.5x, and 2.5-10 
mM, respectively. The final activity buffer contained 20 mM Tris-HCl, 5 mM MgCl2, 
and 0.8 mM EDTA, and the final concentration of HEPES pH 7.5 was 200 mM. Prior to 
running the qPCR instrument, the assay plate was sealed with optical PCR thermal film 
and centrifuged at 1000 rpm for five min. For the assay, the plate was held at 25 °C for 
five minutes and heated from 25 to 85 °C with a heating rate of 0.5 °C/min by qPCR. 
Fluorescence of Sypro Orange was monitored in the qPCR instrument using the 
wavelength corresponding to the max absorption of the fluorescent dyes FAM (491 nm) 
and ROX (610 nm) for excitation and emission, respectively. 
Enzyme activity assay 
CoA produced by the action, as well as the inhibition activity of GlcB, was 
quantified by using coupled-Ellman’s reagent, 5,5’-dithiobis(2-nitrobenzoic acid)  or 
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DTNB, as previously described
154,139
. Briefly, the product of the GlcB forward reaction, 
CoA, reduces disulfide bond of DTNB, producing free NTB
2+
 (2-nitro-5-thiobenzoate) 
where formation is monitored at 412 nm for 20 minutes. The assay was conducted in a 
96 well clear plate with absorption in the visible range and contained 74 l reaction 
volumes with 13 nM GlcB pre-incubated in enzyme assay buffer containing 20 mM Tris, 
pH 7.5, 5 mM MgCl2, 0.8 mM EDTA. Compounds in 100% DMSO were diluted and 
added to the reaction mixture in final screening condition at 2% DMSO. The reaction 
mixture with compounds was incubated at 25 °C for 20 minutes, followed by the 
addition of 0.6 mM AcCoA, and the final addition of 1.2 mM glyoxylate in 0.5 mM 
DTNB (final concentration) initiated the reaction. The initial velocity of each reaction 
was generated by plotting the curves from the readouts and the enzyme kinetics were 
calculated by the software program using the first order algorithm in AU/hr. 
Compound synthesis 
Chemical syntheses of fragment based compounds are described in Appendix C. 
Each compound was synthesized as an acid-ester pair. To improve whole cell activity, a 
prodrug strategy was adapted by masking the carboxylic acids via esterification as a way 
to enhance cellular uptake. Indole- and thienopyrrole-diketo acids were assayed for 
enzyme inhibition and the corresponding methyl esters were assayed in whole cell 
testing.  
Mycobacteria whole-cell assay 
For the Mtb mc
2
 7000 strain
138
, cells were grown in 7H9 media supplemented 
with OADC, 0.05% Tyloxapol, and 25 g/ml pantothenate to an optical density at 600 
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nm (OD600) of 1-1.5. Cells were washed and diluted into testing media to an OD600 of 
0.01; 196 l of the diluted cells was pipeted into each well of sterile 96-well plate. Two 
testing media were used: 7H9 media with 0.4% dextrose, 0.085% NaCl, 0.05% 
Tyloxapol, and 25 g/ml pantothenate; and M9 media with 0.25% sodium acetate, pH 
7.5, 2 mM MgSO4, 0.1 mM CaCl2, 0.05% Tyloxapol, and 25 g/ml pantothenate. Each 
compound was dissolved and diluted in 100% DMSO in 1 half serial dilution, and each 
dilution series was added to each cell-containing well with a final concentration of 
DMSO at 2%. The plates containing 7H9 were incubated for 6 days, while the ones with 
M9 were incubated for 3 weeks before staining with alamar blue (resazurin). All plates 
were incubated at 37 °C with shaking for an additional two days after staining. The 
lowest concentration where resazurin stayed completely unconverted was recorded as 
the MIC99 value. Rifampicin was used as a positive control with MIC99 of 0.125 M 
displayed in 7H9 media supplemented with dextrose and 0.25 M in M9 media 
supplemented with acetate. 
Crystallization, data collection, and data analysis 
GlcB crystals were obtained by hanging drop vapor diffusion within 1-2 months 
using the previously described method
149,139
. Briefly, purified C619A GlcB at a 
concentration of 5 mg/ml in 20 mM Tris-HCl, pH 7.5, was mixed with mother liquor 
containing 20-30% PEG 3350, 0.1 M MgCl2, and 0.1 M Tri-HCl, pH 7-8.5 at a 1:1 
volume ratio in crystallization drops against 500 l mother liquor in a closed reservoir. 
For co-crystallization, 1-4 mM fragment was added to GlcB prior to mixing with mother 
liquor. Hit fragments from DSF screening were soaked in by transferring pre-formed 
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crystals or co-crystals into drops with 15-50 mM fragments in the mother liquor with a 
final concentration of DMSO below 15% for 16-48 hours. The fragment bound GlcB 
crystals belonged to space group P43212 with unit cell dimensions of a = b = 79 Å, c = 
224 Å,  = b =  = 90°, and contained one molecule per asymmetric unit. All crystals 
were cryo-protected by Fomblin and flash frozen in liquid nitrogen for x-ray data 
collection. Data were collected at the Argonne National Lab APS synchrotron, 
beamlines 19-ID and 23-ID, or Lawrence Berkley National Laboratory ALS, beamlines 
8.2 and 8.3, at 0.98-1.01 Å wavelengths.  
Diffraction data were indexed, integrated, and scaled using HKL2000
132
 or 
HKL3000
133
, and were further merged and truncated in CCP4
134
. PDB structures 1N8I 
with only the protein atoms remaining in the refinement was used as the model for the 
initial rigid body refinement of the isomorphous P43212 crystals in REFMAC
155
. The 
ligand model and dictionary files were created using ELBOW from the PHENIX
135
 suite 
and fitted into electron density in COOT
136
. The final fragment bound and product 
bound models were gradually improved by repeating the process of inspection and 
manual modification in COOT and refinement in PHENIX with simulated annealing. 
Table C-2 contains data collections and refinement statistics for all ligands. Unless 
otherwise denoted, all figures showing crystal structures are rendered in CHIMERA
137
. 
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Figure 20: DSF recordings monitor the unfolding of GlcB. A) Fluorescence 
amplification plot with the dye shown as a three ring aromatic molecule. For globular 
GlcB (spherical shape at the baseline of the curve), a basic fluorescence intensity is 
excited by light of 492 nm. Hydrophobic sites become exposed through unfolding and 
strong fluorescent light at 610 nm is emitted by the Sypro Orange bound to them. After 
the peak of intensity, a gradual decrease observed due to GlcB precipitation or 
aggregation. B) Dissociation curve as the first derivative of (A) with the minima 
indicates the midpoint transition temperature as the melting temperature Tm for a 
particular DSF assay.  
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Results and discussion 
GlcB binding assay by differential scanning fluorimetry 
Differential scanning fluorimetry (DSF) using a conventional qPCR instrument 
equipped with thermal cycler was performed to rapidly identify fragments that bind and 
stabilize GlcB. The temperature at which GlcB unfolds (Tm) is measured by an increase 
in the fluorescence of the Sypro Orange dye, which has affinity for hydrophobic sites 
that are exposed during the denaturation of the protein, as depicted in Figure 20A. The 
melting temperature Tm is calculated as the maximum of the first derivative, or the 
inflection point, of the transition curve which is the fluorescence intensity plotted as a 
function of temperature
156
. Binding of a fragment stabilizes the protein, causing GlcB to 
unfold at a higher temperature, as reflected in a positive thermal shiftsTm). Purified 
GlcB without any ligand addition typically unfolds at ~50 °C, as shown in Figure 20B 
(blue curve). Addition of substrates provided a Tm of 2.5-4 °C (Figure 20B green 
curve). Inhibitor 2-Br-PDKA causes a Tm of ~14 °C (Figure 20B maroon curve); 
therefore 2-Br-PDKA is used as the positive control throughout the screening. 
Summary of fragment screening 
The screening of the fragments resulted in Tm values of GlcB ranging between 
3.2-8.6 °C. Out of 1580 fragments screened, 64 fragments were determined as binding 
hits, each producing a Tm >3 °C. In Figure 20B, the gray curve shows the dissociation 
of GlcB with the addition of a hit that produced a Tm of 6.4 °C. Chemical structures and 
the Tm values of the hits from the fragment screening are summarized in Table C-3 of 
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Appendix C. Each hit contained at least one substituted aromatic ring, including five 
membered rings pyrrole, thiophene, and furan, six membered rings benzene, pyridine, 
and pyrimidine, and fused ring systems such as naphthalene, indole, and thienopyrrole. 
More than half of the fragments were substituted diaryl or triaryl compounds, containing 
two or three aromatic or fused rings joined by a single sigma or pi bond, longer alkyl 
linker, or amide bond. The substitutions on the rings included halogens, hydroxyls, alkyl 
groups, nitrile groups, acyl groups, and amine groups. When comparing with the rest of 
the fragments in the libraries, the hits typically fell under a cluster of compounds with 
highly conjugated ring systems. Moreover, the substituted functional groups on the rings 
were either electron withdrawing or electron donating, thereby influencing the 
delocalizations of electrons within the molecules. More than one-third of the hits had 
carboxylate as substitutions that stabilized the fragments through resonance and enable 
them to form H-bonds with the enzyme. Each of the hits from the screen were 
complexed with GlcB for structure determination either by soaking the free GlcB 
crystals with fragment, or by the combination of co-crystallization of GlcB with 
fragment followed by soaking. 
Overview of fragment bound GlcB crystal structures 
In the crystal structure of glyoxylate-bound GlcB, Cys619 was oxidized to 
cysteine sulfenic acid, similar to E. coli MSG
157
, creating an obstruction at the entrance 
of the active site tunnel. Therefore a mutant GlcB C619A was constructed and used on 
all the studies in this chapter which had well correlated activity with the WT GlcB. 
Previous crystal stuctures of the PDKA inhibitors were determined using the C619A 
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mutant, and no significant participation of Cys619 in the binding of those inhibitors was 
reported
139
. A total of18 fragment bound GlcB structures were successfully obtained out 
of 64 hits from the screens using soaking or co-crystallization followed by soaking, and 
they were solved to 1.8-2.2 Å resolution. The chemical structures and Tm values of the 
18 fragments are summarized in Table 2. The overall structure of fragment bound GlcB 
is similar to the structures previously determined in complex with the substrate 
glyoxylate (PDB ID 1N8I)
149
, the products malate and CoA (1N8W and 2GQ3)
78,158
, and 
the PDKA inhibitors (3S9I, 3S9Z, 3SAD, 3SAZ, and 3SB0)
139
. The fold is a mixture of 
/ secondary structures and consists of three domains, as shown in Figure 21. Domain 
I is an 8/8 TIM barrel (residues 115-134 and 266-557). Domain II is formed at the C-
terminus (residues 591-727) containing mostly helices, while domain III is rich in -
strands and inserted between 1 and 2 of the TIM barrel (residues 135-265). In 
addition, the first 90 residues at the N terminus form two strands and three helices close 
to domain III. The active site, a single tunnel, ~25 Å long from the surface, is at the 
interface of the TIM barrel and domain II, with a loop consisting of residues 616-633 
forming a part of this interface. A Mg
2+
 ion required for activity is bound at the bottom 
of the active site in an octahedral coordination by the carboxylate side chains of Glu434 
and Asp462, and water molecules in 13 of 18 fragment complex crystals structures. In 
the other five fragment-bound crystal structures, the Mg
2+
 ion is coordinated by the 
bound fragment, the carboxylate side chains of Glu434 and Asp462, and water 
molecules. More detailed descriptions of each fragment’s binding mode are discussed 
later. 
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Figure 21: Ribbon representation of the overall structure of GlcB. Domain I is the 8/8 
TIM barrel consisting of residues 115-134 and 266-557 shown with  helices in cyan 
and  strands in blue. Domain II consists of residues 591-727 at the C-terminus is mostly 
helical shown in magenta. Domain III is inserted in the TIM barrel between 1 and 2 
(124-134 and 267-271) and is rich in  strands, show in green. The first 110 residues at 
N-terminus are in gray. The Mg
2+
 ion in the active site is in coral. 
 
 
Narrowing of the active site tunnel with the movement of the CoA binding loop 
There are common features among the fragment complex structures around the 
active site distinguished from other Mtb GlcB complex structures. A narrowing of the 
main tunnel by ~2 Å (2.5-2.7 Å measured by the displacement of the side chain Cof 
Glu632) caused by the movement of the loop, containing residues 619-633 (CoA binding 
loop) is observed. This conformation has never been reported before in previously 
determined complex structures with substrate, product, and the PDKA inhibitors. All the 
complex structures of GlcB previously published have the “out” conformation of the 
CoA binding loop, whereas the “in” conformation was observed in the structures of 
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GlcB complexed with fragments. The out and in CoA binding loop conformations were 
also reported previously in E. coli malate synthase G structure complexed with and 
without AcCoA, respectively
157
. Concurrently, there is a slight widening of the cavity 
beyond the active site Mg
2+
 ion in the fragment structures in comparison with the GlcB-
glyoxylate and GlcB-malate-CoA, and GlcB-PDKA structures. This is caused by the 
movements (0.4-0.5 Å) of the Glu434 and Asp462 side chain carboxylates away from 
Mg
2+
 ion. Figure 22 shows the crystal structure of parent PDKA superimposed on one 
of the fragment structures (11 from Table 2). 
 
 
 
Figure 22: A close up of the active site with overlay of crystal structures of GlcB 
complexed with PDKA (white) and fragment 11 (cyan). Black arrow indicates an 
additional portal opening to the surface upon binding of the Group 2 fragments. 
Additional movements include the widening of the cavity behind active site Mg
2+
 and 
narrowing of the mouth of main tunnel which is caused by the movement of the loop 
containing residues 619-633, as indicated by the black doble arrows. Non-carbon atoms: 
chartreuse, magnesium; red, oxygen; blue, nitrogen.  
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Second portal to the surface with the movement of the active site loop  
While all the fragment crystal structures share the same CoA binding loop 
conformation, they show two conformations of the loop containing residues 458-462. 
This loop is part of the active site cleft, and is in close proximity to the Mg
2+
 ion at the 
bottom of the active site, with residue Asp462 at the end of this loop coordinating the 
Mg
2+
 ion. The closed conformation of the loop has been previously observed in Mtb 
GlcB structures in complexes with the substrate glyoxylate, products, and the PDKA 
inhibitors. Compared to the closed conformation, the active site loop open conformation 
becomes more relaxed and straightened at the end of the -helix (corresponding to H in 
E. coli MSG structure, PDB ID 1D8C
159
). As the loop changes from the closed to the 
open conformation, the backbone carbonyl of Thr458 moves outward by ~1 Å and 
swings up 60 degree toward Mg
2+
 ion. Movements of the next two residues, 459 and 
460, are the most significant along this loop. Gly459 backbone rotates approximately 70 
degrees and moves ~3 Å further away from Mg
2+
 ion, and the Phe460 backbone 
displaces by 2.5 Å and side chain flips by 4 Å. The open active site loop movement 
ultimately generates a second solvent accessible portal to the surface, as shown in 
Figure 22. A closed active site loop form was observed in five fragments and an open 
loop form was observed in 13 fragments. 
Binding modes of fragments 
Figure 23 depicts the overlay of 18 fragment-bound GlcB crystal structures. The 
fragments that bind to GlcB active site contain aromatic rings which bind in the 
hydrophobic pocket between the two methionine residues, Met515 and Met631, as with  
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Table 2: Chemical structure and Tm for fragment with complexed crystal structure. 
No. Chemical Structure Tm (°C) No. Chemical Structure Tm (°C) 
Group1 Fragments 
 
Group 2.1 Fragments 
 
1 
 
5.2 
6 
 
7.1 
7 
 
8.6 
2 
 
4.1 
8 5.6 
2* 
9 
 
4.6 
10 5.4 
3 4.6 
11 5.7 
4 3.3 
12 
 
7.0 
5 3.3 
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Table 2: Continued. 
No. Chemical Structure Tm (°C) No. Chemical Structure Tm (°C) 
Group 2.2 Fragments 
 
16 
 
3.6 
13 
 
4.8 
17 
 
6.4 14 
 
6.8 
15 4.6 
18 
 
3.4 
 
 
 
 
Figure 23: Crystal structures overlay of GlcB complexed with fragments 1-18, 
represented by stick model (colored by element) with Mg atom in green sphere, showing 
the relative positions of the fragments occupying the active site tunnel presented by 
protein surface in gray.  
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Figure 24: Crystal structure of GlcB complexed with Group 1 fragments A) 1, B) 2, C) 
3, D) 4, and E) 5 showing the H-bond and metal chelating interactions among the 
fragments, water molecules, and the active site. Atom colors: chartreuse, magnesium; 
darkgrey/black, carbon; red, oxygen; blue, nitrogen; light green, fluorine; green, 
chlorine; brown, bromine; yellow, sulfur.  
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Figure 25: Crystal structure of GlcB complexed with Group 2.1 fragments A) 6, B) 7, 
C) 8, D) 9, E) 10, F) 11, and G) 12 showing the H-bond interactions among the 
fragments, water molecules, and the active site. Atom colors: chartreuse, magnesium; 
tan/sienna, carbon; red, oxygen; blue, nitrogen; green, chlorine; yellow, sulfur.  
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Figure 25: Continued. 
 
 
the phenyl rings of the PDKA inhibitors in the crystal structures. Moreover, the 
fragments have functional groups that are H-bond donors or acceptors, and they form H-
bonds with the active site residues and water molecules. While H-bonds are formed 
between the bound fragments and catalytic residues, Asp633 and Arg339, similar to the 
binding of PDKA, additional interactions were discovered in the fragment complex 
structures which were not seen before. Lastly, the fragments have functional groups with 
metal chelating capabilities including carboxylates. However, only five fragments (1-4, 
18) directly coordinate Mg
2+
 while the other 13 fragments form H-bonds with Mg
2+
 
coordinating water molecules. 
 The 18 fragment bound crystal structures are divided into two main groups. 
Group 1 comprises structures complexed with fragments 1 to 5 (Figure 24A-E) and 
exhibit a closed active site loop conformation; Group 2 is comprised of structures 
complexed with fragments 6 to 18 with an open loop conformation. Fragments 1-5 
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contain substituted phenyl (1, 3-5) or thiophene (2) rings. In the crystal structure of 2, 
the intact oxotetrahydrofuran-3yl ring has been hydrolyzed under the crystallization 
condition to an oxobutenoic acid substituent (2*). The electron density of the 2Fo-Fc 
map following the final refinement is in agreement with the proposed chemical structure 
(2* of Table 2). Fragments 1-4 coordinate Mg
2+
 ion while 5 does not; 1-3 occupy two of 
the Mg
2+
 ion’s six octahedral coordination sites whereas 4 only occupies one site. 
Fragment 1 coordinates Mg
2+
 with both its propanoate (carboxylate) oxygens (Figure 
24A) while 2 and 3 coordinate Mg
2+
 with one of their carboxylate oxygens and the 
adjacent ketone oxygen (Figure 24B-C), which is similar to the Mg
2+
 coordination by 
the diketo acid group of the PDKA in the crystal structure. For 1-3, the remaining Mg
2+
-
coordination sites are filled by one of each of the side chain oxygens of Glu434 and 
Asp462, as well as two water molecules. The crystal structure of 4 shows that only the 
oxime oxygen fills one of the six octahedral coordination sites of Mg, while the other 
one is filled by a third water molecule (Figure 24D). The crystal structure of 5 shows 
that Mg
2+
 ion is coordinated by four water molecules and the side chain carboxylate 
oxygens (one of each) from Glu434 and Asp462. In turn, H-bonds are formed between 
5’s carboxylate oxygens and two of the coordinating water molecules (Figure 24E) with 
2.7-3.3 Å distances. The Mg
2+
 coordination distances in the crystal structures for the 
Group1 fragments are in the range of 2.1-2.4 Å. 
 One common feature seen in all the crystal structures in complex with Group 1 
fragments is the H-bond formed between oxygens on the fragments and one of the 
nitrogens on the Arg339 side chain (dO-N = 2.5-3.0 Å). Another similar feature among 
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the interactions of Group1 fragments is that the H-bonds formed directly (2 and 3) or 
indirectly via water molecules (1, 4, and 5) between a fragment and the backbone of the 
active site loop, particularly Leu461 and Asp462. These H-bonds formed between the 
fragments and the active site loop further stabilize the closed loop conformation. 
Crystal structures of GlcB complexed with Group 2 fragments have the open 
active site loop conformation and through this portal several water molecules gain access 
to the active site, which was absent in the Group 1 fragment complexed structures. The 
displacement of the Phe460 side chain (~4 Å) in the open loop conformation allow these 
water molecules to occupy the space where the Phe460 side chain was once in the closed 
active site loop conformation. More significantly, they form extensive H-bond networks 
between the bound fragments and the active site loop backbone which further stabilize 
the open loop conformation. For example, carboxylate oxygens of fragment 7  interacts 
with water molecule (dO-O = 2.6 Å) which form H-bonds to the backbone nitrogens of 
Leu461 and Asp462 at 3.0-3.2 Å. Additionally, an H-bond formed between many 
fragments and Met631 was observed, therefore Group 2 was further divided into two 
sub-groups based on whether they interact with Met631. The seven fragments with open 
loop conformation, 6 to 12 in Group 2.1, contain either a five membered pyrrole or 
pyrazole moieties (6-9, 11-12), or a six membered pyrazine moiety (10). The nitrogens 
on the pyrrole and pyrazole moieties form H-bonds with the backbone carbonyl oxygen 
of Met631 (dN-O = 2.6-3.5 Å, Figure 25A-G). Fragments 6 and 7 have thienylpyrrole 
rings, 8 has a pyrrole ring, and 9 and 11 each have a single indole ring. Fragment 10 has 
a fused quinoxaline ring, and 12 has a pyrazole and an indole ring as part of diaryl 
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moiety. The nitrogens on the pyrrole/pyrazole/quinoxaline moieties form H-bonds with 
the backbone carbonyl oxygen of Met631 (dN-O = 2.6-3.5 Å, Figure 25). Group 2.2 
fragments (13-18) do not form H-bonds with the backbone of Met631, as seen in Figure 
26. The six fragments have a single phenyl (14 and 15), thienylpyrrole (13), or diaryl 
groups (16, 17 and 18). Fragment 13 has a thienylpyrrole moiety with the pyrrole 
nitrogen on the opposite side of the thiophene sulfur, which is different from 6 and 7 
where the pyrrole nitrogen is on the same side as the thiophene sulfur. The pyrrole 
nitrogen of 13 does not interact with Met631, instead with Asp633 by forming H-bond 
with one of its side chain carboxylate oxygens (dN-O = 3.0 Å). 
Interestingly, the crystal structure of GlcB in complex with 14 indicates two 
molecules of the fragment bound to one molecule of the enzyme (Figure 26B). 
Fragment 14 is a tri-substituted phenyl moiety with nitrile, hydroxyl, and chloro 
substitutions at the 1-, 2-, and 5-positions, respectively. One molecule of 14 binds in the 
hydrophobic pocket of the active site similar to other fragments, forming H-bonds with 
three water molecules with its hydroxyl oxygen (H-bond distances 2.6-2.9 Å). The other 
one binds 4.1 Å away near the entrance of the tunnel in the hydrophobic pocket formed 
by residues Pro120, Phe126, and Met631, and interacts with one water molecule via H-
bond by its hydroxyl oxygen (2.7 Å). Fragment 16 is a phenyl moiety with a thioacrylate 
tail. The crystal structure of the 16-bound GlcB shows that the thioacrylate tail actually 
points away from Mg
2+
 with the terminal carboxylate oxygens forming van der Waals’ 
interactions with the backbone carbonyls of Pro543 and Met631, as seen in Figure 26D. 
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Group 2 fragments do not coordinate Mg
2+
 with the exception of 18. The crystal 
structures of 6-17 all have Mg
2+
 octahedrally coordinated by the side chains of Glu434 
and Asp462, as well as four water molecules (coordinating distances 2.0-2.6 Å). In the 
crystal structure of 18, Mg
2+
 is coordinated by the fragment’s two carboxylate oxygens, 
the side chains of Glu434 and Asp462, and two water molecules (coordinating distances 
2.1-2.4 Å). Moreover, none of the fragments from Group 2 interact with Arg339 in any 
way with the exception of 18. The crystal structure of 18 has many interesting aspects. 
Its chemical structure contains an aromatic pyridine and a non-aromatic thiozolidine ring 
connected by a sigma bond. The overall fragment in the crystal structure appears to be 
non-planar, imparting from the saturating nature of the thiozolidine moiety. The ring 
assumes a half chair conformation with the C4 flipped down (Figure 26F). It is the only 
Group 2 fragment that interacts with both catalytic residues, Asp633 and Arg339. The 
nitrogen of the thiozolidine ring forms an H-bonds with one of the carboxylate oxygens 
of the Asp633 side chain (dN-O = 3.1 Å) while its carboxylate oxygen forms an H-bond 
with one of the Arg339 side chain nitrogens (dO-N = 2.7 Å). Though many of 18’s 
interactions with the enzyme are the same as Group 1 fragments, it is the open 
conformation of the active site loop that relegates 18 to Group 2. Its carboxylate group 
coordinates Mg
2+
 (coordinating distances 2.3 Å) and does not interact with the active site 
loop residues to form H-bonds that would stabilize the closed loop conformation. 
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Figure 26: Crystal structures of GlcB complexed with Group 2.2 fragments A) 13, B) 
14, C) 15, D) 16, E) 17, and F) 18 showing the H-bond and metal chelaing interactions 
among the fragments, water molecules, and the active site. Atom colors: chartreuse, 
magnesium; tan/sienna, carbon; red, oxygen; blue, nitrogen; green, chlorine; yellow, 
sulfur.  
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Fragment scaffolds provide new inhibitor designs 
 To test how the information from fragment bindings can be used to design new 
or improve existing inhibitors, new interactions discovered through the fragment 
complex structures were incorporated into pre-existing series of PDKA inhibitors. One 
of the new interactions was the H-bond between the nitrogen on the Group 2.1 fragments 
and the backbone oxygen of Met631, particularly the indole and thienopyrrole 
containing fragments. Since the Group 2 fragments bind to the different conformation of 
the enzyme compared to PDKA, rather than merely overlaying two or more complex 
structures, the combination of H-bond forming aromatic rings and the diketo acid moiety 
were systematically explored. This resulted in a series of inhibitors presented in Table 3, 
which summarizes the indole and thienopyrrole based inhibitors with their potencies 
against enzyme and whole cells. Compounds 19-21 were designed based on the indole 
containing fragment 9, with the diketo moiety appended at the 3-position of the indole 
ring. Compound 22 was based on fragment 11, with the diketo acid moiety at the 2-
position of the indole ring. The potency of 19 (unsubstituted indole-diketo acid) against 
the enzyme was greater than that of the unsubstituted PDKA (IC50 at 2.0 M) with an 
IC50 of 1.1 M, while the potency of 22 was lower with an IC50 of 4 M versus an IC50 
of 1.1 M for 2-Me-PDKA. In the crystal structure of GlcB complexed with 19 shown in 
Figure 27A, a weak H-bond is formed between the indole and the backbone carbonyl 
oxygen of Met631 (dN-O = 3.3 Å), and the CoA-binding loop is in the in conformation, 
five inhibitors, 23 showed the highest potency with an IC50 of 18 nM from the enzyme 
 100 
 
 
Figure 27: Crystal structures of GlcB complexed with inhibitors A) 19, B) 23, C) 27, 
and D) 28 from fragment-based designs showing the H-bond and metal chelaing 
interactions among the inhibitor, water molecules, and the active site. Atom colors: 
chartreuse, magnesium; slate/dim gray, carbon; red, oxygen; blue, nitrogen; green, 
chlorine; yellow, sulfur.  
 
 
activity assay and 27 with methyl-substitution at 4-position not so far behind with an 
IC50 of 55 nM. H-bonds between the nitrogen of the indole and Met632 in both complex 
crystal structures with 23 and 27 (dN-O = 2.8 Å and 2.6 Å, respectively) were also 
observed, as shown in Figure 27B-C. The CoA binding loop has the in conformation in 
GlcB-23 complexed crystal structure. Interestingly for 27, though the position of the 
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Asp632 side chain remains unchanged, the CoA binding loop is halfway between the in 
and out conformations in the complexed crystal structure, as depicted in Figure 28. All 
three inhibitors 19, 23, and 27 induced the closed active site loop in the complexed 
crystal structures, similar to PDKA, due to the interactions of the diketo acid moiety 
with the active site loop residues Leu461 and Asp462. 
Lastly, the design of appending the diketo acid tail to the 4-position were 
explored on the thienopyrrole ring based on fragments 6 and 7. As a result, compound 28 
was synthesized, and upon evaluation against enzyme activity using the DTNB coupled 
assay, it showed moderate activity in the enzyme assay with an IC50 of ~ 1.3 M. 
Complexed GlcB crystal structure with 28 showed that the thienopyrrole nitrogen was 
hydrolyzed during crystallization, and as a result a strong H-bond was formed between 
the hydroxyl and the Met631 backbone carbonyl oxygen (dO-O = 3.0 Å), as shown in 
Figure 27D. Since the hydroxyl group on the thienopyrrole lengthened the distance 
between the inhibitor and the CoA binding loop, an out conformation was observed for 
the complexed structure of GlcB with 28, similar to PDKA inhibitors. As with inhibitors 
19, 23, and 27, 28 induced the active site to close when bound to the active site by 
making the same H-bonds with backbone nitrogens of Leu461 and Asp462 (dO-N = 2.9 Å 
and  dO-N = 2.9 Å, respectively). 
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Table 3: Enzyme and whole cell activity data for fragment based inhibitors. 
No. Chemical structure* 
IC50 
(M) 
MIC99 for Mtb 
mc
2
 7000 grown 
on dextrose (M) 
MIC99 for Mtb  
mc
2
 7000 grown on 
acetate (M) 
19 
 
1.05 >100 >100 
20 
 
1.96 >100 >100 
21 
 
2.87 >100 >100 
22 
 
4.04 >100 >100 
23 
 
0.0182 >100 >100 
24 
 
10.1 >100 >100 
25 
 
>100 >100 >100 
*R=H for testing enzyme activity and R=CH3 for testing whole cell activity.  
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Table 3: Continued. 
No. Chemical structure* 
IC50 
(M) 
MIC99 for Mtb 
mc
2
 7000 grown 
on dextrose (M) 
MIC99 for Mtb  
mc
2
 7000 grown on 
acetate (M) 
26 
 
1.49 12.5 >100 
27 
 
0.055 >100 >100 
28 
 
1.34 >100 >100 
*R=H for testing enzyme activity and R=CH3 for testing whole cell activity. 
 
 
  
Figure 28: Superimposition of crystal structures of GlcB complexed with 23 (olive), 27 
(gray), and PDKA (tan). None-carbon atom colors: chartreuse, magnesium; red, oxygen; 
blue, nitrogen; green, chlorine; yellow, sulfur.  
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Conclusion 
 Differential scanning fluorimetry using a thermal cycler and a fluorescence dye, 
Sypro Orange, provided a suitable binding assay for the second enzyme of glyoxylate 
shunt GlcB. A strong amplification curve from the fluorescent intensity of the dye was 
observed from using as little as 1 M enzyme and 4.5x Sypro Orange (final 
concentrations in 20 l reaction volume), corresponding to a sharp dissociation peak 
from which a melting temperature could be easily determined. All the ligands with 
binding infinities have resulted in positive thermal shifts in melting temperature, 
including weakly binding fragments. Out of 1580 fragments screened 64 fragments 
produced thermal shifts > 3 °C, of which 18 fragment complexed crystal structures were 
successfully obtained. 
 Information from fragment binding has provided a variety of scaffolds for 
inhibitor design, including aromatic rings that can bind in the active site hydrophobic 
pocket and functional groups that can form interactions. Different conformations of the 
active site loop and the CoA binding loop can be achieved independently of each other 
and thus can be exploited in any combination in the inhibitor design. Therefore, 
inhibitors with functional groups placed to form H-bonds with major residues such as 
Arg339, Asp633, Phe460, Leu461, Asp462, and Met631, to directly or indirectly 
coordinate Mg
2+
, and to sustain stacking interactions with Met631 and Met515 are of 
particular interest. Several fragments have nitrogen containing moieties such as pyrrole, 
indole, thienopyrrole, etc., in which the nitrogen interacts with the backbone of Met631. 
The indole and thienopyrrole moieties have been incorporated into the existing inhibitor 
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series. As a result, inhibitor potency was increased by over 100 fold with IC50s of 18 nM 
for unsubstituted indole-diketo acid versus 2 M for unsubstituted PDKA, and the 
anticipated H-bond between the nitrogen and Met631 was observed. In addition, the 
indole-diketo acid and thienopyrrole-diketo acid inhibitors are more stable than the 
PDKA inhibitors because they are less likely to undergo retro Claisen condensation and 
revert back to ketones. More potent inhibitors could be designed based on the discovered 
interactions with these key residues, providing a platform for future antibacterial 
therapeutic development. 
Future work 
 The thienopyrrole moiety appears to be a suitable aromatic scaffold for binding 
the hydrophobic pocket of the active site. Moreover, the halogen substituted fragment 7 
had the highest thermal shift of all the fragments that had binding affinities to GlcB. 
GlcB inhibitors containing thiophene have been proven to have inhibitory activity 
against Mtb whole cells, therefore, the thienopyrrole moiety in theory would retain the 
whole-cell potency, and the thienopyrrole-diketo acid inhibitor should be elaborated 
further. An immediate future work would be to incorporate the thienopyrrole ring into 
potential inhibitor design with halogen substitution. The inhibitors synthesized from the 
elaboration of the fragments did not have any whole cell activity. Future work would be 
to improve the whole cell potency. Currently the prodrug strategy by masking the acid 
with methyl is used, and an inhibitor is synthesized as an acid-methyl ester pair. Future 
work involves masking the acid with more lipophilic moiety such as tri-peptide or 
phenyl group. 
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 Only 18 out of 64 fragments were successfully obtained for the complexed GlcB 
crystal structures, therefore more complexed crystal structures could be generated. More 
fragment scaffolds can also be explored in the future by expanding the number of 
fragments screened against the enzyme. Out of 64 hits summarized in Table C-3, there 
appears to be a few interesting aromatic moieties for binding in the active site, such as 
thiazole, thiadiazole, and isoxazole. The complex crystal structures with those moieties 
would provide more binding scaffolds for future inhibitor designs. 
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CHAPTER IV  
CRYSTAL STRUCTURES OF FRAGMENT BOUND MALATE SYNTHASE 
PROVIDE INSIGNTS TO ENZYME CATALYSIS 
 
Background and introduction 
 Fragment based approach has been developed to probe the active sites for 
possible binding niches with small ligands
160
. Information from bound fragments is 
treated much like a collection of pieces that fit into certain parts of an active site, which 
can then be linked together into a larger framework that combines potential interactions 
to gain affinity. Alternatively, fragments can be used as “spare parts” to swap for 
moieties of existing inhibitors to create compounds with more desirable characteristics. 
On the other hand, a larger binding molecule can be deconstructed into a set of 
fragments, and after probing for binding of fragments they can be reconstructed back in 
an optimized way or can provide useful building blocks to be incorporated into new 
inhibitors. 
Fragment induced novel conformations adds a fourth dimension to a standard 
fragment based approach, which traditionally treats a target as a static site to be 
efficiently occupied in three dimensions. The fragment bound crystal structures have 
allowed for the characterization of the preferred binding moieties and the interactions 
they make in the active site for stabilizing different conformation states. As seen in the 
previous chapter, the fragment bound crystal structures of GlcB have shown the distinct 
conformations around the active site that have never been reported for Mtb. There are 
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conformational changes of the two loops induced by the bound fragments, the active site 
loop comprising residues 458-462 and the CoA binding loop comprising residues 619-
633. The active site loop moves between open and closed conformations, and upon 
opening, a second portal to the surface is generated. The CoA binding loop transitions 
between in and out conformations which narrows and widens the main active site tunnel, 
respectively. The distinctively different conformations of the two loops are stabilized by 
the bound fragments via interactions between the fragments and the residues comprising 
the loops. The detailed binding modes of the bound fragments have been described in 
Chapter III.   
Distinct conformations around the active site of GlcB have been previously 
reported in E. coli MSA and MSG isoforms. Howard et al. has proposed that there is 
possible mobility of the C-terminal domain in E.coli MSG which would allow for 
substrate entrance and product release
159
. This proposed domain motion is consistent 
with results from the studies of low-angle X-ray scattering and circular dichroism on MS 
from yeast and maize, which both support a change in enzyme’s conformation upon 
substrate binding
161,162,163
. Lohman et al. has reported a considerable multi-loop 
conformational change around the active site of MSA upon substrate and inhibitor 
binding
164
. Particularly, a loop comprising residues 275-278 at the Mg
2+
 binding site 
switches from an “open” conformation in the apo structure to a “closed” conformation 
when complexed with inhibitor, shielding the bound species from solvent. The 
movement of this loop further triggers the transitions of several active site residues, 
prompting the movement of the loop clustered around the AcCoA binding site. In 
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another report, Anstrom et al. has described a domain motion associated with substrate 
binding in MSG. Upon binding of AcCoA, a loop comprising residues 616-632 swings 
up 2.5 Å away from its position in the structure without AcCoA. Although there is no 
direct evidence that complex formations with substrates and products result in 
pronounced domain shifts for Mtb GlcB, the complexed structures with fragments have 
painted a slightly different picture. They have hinted the conformational changes around 
the active site of GlcB to be of physiological relevance, more specifically, to the 
mechanism of the enzyme’s catalysis. 
The mechanism and the order of the GlcB reaction have been determined by the 
isotope exchange experiments
165
 and by using dead-end product inhibition and kinetic 
isotope effects
166
. Figure 29
166
 depicts the proposed chemical mechanism adopted from 
Quartararo and Blanchard. In the active site Mg
2+
 ion is octahedrally coordinated by the 
side chain carboxylate oxygens of active site residues Glu434 and Asp462 and four 
water molecules. Based on the results of inhibition studies and the crystal structure of 
purified apo enzyme, glyoxylate binds first, displacing two coordinating water 
molecules. After the binding of AcCoA, the conserved Asp633 acts as the catalytic base 
with a pKa of 4.6-5.3, abstracting a proton from -methyl group of AcCoA. The 
resulting enolate of AcCoA with negative charge is stabilized by the conserved active 
site acid, Arg339. In the next step of condensation, the electrophilic substrate glyoxylate 
is polarized for nucleophilic attack of the enolate, at which step Mg
2+
 ion is essential. 
The enolate attacks the aldehyde carbon of the glyoxylate, which generates the malyl-
CoA intermediate. The electron flows through the alkoxide malyl-CoA to its oxygen and 
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removes the proton from a nearby coordinating water molecule, creating hydroxide 
anion that attacks the carbonyl of the intermediate. Active site residue Arg339 acts as 
catalytic acid with a pKb of 9.2 and protonates the CoA thiolate, causing the 
decomposition of the tetrahedral intermediate to two products, malate and CoA. 
 
 
 
Figure 29: Proposed chemical mechanism of GlcB. Reprinted with permission from 
Reference 166. 
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The distinct conformations observed from the fragment bound GlcB structures 
have facilitated a closer look at GlcB’s chemical mechanism corresponding to substrate 
and product exchange. Details from the crystallization methods and experiments in the 
literature were further emphasized and adapted in this study. As a result, a mechanism 
driven substrate-product exchange in catalysis reflecting the conformational changes was 
formulated. 
Methods 
Cloning, expression, and purification 
The making of the construct containing the WT GlcB clone has been described 
previously
149
. A 2.23 kb DNA fragment containing the glcB gene was amplified by 
polymerase chain reaction (PCR) from Mtb CDC1551 genomic DNA as a template, 
using the following oligonucleotides as the forward and reverse primers, respectively:  
5’-CAG TAC ATA TGA CAG ATC GCG TGT C-3’ 
5’-ATA TTG GAT CCC GCA AGC GGG CGG T-3’ 
The amplified DNA fragments were digested with restriction endonucleases, NdeI and 
BamHI, and sub-cloned in the corresponding restriction sites in a p6HisF-11d vector to 
yield a full length WT protein with N-terminal His6-tag. 
 GlcB with the Gly459 mutated to Ala was cloned by site directed mutagenesis 
method. PCR amplification was done on the C619A recombinant p6HisF-11d-
glcB(C619A) plasmid as the DNA template with following oligonucleotides as the 
forward and reverse primers, respectively: 
5’-GTG GTG TTC ATC AAC ACC GCC TTC CTG GAC CGC ACC GGC-3’ 
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5’-GCC GGT GCG GTC CAG GAA GGC GGT GTT GAT GAA CAC CAC-3’ 
The expression of GlcB C619A G459A double mutant was carried out in E. coli BL21 
(DE3) cells with the corresponding ampicillin resistant p6HisF-11d-glcB plasmid with 
C619A and G459A mutations. The cells were grown to mid-log exponential phase at 37 
°C in LB plus 50 g/ml carbenicillin and induced by 1 mM IPTG at an OD600 of 0.6-0.8 
at 18 °C for 16 hours or overnight. The cells were then harvested, pelleted, and stored at 
-20 °C. 
 For purification, the harvested cells were re-suspended in the re-suspending 
buffer with 20 mM Tris-HCl, pH 7.5, 100mM NaCl, 5 mM imidazole, with 50 g/ml 
DNAse, 50 g/ PMSF, and 20 g benzamidine. The re-suspended cells were further 
lysed using a French press under a pressure up to 15,000 psi. The lysates were 
centrifuged at 17,000 rpm for 30 minutes to separate the cellular debris from the protein. 
The supernatant of the lysates containing the soluble protein was passed through a 0.5 
m filter and purified to apparent homogeneity by successive chromatographic steps 
first by Ni-affinity using 2 times 5ml commercial HiTrap Q FF column, followed by gel 
filtration using commercial Superdex 200 HiLoad 16/600 column. Eluting fractions with 
the highest UV absorbance were finally pooled and concentrated using a spin dialysis 
column with a molecular weight cutoff of 100 kDa (EMD Millipore). Aliquots of WT 
GlcB at 5 mg/ml were flash frozen with liquid nitrogen (N2) and stored at -80
 °C in 20 
mM Tris-HCl, pH 7.5. The WT enzyme was determined to be ~95% pure as observed 
from SDS-PAGE. As the presence of the His6-tag did not affect the outcomes of the 
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differential scanning fluorimetry assay, the enzyme activity assay, or the crystallization, 
most of the work was done using GlcB with the N-terminal His6-tag intact. 
DSF thermal shift binding assay 
A thermal cycler qPCR (Stratagene Mx3005P, Agilent) and a fluorescence dye 
Sypro Orange were used to conduct differential scanning fluorimetry (DSF) assay to 
screen two fragments libraries against GlcB. The fragments were dissolved in 100% 
DMSO to 100 mM concentration. The total assay volume was 20 l in each well of the 
96 well PCR plates. Solutions of 4-5.5 l of 4.5-30 M GlcB in AB buffer containing 
Tris-HCl, pH 7.5, MgCl2, and EDTA, 14 l of 7x Sypro Orange in 600 mM HEPES 
buffer pH 7.5, and 0.5 l of 100 mM fragment was added to each well with DMSO as a 
blank and the inhibitor 2-bromo-PDKA (2-Br-PDKA) as a positive control. The final 
concentrations of GlcB, Sypro orange, and fragments were 1.5-10 M, 4.5x, and 2.5-10 
mM, respectively. The final AB buffer contained 20 mM Tris-HCl, 5 mM MgCl2, and 
0.8 mM EDTA (1x), and the final concentration of HEPES buffer pH 7.5 was 200 mM. 
Prior to running the RT-PCR instrument, the assay plate was sealed with optical PCR 
thermal film and centrifuged at 1,000 rpm for five min. For the assay, the plate was held 
at 25 °C for five minutes and heated from 25 to 85 °C with a heating rate of 0.5 °C/min 
by qPCR. Fluorescence of Sypro Orange was monitored in the qPCR instrument using 
the wavelength corresponding to the max absorption of the fluorescent dyes FAM (491 
nm) and ROX (610 nm) for excitation and emission, respectively. 
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Enzyme activity assay 
CoA produced by the action, as well as the inhibition activity of GlcB, was 
quantified by using coupled-Ellman’s reagent DTNB as previously described154,139. 
Briefly, the product of the GlcB forward reaction, coenzyme A, reduction of the 
disulfide bond of DTNB producing free NTB
2+
 (2-nitro-5-thiobenzoate) where formation 
is monitored at 412 nm for 20 minutes. The assay was conducted in a 96 well clear plate 
with absorption in the visible range and contained 74 l reaction volumes with 13 nM 
GlcB pre-incubated in enzyme assay buffer containing 20 mM Tris, pH 7.5, 5 mM 
MgCl2, 0.8 mM EDTA. Compounds in 100% DMSO were diluted and added to the 
reaction mixture in final screening condition at 2% DMSO. The reaction mixture with 
compounds was incubated at 25 °C for 20 minutes, followed by the addition of 0.6 mM 
AcCoA, and the final addition of 1.2 mM glyoxylate in 0.5 mM DTNB (final 
concentration) initiated the reaction. The initial velocity of each reaction was generated 
by plotting the curves from the readouts and the enzyme kinetics were calculated by the 
software program using the first order algorithm in AU/hr. 
Crystallization, data collection, and data analysis 
GlcB crystals were obtained by hanging drop vapor diffusion within 1-2 months 
using the previously described method
149,139
. Briefly, purified GlcB WT, single C619A 
mutant, and double C619A G459A mutant enzymes (with His6 tag) at a concentration of 
5 mg/ml in 20 mM Tris-HCl, pH 7.5, was mixed with mother liquor containing 20-30% 
PEG 3350, 0.1 M MgCl2, and 0.1 M Tri-HCl, pH 7-8.5 at a 1:1 volume ratio for 
crystallization by vapor diffusion. For co-crystallization, 1-4 mM of fragment was added 
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to GlcB prior to mixing with mother liquor. Hit fragments from DSF screening were 
soaked in by transferring pre-formed crystals or co-crystals into drops with 15-50 mM 
fragments in the mother liquor with a final concentration of DMSO below 15% for 16-
48 hours. The fragment bound GlcB crystals belonged to space group P43212 with unit 
cell dimensions of a = b = 79 Å, c = 224 Å,  = b =  = 90°, and contained one molecule 
per asymmetric unit.  
For malate and CoA product bound crystals, purified WT GlcB (~ 5 mg/ml) was 
pre-incubated for 20, 40, and 60 minutes with 2 mM substrates glyoxylate and AcCoA 
each in 20 mM Tris-HCl, pH 8.0, and 10 mM MgCl2 at room temperature. The protein 
mixture was then mixed at 1:1 volume ratio with 1.6 M (NH4)2SO4, 0.1 M MES, pH 6.5, 
and 10% dioxane. These crystals belonged to space group P41212 with unit cell 
dimensions of a = b = 121 Å, c = 233 Å,  = b =  = 90°, and contained two molecules 
per asymmetric unit. For apo enzyme crystallization, the purified WT GlcB was diluted 
to 0.1 mg/ml in the assay buffer containing 5 mM of Mg
2+
, and incubated with AcCoA 
to react residual glyoxylate away. This yielded the crystal in the P43212 space group, 
which has a cell dimension similar to the fragment bound crystals. After one hour, the 
enzyme was extensively washed with the excess assay buffer and concentrated back to 5 
mg/ml. All crystals were cryo-protected by Fomblin and flash frozen in liquid nitrogen 
for x-ray data collection. Data were collected at the Argonne National Lab APS 
synchrotron, beamlines 19-ID and 23-ID, or Lawrence Berkley National Laboratory 
ALS, beamlines 8.2 and 8.3, at 0.98-1.01 Å wavelengths.  
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Diffraction data were indexed, integrated, and scaled using HKL2000
132
 or 
HKL3000
133
, and were further merged and truncated in CCP4
134
. PDB structures 1N8I 
and 1N8W
148
 with only the protein atoms remaining in the refinement was used as the 
model for the initial rigid body refinement of the isomorphous P43212 and P41212 
crystals, respectively, in REFMAC
155
. The ligand model and dictionary files were 
created using ELBOW from the PHENIX
135
 suite and fitted into electron density in 
COOT
136
. The final fragment bound and product bound models were gradually improved 
by repeating the process of inspection and manual modification in COOT and refinement 
in PHENIX with simulated annealing. Table C-4 contains data collections and 
refinement statistics for all ligands. Unless otherwise denoted, all images showing 
crystal structures are rendered in CHIMERA
137
. 
Results and discussion 
Crystal structures of malate bound GlcB 
 The open conformation of the active site loop has been observed once in the 
structure of malate synthase isoform A from E. coli
164
. The enzyme had only an Mg
2+
 
ion bound in the active site, similar to conformational changes in the fragment bound 
structures: the opening of the active site loop concurrent with the narrowing of the main 
channel due to the CoA binding loop moving to the in conformation. Although this is a 
different isoform of malate synthase from that of Mtb (A versus G) with an 18-20% 
sequence identity, the catalytic residues, as well as the residues of the CoA binding loop 
and the active site loop, are conserved. Together with the fact that no distribution of 
positions but rather two distinct conformations of the enzyme were observed throughout 
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the fragment bound structures led to the notion that these conformational changes are 
physiologically relevant, and further investigation on the reaction associated with the 
structural changes of malate synthase is conducted. 
 Since the published structures of malate synthase with its substrate glyoxylate 
and products malate and CoA were virtually identical, the enzyme was never viewed as 
undergoing conformational changes upon catalysis. More transient states malate 
synthase assumes during turnover were captured by using fragments as probes. While all 
published structures (PDB IDs 1N8W
149
 and 2GQ3
158
) agree on the conformation of the 
enzyme, structures of Mtb GlcB show malate itself in two different positions in the 
active site. In the first structure, malate participates with two oxygens in a distorted 
pyramidal Mg
2+
 coordination, along with Glu434, Asp462, and one water molecule. In 
the second structure, malate essentially overlaps with the glyoxylate position, giving 
Mg
2+
 perfect octahedral coordination. In the first structure, malate participates with two 
oxygens in a distorted pyramidal Mg
2+
 coordination, along with Glu434, Asp462, and 
one water molecule, as shown in Figure 30A. In the second structure, malate essentially 
overlaps with the glyoxylate position, giving Mg
2+
 perfect octahedral coordination, as 
shown in Figure 30B. Since the P41212 crystal form has an inherently lesser quality and 
relatively low resolution (~2.8 Å) compared to the glyoxylate bound crystals (space 
group P43212), the fitting of malate in the 1N8W model was controversial. 
 While considering the forces driving the observed conformational changes for 
experimentations, an important difference was noted in the methods resulting in the two 
contrasting malate bound structures. The 1N8W structure was solved from a crystal in 
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which the enzyme had been pre-incubated with the substrate and hence captured the 
formed products, while GlcB was pre-incubated with chemically pure products for the 
2GQ3 structure. Since the protonation states of malate and the catalytic residues differed 
between these two methods, both malate bound structures were correct. As a part of the 
structural investigation of catalysis driven conformational changes, the 1N8W structure 
from Smith et al. were reproduced by pre-incubating wild-type GlcB with equal 
concentrations of substrates glyoxylate and AcCoA (2 mM each) for 20 minutes prior to 
setting up the crystal plate, with the active site shown in Figure 31A (Huang et al., 
manuscript in preparation). Three data sets from three independent experiments show 
density consistent with the conformation of malate in the 1N8W structure, the best one at 
2.5 Å. The position of CoA slightly differs among them in agreement with previous 
observations, and it is likely that after turnover, CoA is not bound tightly enough to 
result in well ordered density. 
 
 
 
Figure 30: Malate positions in crystal structure A) 1N8W showing a distorted pyramidal 
Mg
2+
 coordination, and in B) 2GQ3 showing a perfect octahedral Mg
2+
 coordination. 
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GlcB was crystallized after a longer pre-incubation with the substrate (up to 60 
minutes) to see if different stages of product dissociation could be captured. Electron 
density disappearance of CoA and disordering of Mg
2+
 coordination were observed at 
various pre-incubation times. The Mg
2+
 ion and the coordinated water molecule peak 
intensities diminish, and the Asp462 side chain becomes partially disordered, losing 
coordinating contact with Mg
2+
. One data set is represented here and shown in Figure 
31B (Huang et al., manuscript in preparation) as an overview of the enzyme after longer 
incubation with the substrates. No density for CoA was observed in this particular data 
set, as CoA most likely has dissociated from the main tunnel. Malate position shifts 
toward Phe460 from its position in the 1N8W model. One carboxylate oxygen of malate 
remains in contact with Mg
2+
, but the other carboxylate oxygen rotates, maintaining the 
H-bond with Asp633 and forming a new H-bond with Arg339. Malate hydroxyl is 2.8 Å 
away from Mg
2+
, making metal coordination unlikely, though it may make a transient H-
bond with the carboxylate oxygen of Glu434 (3.1 Å). The active site loop is closed, as 
malate still maintains H-bonds with the backbone nitrogens of Phe460 and Leu461 by 
another carboxylate oxygen (3.2 Å and 2.4 Å, respectively). 
GlcB C619A G459A mutant enzyme and crystallization 
Based on the proposition that active site loop opening allows for product-
substrate exchange, a G459A mutant as Gly459 undergoes the largest main chain 
movement upon opening was made. As expected, the addition of a methyl group 
restricted the conformation change, and the mutant had 20% of the activity when tested 
in the enzyme assay. The purified mutant was incubated with substrate for crystallization 
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as described above. The crystals were significantly harder to obtain, presumably the 
slower rate resulted in the greater variations of catalytic stages in the sample. The 
successfully collected crystal was in the P43212 space group and diffracted fairly (2.2 Å). 
As expected, it had no density for CoA, as packing of the enzyme in this space group is 
not CoA compatible, and had well-ordered malate trapped in the active site. 
Interestingly, this crystal shows the in conformation of the CoA binding loop, with 
Asp633 drawn closer to the Mg
2+
, making interactions with the oxygens of the malate 
carboxylate and hydroxyl. The Mg
2+
 ion is in the pyramidal coordination with two water 
molecules, Glu434, Asp462, and one malate carboxylate oxygen, as shown in Figure 
31C (Huang et al., manuscript in preparation). The other oxygen on the malate 
carboxylate coordinating Mg
2+
 ion interacts with the mutated Ala459 side chain by Van 
der Waals interactions (3.1 Å). 
Crystal structure of apo GlcB 
Finally, crystals of ligand-free GlcB were obtained to demonstrate that the 
conformation of the enzyme discovered through fragment probing corresponded to the 
apo form of the enzyme. Since glyoxylate tends to co-purify with GlcB, the apo crystal 
was achieved by pre-incubating the enzyme for one hour prior to crystallization with 
substrates to react with residual glyoxylate after diluting, washing with excess buffer, 
and re-concentrating. This sample produced the highest quality crystal of the P43212 
space group which diffracted to 2.2 Å, yielding well-defined density for the CoA binding 
loop in the in conformation and the open active site loop. This is consistent with the 
conformation observed for the Group 2 fragments, which don’t have ligand bound in the 
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active site. Interestingly, there is no electron density for ordered Mg
2+
, with only a water 
molecule built into its corresponding position with a peak intensity for Fo-Fc at 2, as 
shown in Figure 31D (Huang et al., manuscript in preparation). The uniformity in the 
conformation of the structures with moving loops took many crystal trials and multiple 
crystals to achieve, and the quality of the crystals were still of lesser quality than the 
glyoxylate bound crystals used to soak the fragments. Nevertheless, using fragments as 
probing tools, crystal structures were successfully produced with more physiologically 
transient conformations by first stabilizing them through interaction with a fragment. 
 
 
 
Figure 31: Active site with different positions of malate bound in the structures of A) 
co-crystal from pre-incubation with substrates for 20 min, B) co-crystal from pre-
incubation with substrates for 40-60 min, C) co-crystal from pre-incubation of C619A 
G459A mutant enzyme with substrates, and D) WT apo enzyme resulted from the pre-
incubation with substrates for more than 60 min. 
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Figure 32: Chemical mechanism of GlcB with formulated conformational changes. 
ASL, active site loop, is denoted in purple with movements depicted by purple arrows; 
CBL, CoA binding loop, is denoted in pink with movements depicted by pink arrows. 
 
 
Catalysis driven conformational change 
Combining the observations from all the crystal structures and published kinetic 
studies thus far, it is proposed that glyoxylate binds first to the apo enzyme (active site 
loop open and CoA binding loop in) entering through the second portal by the open 
active site loop. Upon making two strong H-bonds with the backbone nitrogen atoms of 
Glu434 and Asp462, it induces closing of the active site loop. Subsequently, glyoxylate 
brings order to the Mg
2+
 coordination, enabling the ideal octahedral geometry, and the 
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H-bond network surrounding the Mg
2+
-glyoxylate complex pushes Asp633 back to 
establish the CoA binding loop to the out conformation. This widens the main tunnel 
sufficiently for the pantothenate tail of AcCoA to enter and bind productively. Once the 
reaction is complete, CoA starts to dissociate, and Asp633 is released from the 
interaction with malyl-CoA. In the active site where Mg
2+
 coordination and the catalytic 
acid-base pair are shielded from solvent, the H-bond network drastically changes as a 
result of catalytic turnover in the active site in response to the changes in the protonation 
states of the active site participants. The protonation state of Asp633 is not in favor of 
malate binding because the carboxylate groups of both parties are protonated. Asp633 
then moves toward Mg
2+
 and displaces malate so that the malate carboxylate group is 
within H-bonding distance of both Asp633 and Arg339 as observed in the malate bound 
structure. The hydroxyl group of malate binds in the place of the Mg
2+
 coordinating 
glyoxylate carbonyl group, and one of the Mg
2+
 coordinating water molecules is lost to 
the hydrolysis of the malyl-CoA intermediate. This stabilizes the octahedral coordination 
of Mg
2+
 which reflects on the position of the Asp462 side chain as it belongs to the same 
coordination sphere. The end of the alpha helix of the active site loop starting from the 
Mg
2+
 coordinating Asp462 down to Gly459 starts to relax. The helix unwinding with the 
loss of the H-bond between the Asp462 backbone nitrogen and glyoxylate, which is not 
maintained by the malate hydroxyl, the existing closed conformation to destabilize. The 
last turn of the active site loop helix unwinds with the largest main chain transition at 
Gly459, and the bulky side chains of Phe460 and Leu461 relocate to open a solvent 
access portal. It is through this portal that malate exits and new glyoxylate enters for the 
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next round of catalysis. Figure 32 summarizes the conformational changes of the two 
loops around the active site to reflect the chemical mechanism of enzyme’s catalysis. 
The open conformation of the active site loop has previously been observed in 
both the E. coli malate synthase A (MSA). Mtb only has the G isoform, and it shares a 
56% identity and 71% similarity with E. coli MSG, showing an 18% identity with the 
MSA isoform
164
. Lohman and coworkers proposed that the active site loop open 
conformation is related to substrate/product exchange during catalysis. Though the E. 
coli MSA isoform has residues Arg276 and Trp277 in place of Mtb GlcB Phe460 and 
Leu461 (Phe453 and Leu454 in E. coli MSG), they serve a similar purpose of blocking 
the entrance of the second portal by the movement of their bulky side chains. Meanwhile 
the transition of the active site loop main chain from closed to open remains the same, 
and Gly459 (Gly452 in E. coli MSG) as the conserved residue, sustains the most 
significant twist with its smallest hydrogen side chain. The side chain of nearby residue 
Tyr492 forms an H-bond with the backbone nitrogen atom of Gly459 regardless of the 
active site loop conformation. All of these residues, Gly459, Tyr492, Glu632, Ala635, 
and Thr636 are conserved not only across different species of GlcB but across two 
isoforms of GlcB as well, supporting the view that these two conformations are 
physiologically relevant.  
While all fragments have essentially similar chemical moieties which interact 
with the same residues, it is the particular spacing and positioning of the H-bond 
donating and accepting groups that enable a particular fragment to stabilize one of the 
two distinct conformations. Four of five fragments (1-4 from Table 2) inducing closure 
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of the active site loop coordinate Mg
2+
 with their carboxylate groups; two of those four 
fragments (2, 3 from Table 2) coordinate Mg
2+
 in a similar way to glyoxylate or PDKA, 
making the same stabilizing interactions with the backbones of Leu461 and Asp462. One 
of the five fragments (5 from Table 2) inducing active site loop closure indirectly 
interacts with Mg
2+
 via a H-bond network with the Mg
2+
 coordinating water molecules. 
All five fragments that induce the closed active site loop interact with Arg339 via H-
bonds. The fragments (6-17 from Table 2) inducing the opening of the active site loop 
point their carboxylate groups away from Mg
2+
, in the direction of the open active site 
loop residues 459-461, and interact with the backbone of Phe460 and Leu461 of the loop 
either directly or indirectly via water molecules that come in through the opening. 
Conclusion 
 The fragments have been used to probe the active site of the second glyoxylate 
shunt enzyme GlcB for conformational changes which prompted for more detailed 
investigation. Structural data and kinetic studies of the chemical mechanism available in 
the literature from Mtb and E. coli further assisted in the analysis of structural changes 
and revealed invaluable information associated with catalysis. After calculated 
experimentations and numerous crystallizations with substrates glyoxylate and AcCoA, 
structures of GlcB complexed with products malate and CoA at various stages of 
turnover, as well as a structure of apo enzyme, were obtained.  
Through all the crystal structures from fragment based and catalysis studies, 
enzyme’s chemical mechanism reflecting the series of conformational changes around 
the active site was formulated. Glyoxylate enters through the second portal by the open 
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active site loop and binds first to the apo enzyme (CoA binding loop in). The binding of 
glyoxylate induces the closing of the active site loop, enabling the ideal octahedral 
geometry and the H-bond network surrounding the Mg
2+
-glyoxylate complex to 
establish the CoA binding loop to the out conformation. This widens the main tunnel 
sufficiently for the pantothenate tail of AcCoA to enter and bind productively, followed 
by the GlcB reaction. The catalytic base Asp633 abstracts a proton from AcCoA to 
produce an enolate, which attacks the polarized glyoxylate to generate malyl-CoA 
intermediate. The catalytic acid Arg339 protonates the malyl-CoA thiolate which causes 
the intermediate to decompose into malate and CoA. Once the reaction is complete, 
product CoA starts to dissociate. In the active site where Mg
2+
 coordination and the 
catalytic acid-base pair are shielded from solvent, the H-bond network drastically 
changes as a result of catalytic turnover in the active site in response to the changes in 
the protonation states of the active site participants. The protonation state of Asp633 
does not support malate binding because the carboxylate groups of both parties are 
protonated. Asp633 moves toward Mg
2+
 and displaces malate so that the malate 
carboxylate group is within H-bonding distance of both Asp633 and Arg339. Malate 
binds by coordinating Mg
2+
 in a distorted pyramidal geometry as one of the Mg
2+
 
coordinating water molecules is lost to the hydrolysis of the malyl-CoA intermediate. 
The end of the alpha helix of the active site loop starting from the Mg
2+
 coordinating 
Asp462 down to Gly459 starts to relax. The helix unwinds with the loss of the H-bond 
between the Asp462 and the malate hydroxyl, and the existing closed conformation 
destabilizes. The last turn of the active site loop helix unwinds with the largest main 
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chain movement at Gly459, and the bulky side chains of Phe460 and Leu461 displace to 
open a solvent access portal. Malate exits and a new glyoxylate enters for the next round 
of catalysis through the second portal by the open active site loop. 
Future work 
Numerous crystal trials with pre-incubation of substrates and countless crystals 
were used throughout the investigation of the conformational changes associated with 
catalysis. Yet most of the crystals with X-ray data sets collected only diffracted fairly 
with moderate resolution, up to 2.5 Å. Future work would be to improve the quality of 
the crystals for obtaining higher resolution X-ray diffraction data. 
Crystal structures reflect static 3D protein packing and folding; therefore the 
structures with protein conformations that were captured throughout this study might not 
tell the whole story when pieced together. For more dynamic conformational study, 
another structural method, such as NMR, might be required to complement the crystal 
structures. Previously NMR spectroscopic data has been obtained for E. coli MSG 
showing changes in 
15
N and 
1
HN chemical shifts observed in the 616–632 loop region 
and in the nearby 300-310 loop region in response to binding of both pyruvate and 
AcCoA
167
. Similar study could be extended to Mtb GlcB to confirm the anticipated 
chemical shifts in the same active site loop and the CoA binding loop regions upon 
substrate binding. 
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CHAPTER V 
SUMMARY 
 
Structural biology has advanced over the last three decades and resulted in a 
great wealth of structural data (over 100,000 structures available in PDB database) with 
developments in anomalous scattering based phasing algorithms and X-ray instruments. 
Structural coverage was greatly enhanced by the focus of structural genomics initiatives 
with special interest for potential drug development. Currently structure based drug 
design is a standard technique routinely employed by academia and industries to 
discover new hits through virtual screening and/or to guide a medicinal chemistry 
through exploring SAR in hit optimization process. Ultimately structural information 
greatly improves the advancement of a lead compound with desirable affinity and 
ADMET profile for pre-clinical assessment compared to old-fashioned screening and 
systematic analogues exploration.  
Tuberculosis (TB) remains as a global health emergency despite the treatment of 
the first and second-line antibiotics, and there is a high demand for the discovery and 
development of novel anti-tubercular drugs. The glyoxylate shunt plays a crucial role in 
fatty acid metabolism and is essential for the survival of TB causing agent 
Mycobacterium tuberculosis (Mtb) during chronic infection. Two enzymes of the 
glyoxylate shunt are potential targets for drug development due to the essentiality of the 
glyoxylate shunt under chronic infection and their absence in mammals. Targeting ICL 
has not yielded any drug-like hits, possibly due to its relatively small and highly charged 
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active site that becomes solvent inaccessible upon substrate binding. ICL active site loop 
undergoes a large conformational change during catalysis thus presenting a serious 
challenge for virtual screening or rational drug design. On the contrary, the active site of 
GlcB has a more druggable profile without a significant conformational change during 
catalysis. Crystal structures of both glyoxylate bound and product bound GlcB show that 
the overall protein structure and the active site in particular does not change between 
these two states. Despite a well-defined active site, multiple efforts in virtual screening 
failed to produce hits with reasonable activity. Structure-guided design was later used to 
develop an initial phenyl-diketo acid (PDKA) hit into a series of potent inhibitors of 
GlcB, which allowed chemical validation of GlcB as a target in a mouse model infected 
with Mtb. However PDKA chemotype suffers from limitations including poor stability 
and potential reactivity. More effective approaches are therefore needed to explore the 
two enzymes as targets for drug development.  
A mechanism based approach was applied for the structural and biochemical 
studies of the first glyoxylate shunt enzyme isocitrate lyase (ICL). The crystal structure 
of Mtb ICL Cys191Ser mutant in complex with substrate isocitrate was determined by 
X-ray crystallography at 1.8 Å resolution for the elucidation of the enzyme’s catalytic 
mechanism. The C191S mutant enzyme was originally designed to capture isocitrate in 
the active site. Although no activity was detected for isocitrate, the crystal structure of 
ICL C191S treated with isocitrate showed that the products of isocitrate, glyoxylate and 
succinate, bind in the active site. Not all subunits were equivalent in the crystal structure, 
where clear density of glyoxylate was observed in all monomers, and succinate was 
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either absent or already dissociated from the active site in two subunits. The enzyme 
assumes closed active site loop conformation in the two subunits in which succinate was 
bound and open active site loop conformation in the other two subunits absent of 
succinate. The structure suggested that isocitrate could bind to the enzyme in the 
presence of serine, and that serine in the Cys191 position could carry out the reaction of 
ICL, albeit at a significantly slower rate. 
 Previously determined crystal structure of ICL complexed with inhibitor 3-
bromopyruvate has demonstrated the ability of the active site nucleophile Cys191 to 
withstand covalent modification for the basis of the inactivation. The crystal structures 
of Mtb ICL in complexes with itaconate and 2-vinyl isocitrate were further determined 
by X-ray crystallography at 2.6 and 1.8 Å resolution, respectively. In both structures, the 
active site Cys191 was covalently modified to S-methylsuccinyl and S-homopyruvoyl 
adducts following the inactivations by itaconate and 2-VIC, respectively. Unlike the 
structure of ICL C191S treated with substrate isocitrate, the four monomers were 
equivalent with clear density of thiolate adduct formed from the inactivation in the active 
site. All subunits had the closed active site loop conformation with clear electron 
density, and as a result, the C-terminal loop of the adjacent subunit moved in on top of 
the closed active site loop to render the active site solvent inaccessible.  
The mechanism of inhibition for itaconate followed the direct nucleophilic attack 
on the vinyl group of itaconate by the active site Cys191, which resulted in the S-
methylsuccinyl-cysteine. The crystal structure of ICL treated with itaconate showed that 
the S-methylsuccinylated adduct formed between the inhibitor and Cys191 and 
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coordinated Mg
2+
 ion in the active site. The inactivation of 2-VIC was based on the 
mechanism of the ICL reaction of aldo-cleavage of isocitrate, and the structure of ICL 
treated with 2-VIC showing the S-homopyruvoyl adduct covalent linked to active site 
Cys191 confirmed the proposed mechanism. 
 For the second glyoxylate shunt enzyme malate synthase (GlcB) a fragment 
based approach was employed. Fragments are small molecules with molecular mass 
<300 with fewer functionalities, and they have the advantages of sampling larger 
chemical space and providing high-quality interactions which they make with the target 
to bind with sufficient affinity for detection. Differential scanning fluorimetry (DSF) 
with a thermal cycler and the fluorescence dye Sypro Orange provided a suitable binding 
assay for malate synthase in a high-throughput screening format. All fragments with 
binding infinities resulted in positive thermal shifts in melting temperature, including 
weakly binding fragments. Out of 1580 fragments screened 64 fragments produced 
thermal shifts > 3 °C, of which 18 fragment complex crystal structures were successfully 
obtained. From the fragment bound crystal structures, conformations around the active 
site of the enzyme involving the movements of the two loops, the active site loop and the 
CoA binding loop, were observed. The active site loop moved from closed to open 
conformations which generated an additional portal to the surface, and the CoA binding 
loop narrowed the active site tunnel when it transitioned from out to in. 
 Information from fragment binding has provided a variety of scaffolds for 
inhibitor designs, including aromatic rings that can bind in the active site and functional 
groups that can form interactions. Different conformations of the active site loop and the 
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CoA binding loop can be achieved independently of each other and thus can be exploited 
in any combination in the inhibitor designs. Therefore, inhibitors with functional groups 
placed to form H-bonds with major residues such as Arg339, Asp633, Phe460, Leu461, 
Asp462, and Met631, to directly or indirectly coordinate Mg
2+
, and to sustain stacking 
interactions with Met631 and Met515 are of particular interest. Several fragments have 
nitrogen-containing moieties such as pyrrole, indole, and thienopyrrole, in which the 
nitrogen interacts with the backbone of Met631. The indole and thienopyrrole moieties 
were incorporated into the existing inhibitor template. As a result, inhibitor potency was 
increased by over 100 fold with an IC50 of 18 nM for unsubstituted indole-diketo acid 
versus 2 M for unsubstituted PDKA, and the anticipated H-bond between the nitrogen 
and Met631 was observed. In addition, the non-substituted indole-diketo acid inhibitor 
was more stable than the parent PDKA and less likely to undergo retro Claisen 
condensation and revert back to ketones. More potent inhibitors could be designed based 
on the discovered interactions with these key residues, providing a platform for future 
antibacterial therapeutic development. 
 In addition to potential drug designs from fragment based approach, the 
fragments have been proven useful in probing the active site for conformational changes 
and prompted for more detailed investigation. Structural data and kinetic studies of the 
chemical mechanism available in literature from Mtb and E. coli further assisted in the 
analysis of structural changes and revealed invaluable information associated with 
catalysis. After calculated experimentations and numerous crystallizations with 
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substrates glyoxylate and acetyl-CoA, structures of GlcB complexed with products at 
various stages of turnover and a structure of apo enzyme were obtained.  
Through all the crystal structures from fragment based studies, enzyme’s 
catalytic mechanism reflecting the series of conformational changes around the active 
site was proposed. Glyoxylate enters through the second portal by the open active site 
loop and binds first to the apo enzyme (CoA binding loop in). The binding of glyoxylate 
induces the closing of the active site loop, enabling the ideal octahedral geometry and 
the H-bond network surrounding the Mg
2+
-glyoxylate complex to establish the CoA 
binding loop to the out conformation. This widens the main tunnel sufficiently for the 
pantothenate tail of acetyl-CoA to enter and bind productively, followed by the GlcB 
reaction. The catalytic base Asp633 abstracts a proton from acetyl-CoA to produce an 
enolate, which attacks the polarized glyoxylate to generate malyl-CoA intermediate. The 
catalytic acid Arg339 protonates the malyl-CoA thiolate which causes the intermediate 
to decompose into malate and CoA. Once the reaction is complete, product CoA starts to 
dissociate. In the active site where Mg
2+
 coordination and the catalytic acid-base pair are 
shielded from solvent, the H-bond network drastically changes as a result of catalytic 
turnover in the active site in response to the changes in the protonation states of the 
active site participants. The protonation state of Asp633 does not support malate binding 
because the carboxylate groups of both parties are protonated. Asp633 moves toward 
Mg
2+
 and displaces malate so that the malate carboxylate group is within H-bonding 
distance of both Asp633 and Arg339. Malate binds by coordinating Mg
2+
 in a distorted 
pyramidal geometry as one of the Mg
2+
 coordinating water molecules is lost to the 
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hydrolysis of the malyl-CoA intermediate. The end of the alpha helix of the active site 
loop starting from the Mg
2+
 coordinating Asp462 down to Gly459 starts to relax. The 
helix unwinds with the loss of the H-bond between the Asp462 and the malate hydroxyl, 
and the existing closed conformation destabilizes. The last turn of the active site loop 
helix unwinds with the largest main chain movement at Gly459, and the bulky side 
chains of Phe460 and Leu461 displace to open a solvent access portal. Malate exits and a 
new glyoxylate enters for the next round of catalysis through the second portal by the 
open active site loop. 
Due to their roles in the glyoxylate shunt, two enzymes ICL and GlcB have been 
studied as potential targets by two distinct approaches to drug discovery, a mechanism 
based approach for ICL and a fragment based approach for GlcB. Each approach was 
ideally suited for each enzyme, and the structural data has further provided support in 
medicinal chemistry for drug discovery in lieu of the more traditional approach by 
screening compound libraries. Although more future work is required to elaborate on the 
covalent inhibitors for ICL and on the indole- and thienopyrrole-dikeo acid inhibitors for 
GlcB, the research presented in this dissertation has well paved the way to target the 
glyoxylate shunt enzymes for novel anti-tubercular therapeutics. 
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APPENDIX A  
NOMENCLATURE 
 
3D    Three-dimensional 
NMR    Nuclear magnetic resonance 
EM    Electron microscopy  
PDB    Protein Data Bank 
MIR    Multiple isomorphous replacement 
MAD    Multiwavelength anomalous dispersion 
E. coli    Escherichia coli 
TB    Tuberculosis 
WHO    World Health Organization 
HIV    Human immunodeficiency virus 
DNA    Deoxyribonucleic acid 
BC    Before Christ 
AD    Anno domini 
Mtb or M. tuberculosis Mycobacterium tuberculosis  
M. bovis   Mycobacterium bovis 
BCG    Bacillus Calmette-Guérin  
MRC    Medical Research Council 
USPHS   United States Public Health Service 
LJ    Löwenstein-Jensen 
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AFB    Acid-fast bacilli 
MGIT    Mycobacterial Growth Indicator Tube 
MODS    Microscopically observed drug susceptibility 
DST    Drug susceptibility test 
LPA    Line probe assay 
NAAT    Nucleic acid amplification test 
IGRA    Interferon- release assay 
ATS    American Thoracic Society 
IDSA    Infectious Diseases Society of America 
CDC    Centers for Disease Control and Prevention 
DOT    Directly observed therapy 
MDR    Multidrug-resistant 
XDR    Extensively drug-resistant 
TDR    Totally drug-resistant 
SAR    Structure-activity relationship 
TBSGC   Tuberculosis Structural Genomics Consortium 
ORF    Open reading frame 
HTS    High-throughput screening 
MW    Molecular weight 
RO3    Rule of Three 
H-bond  Hydrogen bond 
DMSO   Dimethyl sulfoxide 
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TS    Thermal shift 
SPR    Surface plasmon resonance 
MS    Mass spectrometry 
ITC    Isothermal titration calorimetry 
2D    Two-dimensional 
LC    Liquid chromatography 
CCM    Central carbon metabolism 
TCA    Tricarboxylic acid 
TraSH    Transposon site hybridization 
ATP    Adenosine triphosphate 
CoA    Coenzyme A 
KOR    Ketoglutarate ferredoxin oxidoreductase 
GABA    -Aminobutyrate 
PEP    Phosphoenolpyruvate 
PEPCK   Phosphoenolpyruvate carboxykinase 
ICL    Isocitrate lyase 
GlcB or MS   Malate synthase 
cDNA    Complementary DNA 
EC    Enzyme commission 
Lys or K   Lysine 
Cys or C   Cysteine 
His or H   Histidine 
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SDS-PAGE Sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis 
Da    Dalton 
M. avium   Mycobacterium avium 
AA    Amino acid 
A. nidulans   Aspergillus nidulans 
Gly or G   Glycine 
INF-    Human immune interferon 
MCL    2-Methylisocitrate lyase 
S. typhimurium  Salmonella typhimurium 
S. cerevisiae   Saccharomyces cerevisiae 
P. indigofera   Pseudomonas indigofera 
3-NP    3-Nitropropionate 
IC50    Half minimal inhibitory concentration 
Trp or W   Tryptophan 
Phe or F   Phenylalanine 
Thr or T   Threonine 
2-VIC 2-vinyl isocitrate, 2-vinyl-D-isocitrate, (2R,3S)-2-vinyl 
isocitrate, or (2S,3R)-3-hydroxypent-4-ene-1,2,3-
tricarboxylate 
PCR    Polymerase chain reaction 
G    Guanine 
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A    Adenine 
T    Thymine 
C    Cytosine 
WT    Wild-type 
Ser or S   Serine 
LB    Lauryl broth 
IPTG    Isopropyl--D-1-thiogalactopyranoside 
OD or OD600   Optical density measured at wavelength 600 nm 
EDTA    Ethylenediaminetetraacetic acid 
DTT    Dithiothreitol 
PMSF    Phenylmethylsulfonyl fluoride 
psi    pounds per square inch 
rpm    Revolutions per minute 
UV    Ultraviolet  
OADC    Oleic acid, bovine albumin, dextrose, catalase 
PEG    Polyethylene glycol 
SBC    Structural Biology Center 
APS    Advanced Photon Source 
CCP4    Collaborative Computational Project, Number 4 
NADH    Nicotinamide adenine dinucleotide (reduced) 
HEPES   4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
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MIC or MIC99 Minimum inhibitory concentration that inhibits 99% of 
bacterial isolates 
Asp or D  Aspartic acid 
Asn or N   Asparagine 
Arg or R  Argenine 
Glu or E  Glutamic acid 
KIE  Kinetic isotope effect 
Tyr or Y  Tyrosine 
AcCoA   Acetyl coenzyme A or acetyl-CoA 
aceB or MSA   Malate synthase A  
C. glutamicum   Corynebacterium glutamicum 
Y. pestis   Yersinia pestis 
MSG    Malate synthase G 
PDKA Phenyl-diketo acid or (Z)-2-hydroxy-4-oxo-4-phenylbut-2-
enoic acid 
2-Br-PDKA 2-bromo-phenyl-diketo acid or (Z)-4-(2-bromophenyl)-4-
hydroxy-2-oxobut-3-enoic acid 
mRNA    Messenger RNA or messenger ribonucleic acid  
DSF    Differential screening fluorimetry 
qPCR    Real-time PCR or quantitative PCR 
FAM    Fluorescein amidite 
ROX    Carboxy-X-rhodamine 
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AU    Absorbance unit 
Ala or A   Alanine 
DTNB    5,5’-dithiobis(2-nitrobenzoic acid) 
NTB
2+
   2-nitro-5-thiobenzoate 
ALS    Advanced Light Source 
Met or M   Methionine 
Leu or L   Leucine 
Pro or P   Proline 
MES    2-(N-morpholino)ethanesulfonic acid 
ASL    Active site loop 
CBL    CoA binding loop 
ADMET    Absorption, distribution, metabolism, excretion, toxicity  
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Table B-2: Crystal data collection and refinement statistics. 
Statistics 
ICL1 C191S-glyoxylate- 
pyruvate complex  
ICL1 treated 
with ITA 
ICL1 treated 
with 2-VIC 
Data Collection 
   Space group P212121 P212121 P212121 
Cell dimensions 
   
a, b, c (Å) 79.55, 133.15, 158.5 
75.47, 129.25, 
168.98 
75.09, 129.24, 
167.95 
, ,  (°) 90, 90, 90 90, 90, 90 90, 90, 90 
Rsym or Rmerge 0.113 (0.952) 0.182 (0.601) 0.095 (0.167) 
I/I 27.72 19.86 14.01 
Completeness (%) 99.43 (95.40) 99.35 (96.20) 99.61 (96.85) 
Redundancy 11.6 (9.6) 10 (10.2) 7.7 (4.1) 
Refinement 
   
Resolution (Å) 42.74-2.0 (2.03-2.0) 
42.62-2.61        
(2.66-2.61) 
42.31-1.78       
(1.81-1.78) 
No. of reflections 114024 50652 155553 
Rwork/Rfree 0.1606/0.2187 0.1638/0.2456 0.2106/0.2559 
No. of atoms 
   Protein 13232 13232 13232 
Ligand/ion 56 40 32 
Water 1768 1173 1185 
B factors 
   Protein 21.7 28.7 34.4 
Ligand/ion 24.5 29.4 34.2 
Water 32.4 27.3 36.5 
Rmsd 
   Bond length (Å) 0.008 0.008 0.008 
Bond angles (°) 1.16 1.16 2.15 
Statistics for the highest-resolution shell are shown in parentheses. 
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Scheme B-1: D-Isocitrate, 2-vinyl isocitrate, and 2-vinyl glyoxylate. 
 
 
 
Scheme B-2: Synthesis steps for 2-VIC. 
 
 
Synthesis of 2-vinyl isocitrate 
The synthesis of  (2S,3R)-3-hydroxypent-4-ene-1,2,3-tricarboxylate) or 2-VIC, 
and  (2R,3R)-3-hydroxypent-4-ene-1,2,3-tricarboxylate) or (2R,3R)-VIC (Scheme B-1) 
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is described in a separate publication (Harris et al. manuscript in preparation). Briefly, 
the dimethyl ester -lactone of 2-vinyl isocitrate was prepared in 22 steps from L-xylose 
in an overall yield of 0.4% with an average of 78% yield/step (Scheme B-2). X-ray 
crystallographic analysis of a single crystal of precursor confirmed the structure, and 
showed the anti-relationship of the two methyl ester groups in the γ-lactone. Base-
catalyzed hydrolysis effected epimerization at the C3-position to yield a mixture of (3R)-
3-hydroxypent-4-ene-1,2,3-tricarboxylic acid which was separated by preparative HPLC 
to afford the two diastereomers. The lyophilized salts of the isocitrate analogues were 
dissolved in doubly-deionized water to provide solution concentrations of 13-50 mM. 
Concentrations were determined gravimetrically, with correction for the amount of 
NaOH remaining in the lyophilisates. To prevent lactonization, aliquots of stock 
solutions were neutralized by the addition of sulfuric acid immediately prior to addition 
to reaction mixtures. The diastereomers used in the present study are depicted in Scheme 
B-2, in which 2-vinyl isocitrate possesses the same stereochemistry as the substrate D-
isocitrate, and its epimer is (2R,3R)-VIC. 
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APPENDIX C  
SUPPLEMENTAL MATERIAL FOR CHAPTERS III AND IV 
 
Table C-1: Indole-diketo acid inhibitor and starting material for synthesis. 
No. Chemical structure No. Starting aldehyde 
19 
 
19a 
 
20 
 
19a 
 
21 
 
21a 
 
22 
 
22a 
 
23 
 
23a 
 
R=CH3 for methyl ester and R= H for acid. 
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Table C-1: Continued. 
No. Chemical structure No. Starting aldehyde 
24 
 
24a 
 
25 
 
25a 
 
26 
 
26a 
 
27 
 
27a 
 
R=CH3 for methyl ester and R= H for acid. 
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Scheme C-1: Synthesis steps for indole-diketo acids, 19-27. 
 
 
Compounds 19-27 were synthesized via the synthetic procedure depicted in 
Scheme C-1 as follows: To slurry of 
t
BuONa (1.00 g, 5.36 mmol) in dry THF under N2 
(8 mL) a solution of starting aldehyde (19-27a) in 2.0 mL anhydrous THF was added 
and via syringe. The mixture was stirred at room temperature for 30 min. and then 
dimethyl oxalate (2.2 equiv, 11.8 mmol, 1.39 g) was added. After 48 h, the reaction 
mixture was quenched with 2.0 mL of 2 M HCl (aq) and extracted with EtOAc. The 
combined organic layer was washed with 10 mL brine solution, dried over anhydrous 
Na2SO4, filtered, and concentrated in vacuo. The crude mixture was purified by a silica 
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gel column chromatography to afford the desired methyl ester (19-27, R=CH3) as an 
amorphous white solid. Compound 28 was synthesized via the synthetic procedure 
depicted in Scheme C-2. 
 
 
 
Scheme C-2: Synthesis steps for thienopyrrole-diketo acid, 28. 1) NaOMe, -25 
o
C for 1 
hour at room temperature, followed by 2 hour of MeOH, 2) toluene at 120 
o
C for 1.5 
hours, 3) LiAlH4/THF at 0 
o
C, then reflux for 24 hours followed by aq NaOH for 1 hour, 
4) AcCl/CH2Cl2 at -78
 o
C to temperature for overnight, 5)
 
dimethyloxalate/tBuOK/ THF 
for 48 hours, and 6) de-esterification of methyl ester to acid, see below. 
 
 
Methyl ester of 19-28 was dissolved in 4 mL of 2:1:1 mixture of 
THF/CH3OH/H2O and 0.212 mmol of LiOH monohydrate were added. The yellow 
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solution was stirred for 6 h, and after completion of hydrolysis the reaction mixture was 
acidified to pH 4 with 2 M HCl (aq), and the resulting mixture was extracted with 2x5 
mL EtOAc. The combined organic phase was dried (Na2SO4), filtered, and concentrated 
to afford the desired acid product (19-28, R=H) as a solid. Chemical information is as 
follows: 
Compound 19, (Z)-2-hydroxy-4-(1H-indol-3-yl)-4-oxobut-2-enoic acid: 
1
H NMR 
(400 MHz, DMSO-d6) δ 8.29 (s, 1H), 8.18 (d, J = 7.2 Hz, 1H) , 7.47 (d, J = 7.5 Hz, 1H), 
7.23-7.16 (m, 2H), 2.50 (s, 3H); 
13
C NMR (100 MHz, CDCl3) δ 137.11, 134.74 (2C), 
125.75, 123.14 (2C), 122.06 (2C), 121.76 (2C), 117.26, 112.50 (2C); MS (ESI) m/z 
511.37 (M + Na)
+
. 
Compound 20, (Z)-4-(1H-indol-3-yl)-2-methoxy-4-oxobut-2-enoic acid: 
1
H 
NMR (400 MHz, DMSO-d6) δ 8.71 (s, 1H), 8.24 (d, J = 7.3 Hz, 1H) , 7.60-7.56 (m, 1H), 
7.36-7.24 (m, 3H), 6.94 (s, 1H), 3.89 (s, 3H); 
13
C NMR (100 MHz, CDCl3) δ 164.25, 
163.70, 139.47, 138.25, 126.06, 123.94, 123.25, 122.09, 114.10, 111.59, 100.64, 33.90; 
MS (ESI) m/z 511.37 (M + Na)
+
. 
Compound 21, (Z)-2-hydroxy-4-(2-methyl-1H-indol-3-yl)-4-oxobut-2-enoic 
acid: 
1
H NMR (400 MHz, DMSO-d6) δ 8.05-7.95 (m, 1H), 7.49-7.38 (m, 1H) , 7.28-7.17 
(m, 2H)
 
, 6.86 (s, 1H), 2.74 (s, 3H); 
13
C NMR (100 MHz, CDCl3) δ 188.27, 167.92, 
164.31, 146.84, 135.76, 126.74, 123.07, 122.60, 12081, 112.28, 110.70, 100.35, 15.73; 
MS (ESI) m/z 511.37 (M + Na)
+
. 
Compound 22, (Z)-2-hydroxy-4-(3-methyl-1H-indol-2-yl)-4-oxobut-2-enoic 
acid: 
1
H NMR (400 MHz, DMSO-d6) δ 8.05-7.95 (m, 1H), 7.49-7.38 (m, 1H) , 7.28-7.17 
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(m, 2H)
 
, 6.86 (s, 1H), 2.74 (s, 3H); 
13
C NMR (100 MHz, CDCl3) δ 188.27, 167.92, 
164.31, 146.84, 135.76, 126.74, 123.07, 122.60, 12081, 112.28, 110.70, 100.35, 15.73; 
MS (ESI) m/z 511.37 (M + Na)
+
. 
Compound 23, (Z)-2-hydroxy-4-(1H-indol-5-yl)-4-oxobut-2-enoic acid: 
1
H NMR 
(400 MHz, DMSO-d6) δ 8.44 (s, 1H), 7.83 (dd, J = 8.6, 1.2 Hz, 1H) , 7.56-7.45 (m, 2H) , 
7.17 (s, 1H), 6.65-6.59 (m, 1H); 
13
C NMR (100 MHz, CDCl3) δ 163.94, 139.69, 128.13, 
126.46, 122.88, 121.27, 112.45, 103.77, 98.27; MS (ESI) m/z 511.37 (M + Na)
+
. 
Compound 24, (Z)-4-(1,4-dimethyl-1H-indol-5-yl)-2-hydroxy-4-oxobut-2-enoic 
acid: 
1
H NMR (400 MHz, DMSO-d6) δ 7.59 (d, J = 8.7 Hz, 1H), 7.47-7.35 (m, 2H)  , 
6.87 (s, 1H), 6.69 (d, J = 2.9 Hz, 1H), 3.82 (s, 3H), 2.73 (s, 3H); 
13
C NMR (100 MHz, 
CDCl3) δ 183.43, 163.93, 138.22, 132.86, 131.44, 129.81, 126.36, 123.30, 108.22, 
102.18, 101.67, 33.17, 17.62; MS (ESI) m/z 511.37 (M + Na)
+
. 
Compound 25, (Z)-2-hydroxy-4-(3-methyl-1H-indol-5-yl)-4-oxobut-2-enoic 
acid: 
1
H NMR (400 MHz, DMSO-d6) δ 8.33 (d, J = 8.2 Hz, 1H), 7.83 (d, J = 8.2 Hz, 
1H)
  
, 7.62-7.57 (m, 1H), 7.43-7.39 (m, 1H), 6.03 (s, 1H), 2.61 (s, 3H); 
13
C NMR (100 
MHz, CDCl3) δ 183.43, 163.93, 138.22, 132.86, 131.44, 129.81, 126.36, 123.30, 108.22, 
102.18, 101.67, 33.17, 17.62; MS (ESI) m/z 511.37 (M + Na)
+
. 
Compound 26, (Z)-2-hydroxy-4-(6-methyl-1H-indol-5-yl)-4-oxobut-2-enoic 
acid: 
1
H NMR (400 MHz, DMSO-d6) δ 11.34 (s, 1H), 8.14 (s, 1H), 7.45-7.38 (m, 1H) , 
7.36-7.29 (m, 1H)
 
, 6.95 (s, 1H), 6.56 (s, 1H), 2.61 (s, 3H); 
13
C NMR (100 MHz, CDCl3) 
δ 163.96, 138.79, 131.59, 127.74, 127.29, 126.08, 124.15, 114.58, 103.10, 101.77, 
22.45; MS (ESI) m/z 511.37 (M + Na)
+
. 
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Compound 27, (Z)-2-hydroxy-4-(4-methyl-1H-indol-5-yl)-4-oxobut-2-enoic 
acid: 
1
H NMR (400 MHz, DMSO-d6) δ 7.55 (d, J = 8.5 Hz, 1H), 7.50-7.44 (m, 1H)  , 
7.37 (d, J = 8.5 Hz, 1H), 6.89 (s, 1H), 6.75-6.67 (m, 1H), 2.75 (s, 3H); 
13
C NMR (100 
MHz, CDCl3) δ 183.43, 163.93, 138.22, 132.86, 131.44, 129.81, 126.36, 123.30, 108.22, 
102.18, 101.67, 33.17, 17.62; MS (ESI) m/z 511.37 (M + Na)
+
. 
Compound 28, (Z)-2-hydroxy-4-(5-methyl-6H-thieno[2,3-b]pyrrol-4-yl)-4-
oxobut-2-enoic acid: 
1
H NMR (400 MHz, CD3OD) δ 7.25-7.21 (m, 1H), 7.14-7.12 (m, 
1H), 6.94 (bs, 1H), 3.73 (s, 2H), 2.75 (s, 3H); 
13
C NMR (100 MHz, CDCl3) δ 173.55, 
173.03, 139.48, 129.10 (2C), 127.85 (2C), 125.65, 68.30, 66.40 (4C), 52.95, 45.19, 
40.86, 40.58, 36.95, 34.41, 31.85, 29.28, 29.05, 28.78, 27.26, 22.73 (2C), 22.32 (2C) 
(20); MS (ESI) m/z 511.37 (M + Na)
+
. 
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Table C-2: Crystal data collection and refinement statistics. 
Statistics 
GlcB-1 
complex 
GlcB-2 
complex 
GlcB-3 
complex 
GlcB-4 
complex 
Data Collection 
    Space group P43212 P43212 P43212 P43212 
Cell dimensions 
    
a, b, c (Å) 
78.50, 78.50, 
224.28 
78.85, 78.85, 
224.93 
78.74, 78.74, 
224.66 
78.21, 78.21, 
223.82 
, ,  (°) 90, 90, 90 90, 90, 90 90, 90, 90 90, 90, 90 
Rsym or Rmerge 0.189 (0.799) 0.160 (0.574) 0.114 (0.530) 0.203 (0.724) 
I/I 7.63 23.3 24.21 18.82 
Completeness (%) 98.47 (96.94) 99.36 (98.42) 93.48 (97.19) 96.03 (98.92) 
Redundancy 6.5 (4.1) 13.5 (11.4) 4.5 (4.3) 9.4 (8.3) 
Refinement 
    
Resolution (Å) 
49.75-2.26    
(2.32-2.26) 
45.78-2.04     
(2.08-2.04) 
44.68-1.95      
(1.98-1.95) 
44.43-2.07    
(2.11-2.07) 
No. of reflections 47430 46135 49254 40353 
Rwork/Rfree 0.2092/0.2647 0.1756/0.2206 0.1914/0.2549 0.1910/0.2470 
No. of atoms 
    Protein 5440 5404 5372 5424 
Ligand/ion 14 16 16 15 
Water 472 474 658 585 
B factors 
    Protein 39.9 35.6 36.4 33.1 
Ligand/ion 38.4 28.9 39.2 38.4 
Water 43.9 40.9 46.2 39.5 
Rmsd 
    Bond length (Å) 0.008 0.009 0.008 0.009 
Bond angles (°) 1.12 1.12 1.07 1.07 
Statistics for the highest-resolution shell are shown in parentheses. 
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Table C-2: Continued. 
Statistics 
GlcB-5 
complex 
GlcB-6 
complex 
GlcB-7 
complex 
GlcB-8 
complex 
Data Collection 
    Space group P43212 P43212 P43212 P43212 
Cell dimensions 
    
a, b, c (Å) 
79.36, 79.36, 
225.31 
80.69,80.69, 
226.29 
81.66, 81.66, 
226.56 
78.88, 78.88, 
224.66 
, ,  (°) 90, 90, 90 90, 90, 90 90, 90, 90 90, 90, 90 
Rsym or Rmerge 0.120 (0.597) 0.103 (0.598) 0.367 (0.651) 0.205 (0.738) 
I/I 26.24 15.49 14.61 18.15 
Completeness (%) 95.33 (94.74) 99.45 (99.16) 98.63 (92.87) 99.37 (97.87) 
Redundancy 9.2 (8.4) 6.6 (6.6) 8.6 (4.9) 13.5 (13.6) 
Refinement 
    
Resolution (Å) 
35.14-2.10    
(2.15-2.10) 
39.47-2.3        
(2.34-2.3) 
35.92-1.94     
(2.01-1.94) 
49.96-2.50    
(2.59-2.50) 
No. of reflections 40993 33871 56725 25218 
Rwork/Rfree 0.1748/0.2434 0.2171/0.3004 0.2240/0.3016 0.1637/0.2582 
No. of atoms 
    Protein 5451 5378 5440 5474 
Ligand/ion 14 12 15 10 
Water 676 511 515 438 
B factors 
    Protein 42.6 37.2 53 43 
Ligand/ion 39.8 33 47.9 37.4 
Water 50.5 39.5 56.4 43.2 
Rmsd 
    Bond length (Å) 0.007 0.008 0.008 0.008 
Bond angles (°) 1.1 1.12 1.07 1.15 
Statistics for the highest-resolution shell are shown in parentheses. 
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Table C-2: Continued. 
Statistics 
GlcB-9 
complex 
GlcB-10 
complex 
GlcB-11 
complex 
GlcB-12 
complex 
Data Collection 
    Space group P43212 P43212 P43212 P43212 
Cell dimensions 
    
a, b, c (Å) 
78.24, 78.24, 
223.57 
78.81, 78.81, 
223.82 
78.73, 78.73, 
225.58 
80.82, 80.82, 
225.99 
, ,  (°) 90, 90, 90 90, 90, 90 90, 90, 90 90, 90, 90 
Rsym or Rmerge 0.146 (0.539) 0.111 (0.423) 0.153 (0.183) 0.164 (0.724) 
I/I 23.12 25.49 27.54 23.45 
Completeness (%) 99.04 (94.39) 97.62 (94.86) 99.55 (95.77) 99.81 (98.89) 
Redundancy 5.6 (4.1) 8.1 (7.1) 11.4 (11.5) 13.1 (7.6) 
Refinement 
    
Resolution (Å) 
49.58-1.99    
(2.00-1.99) 
44.65-2.19   
(2.24-2.19) 
44.67-2.00       
(2.04-2.00) 
45.53-2.08    
(2.12-2.08) 
No. of reflections 47969 36629 48288 50605 
Rwork/Rfree 0.1745/0.2323 0.1809/0.2340 0.1692/0.2194 0.2254/0.2825 
No. of atoms 
    Protein 5367 5421 5472 5378 
Ligand/ion 16 19 13 18 
Water 533 532 641 417 
B factors 
    Protein 25.7 28.7 30.3 44.6 
Ligand/ion 29.9 28.4 34.7 41.1 
Water 31.8 34.9 37.3 46.5 
Rmsd 
    Bond length (Å) 0.005 0.009 0.008 0.006 
Bond angles (°) 0.92 1.18 1.07 1.02 
Statistics for the highest-resolution shell are shown in parentheses. 
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Table C-2: Continued. 
Statistics 
GlcB-13 
complex 
GlcB-14 
complex 
GlcB-15 
complex 
GlcB-16 
complex 
Data Collection 
    Space group P43212 P43212 P43212 P43212 
Cell dimensions 
    
a, b, c (Å) 
80.76, 80.76, 
226.6 
79.8, 79.8, 
225.06 
79.03,79.03, 
225.86 
81.51, 81.51, 
227.03 
, ,  (°) 90, 90, 90 90, 90, 90 90, 90, 90 90, 90, 90 
Rsym or Rmerge 0.140 (0.781) 0.165 (0.756) 0.236 (0.791) 0.151 (0.732) 
I/I 13.38 25.86 15.81 30.62 
Completeness (%) 98.19 (86.95) 98.38 (88.26) 88.9 (91.70) 97.48 (93.87) 
Redundancy 16.5 (17.3) 8.7 (4.7) 5.4 (3.3) 15.9 (11.6) 
Refinement 
    
Resolution (Å) 
40.22-2.78    
(2.78-2.89) 
45.10-1.99    
(2.00-1.99) 
44.87-1.95    
(1.98-1.95) 
35.88-2.21    
(2.25-2.21) 
No. of reflections 42208 50244 46965 42379 
Rwork/Rfree 0.2297/0.3066 0.2258/0.2736 0.2249-0.2753 0.2091/0.2700 
No. of atoms 
    Protein 5367 5379 5372 5378 
Ligand/ion 13 21 13 15 
Water 373 430 468 433 
B factors 
    Protein 42.6 40.5 41.7 35.1 
Ligand/ion 44.2 38.2 51.2 35.2 
Water 42.1 45.2 48.2 38.6 
Rmsd 
    Bond length (Å) 0.009 0.007 0.006 0.008 
Bond angles (°) 1.17 1.39 0.96 1.08 
Statistics for the highest-resolution shell are shown in parentheses. 
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Table C-2: Continued. 
Statistics 
GlcB-17 
complex 
GlcB-18 
complex 
GlcB-19 
complex 
GlcB-23 
complex 
Data Collection 
    Space group P43212 P43212 P43212 P43212 
Cell dimensions 
    
a, b, c (Å) 
78.95, 78.95, 
225.13 
77.41, 77.41, 
222.17 
78.96, 78.96, 
224.97 
79.30,79.30, 
224.98 
, ,  (°) 90, 90, 90 90, 90, 90 90, 90, 90 90, 90, 90 
Rsym or Rmerge 0.129 (0.627) 0.209 (0.641) 0.108 (0.439) 0.226 (0.836) 
I/I 19.64 17.58 21.43 20.02 
Completeness (%) 90.83 (96.12) 96.07 (99.53) 87.82 (93.30) 93.53 (99.10) 
Redundancy 8.4 (8.5) 6.7 (6.3) 6.6 (7.5) 12.9 (14.0) 
Refinement 
    
Resolution (Å) 
34.94-2.1     
(2.14-2.1) 
44.02-1.99    
(2.02-1.99) 
44.78-2.18    
(2.22-2.18) 
44.91-2.80    
(2.85-2.80) 
No. of reflections 38777 45763 33398 17322 
Rwork/Rfree 0.1885/0.2656 0.2069/0.2924 0.1807/0.2569 0.1712/0.2956 
No. of atoms 
    Protein 5421 5431 5417 5419 
Ligand/ion 15 15 19 18 
Water 483 616 489 425 
B factors 
    Protein 33.7 36.3 26.2 30 
Ligand/ion 45.4 41.6 27.8 20.8 
Water 38.4 45.5 32.2 29.7 
Rmsd 
    Bond length (Å) 0.008 0.009 0.007 0.011 
Bond angles (°) 1.1 1.16 1.07 1.11 
Statistics for the highest-resolution shell are shown in parentheses. 
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Table C-2: Continued. 
Statistics 
GlcB-27 
complex 
GlcB-28 
complex 
Data Collection 
  Space group P43212 P43212 
Cell dimensions 
  
a, b, c (Å) 77.79, 77.79, 
222.98 
78.48, 78.48, 
223.94 
, ,  (°) 90, 90, 90 90, 90, 90 
Rsym or Rmerge 0.128 (0.681) 0.107 (0.666) 
I/I 11.6 20.1 
Completeness (%) 97.70 (97.80) 96.24 (99.83) 
Redundancy 6.5 (4.3) 11.9 (11.3) 
Refinement 
  
Resolution (Å) 44.22-2.08    
(2.13-2.08) 
49.72-2.09    
(2.13-2.09) 
No. of reflections 40878 40902 
Rwork/Rfree 0.1780/0.2390 0.1906/0.2508 
No. of atoms 
  Protein 5456 5424 
Ligand/ion 19 20 
Water 522 570 
B factors 
  Protein 28.9 45.3 
Ligand/ion 21.6 38.6 
Water 36.1 51.5 
Rmsd 
  Bond length (Å) 0.009 0.008 
Bond angles (°) 1.12 1.10 
Statistics for the highest-resolution shell are shown in parentheses. 
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Table C-3: Chemical structure and Tm for hit from the fragment screening by DSF.  
Chemical Structure Tm (°C) Chemical Structure Tm (°C) 
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Table C-3: Continued. 
Chemical Structure Tm (°C) Chemical Structure Tm (°C) 
 
  
7.0 
 
  
3.4 
 
 
  
 
 
7.1 
 
  
 
 
4.8 
 
3.1 
 
 
 
  
6.8 
 
 
3.4  
 
  
4.6  
 
3.1 
 
  
 
 
3.6 
 
  
6.4 
 
3.4  
 
 
 
 
 183 
 
Table C-3: Continued. 
Chemical Structure Tm (°C) Chemical Structure Tm (°C) 
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Table C-3: Continued. 
Chemical Structure Tm (°C) Chemical Structure Tm (°C) 
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Table C-3: Continued. 
Chemical Structure Tm (°C) Chemical Structure Tm (°C) 
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Table C-3: Continued. 
Chemical Structure Tm (°C) Chemical Structure Tm (°C) 
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Table C-4: Crystal data collection and refinement statistics. 
Statistics 
WT GlcB-malate 
complex 
GlcB G459A- malate 
complex  
WT GlcB apo 
Data Collection 
   Space group P41212 P43212 P43212 
Cell dimensions 
   
a, b, c (Å) 
120.66, 120.66, 
232.22 
80.26, 80.26, 226.44 
81.79, 81.79, 
227.08 
, ,  (°) 90, 90, 90 90, 90, 90 90, 90, 90 
Rsym or Rmerge 0.108 (0.94) 0.418 (0.935) 0.119 (0.972) 
I/I 14.96 16.75 11.66 
Completeness 
(%) 85.51 (11.96) 89.53 (45.14) 98.2 (100.0) 
Redudancy 14.4 (16.3) 19.4 (17.9) 12.6 (13.1) 
Refinement 
   
Resolution (Å) 
48.93-2.85                  
(2.9-2.85) 
45.36-2.70         
(2.75-2.7) 
45.96-2.10 
(2.14-2.10) 
No. of 
refelctions 66430 34332 40305 
Rwork/Rfree 0.2263/0.2765 0.2260/0.3242 0.3113/0.2503 
No. of atoms 
   Protein 10988 5421 5394 
Ligand/ion 17 10 N/A 
Water 60 58 102 
B factors 
   Protein 78.9 47.8 34.6 
Ligand/ion 76.1 47.5 N/A 
Water 64.8 37.6 27.7 
Rmsd 
   Bond length (Å) 0.003 0.008 0.008 
Bond angles (°) 0.62 1.14 1.16 
Statistics for the highest-resolution shell are shown in parentheses. 
